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1  Introduction 
1.1  Normal hematopoiesis 
The term hematopoiesis refers to the highly orchestrated process of blood cell production and 
homeostasis. In adults, hematopoiesis occurs in bone marrow. The cells from the 
hematopoietic system are continually generated from self-renewing progenitors in the bone 
marrow called hematopoietic stem cells (HSCs), which have been isolated in both humans 
and mice. HSCs can be divided into a long-term subset (LT-HSC), capable of indefinite self-
renewal, and a short-term subset (ST-HSC) that self-renew for a defined interval. HSCs give 
rise to non-self-renewing oligolineage progenitors, which in turn give rise to progeny that are 
more restricted in their differentiation potential and finally to functionally mature 
cells.(Passegue et al., 2003) 
HSC generates the multiple hematopoietic lineages through a successive series of 
intermediate progenitors. These multipotent stem and/or progenitor cells then commit either 
to the myeloid or lymphoid lineage by differentiating to common myeloid progenitors (CMP) 
or common lymphoid progenitors (CLP) (Passegue et al., 2003). These progenitor cells go 
through a number of proliferation and commitment steps to give rise to all the myeloid and 
lymphoid lineages of the blood. The CLP give rise to T cells, B cells, natural killer (NK) 
cells, and antigen presenting dendritic cells. The CMP give rise to granulocytes, monocytes, 
megakaryocytes, erythrocyte and dendritic cells. Ultimately, terminally differentiated cells are 
produced that cannot divide and undergo apoptosis after a period of time ranging from hours 
(for  neutrophils) to decades (for some lymphocytes). Process of hematopoiesis is 
schematically shown in Figure 1(Passegue  et al., 2003). The regulation of hematopoiesis 
involves a complex interplay between the intrinsic genetic processes of blood cells and their 
environment. This interplay determines whether HSCs, progenitors, and mature blood cells 
remain quiescent, proliferate, differentiate, self-renew, or undergo apoptosis. 
1.2  Leukemia 
Leukemia is used to describe a variety of cancers of the white blood cells that have their 
origin in blood-forming cells of the bone marrow. White blood cells evolve from the 
immature cells referred to as blasts, some of which are lymphoblasts and myeloblasts, 
depending on whether they eventually mature into lymphocytes or myeloid cells. Normally, 
blasts constitute less than 5% of healthy bone marrow. In leukemia, however, these blasts 
remain abnormally immature and multiply continuously, eventually constituting from 30% to 
100% of the bone marrow. The malignant cells fill up the marrow and prevent production of Introduction  15 
 
healthy red cells, platelets, and white cells. They often leave the marrow and migrate into the 
blood stream and lymphatic system and occasionally to the central nervous system. As the 
number  of normal cells declines, symptoms develop which, if untreated, become lethal 
(Lemez, 1989). Leukemias are divided into two measure types: acute (which progresses 
quickly with many immature white cells) and chronic (which progresses more slowly and has 
more mature white cells (Seipelt et al., 1998). 
 
 
Figure 1- Normal hematopoiesis: ST-HSCs differentiate into multipotent progenitors (MPPs), which do not or 
briefly self-renew, and have the ability to differentiate into oligolineage-restricted progenitors that ultimately 
give rise to differentiated progeny through functionally irreversible maturation steps. The CLPs give rise to T 
lymphocytes, B lymphocytes and natural killer (NK) cells. The CMPs give rise to GMPs, which then differen-
tiate into monocytes/macrophages and granulocytes, and to megakaryotic/erythroid progenitors (MEP), which 
produce megakaryocyte/platelets and erythrocytes. Both CMPs and CLPs can give rise to dendritic cells 
(Passegue et al., 2003). 
1.2.1  Acute leukemia 
Acute leukemias are clonal hematopoietic stem cell disorders and  characterized by the 
uncontrolled growth of the immature blast cells which usually constitute more than 30% of 
bone marrow cells. The immature cells also accumulate in the peripheral blood, infiltrate 
other tissues and cause bone marrow failure. The clinical picture of acute leukemia is marked 
by the effects of anemia, which is usually severe (fatigue, malaise), an absence of functioning 
granulocytes (proneness to infection and inflammation), and thrombocytopenia (hemorrhagic 
diathesis) (Hoelzer and Seipelt, 1998). When untreated, patients have a life span of several 
weeks or months, because their normal blood cells become outnumbered by the leukemic Introduction  16 
 
ones. Acute leukemias require immediate and aggressive treatment (Hoelzer and Seipelt, 
1998). It is important to distinguish between acute lymphoid (ALL) and acute myeloid 
leukemia (AML) because of the different therapeutic approaches which must be undertaken 
by these two malignancies. They can be distinguished based on a variety of morphological, 
cytoplasmatic, cytochemical and biochemical features. 
1.2.1.1  Acute lymphoid leukemia (ALL) 
The acute lymphoid leukemia results from the malignant transformation of immature 
lymphoid blast cells in the bone marrow, thymus or other lymphoid organs (Hoelzer and 
Seipelt, 1998). According to FAB classification acute lymphoid leukemia is divided into 3 
subgroups as shown in Table 1. Acute lymphoid leukaemia can also be subdivided based on 
immunologic and cytogenetic abnormalities (Table 2). Major cytogenetic subgroups include 
the t(9;22) (Philadelphia chromosome-positive acute lymphoblastic leukemia) and the t(8;14) 
found in the L3 or Burkitt’s lymphoma. 
Acute lymphoid 
leukaemia 
Features 
L1  Small cells, high nuclear/cytoplasmic ratio 
L2  Larger cells, lower high nuclear/cytoplasmic ratio 
L3  Vacuolated, basophilic blast cells 
 
Table 1 : FAB classification of acute lymphoid leukemia(Begemann et al., 1998a)  
 
Immunologic 
subtype 
% of cases  FAB subtype  Cytogenetic abnormality 
Pre-B ALL  75  L1, L2  t(9;22), t(4;11), t(1;19) 
T cell ALL  20  L1, L2  14q11 or 7q34 
T cell ALL  5  L3  t(8;14). t(8;12). t(2;8) 
 
Table 2: Immunological subtypes of acute lymphoid leukemia (Begemann et al., 1998a) 
 
Treatment results in elderly patients with acute lymphoblastic leukemia (ALL) are poor. 
Chemotherapy induces complete remission (CR) in approximately 50% of patients, with re-
mission duration ranging from 3 to 12 months and a probability of long-term survival below Introduction  17 
 
10%.1–9 Comorbidity, poor tolerability of cytotoxic drugs, high induction mortality, and the 
high frequency of the Philadelphia (Ph) chromosome contribute to the dismal prognosis of 
elderly patients(Annino et al., 2002), The Ph chromosome, resulting from a reciprocal trans-
location between chromosomes 9 and 22 [t(9;22)], confers an extremely poor prognosis even 
in younger patients,(Annino et al., 2002) and dose-intensification has not significantly af-
fected survival despite higher rates of CR  (Annino  et al., 2002; Delannoy  et al., 1990; 
Gleissner et al., 2002). Allogeneic stem cell transplantation (SCT) is potentially curative but 
is not generally applicable in elderly patients (Radich, 2001).  
Children with acute lymphoblastic leukemia (ALL) are treated with combination 
chemotherapy with an expected cure rate of 80%. However a small proportion of children 
treated for ALL develop secondary acute myelogenous leukemia (AML). For B cell ALL (B-
ALL) t(12;21)/TEL-AML1 and t(1;19)/E2A-PBX1 translocations define patients with 
relatively good treatment outcome, especially following dose intensified chemotherapy. 
Patients with t(9;22)/BCR/ABL or t(4;11)/MLL-AF4 translocations have a relatively poor p 
rognosis(Ford et al., 1993; Gokbuget et al., 2000) . 
1.2.1.2   Acute myeloid leukemia (AML) 
Acute myeloid leukemia (AML) represents a group of clonal hematopoietic stem cell 
disorders in which both over proliferation and failure to differentiate in the stem cell 
compartment result in accumulation of non-functional cells termed blasts (Hoelzer and 
Seipelt, 1998). AML is the most common acute leukemia in adults. It is possible to 
distinguish between de  novo, primary AML, and secondary AML, which arises as a 
consequence of myelodysplastic syndrome, exposure to mutagenic agents or 
chemo/radiotherapy due to treatment of another cancer. There are several other factors, which 
can provoke the onset of secondary leukemias and among which are exposure to benzene, 
different genetic abnormalities (trisomy 21) and Fancony’s anemia (Ferti et al., 1996). 
In AML, blast cells are blocked in their normal differentiation at very early stage in their 
myelopoiesis. In bone marrow and peripheral blood, AML leads to accumulation of large 
number of proliferating precursors, which are not able to terminally differentiate and become 
functional blood cells. In this way space needed for normal hematopoietic processes is 
occupied by leukemic blasts which will finally be clinically manifested as leukemia. 
In 1976, a group of hematologists from France, America and England has founded a 
morphologically and cytochemically based classification of myeloid and lymphoid leukemias 
(FAB classification). According to FAB classification, acute myeloid leukemias are divided Introduction  18 
 
into 8 subtypes designated M0 through M7. The percentage of blasts, the presence of 
cytochemical myeloperoxidase, and the major cell types present defined by morphology and 
esterase cytochemistry, and the immunophenotype define the 8 FAB subtypes (Bennett et al., 
1985) (Table 3) 
Myeloid 
leukemia 
Features 
 
M0  Undifferentiated by morphology + cytochemistry, peroxidase -, 
CD13 +, CD33 + 
M1  Little differentiation , > 90% blasts, peroxidase -/+ 
M2  Differentiated, 30-90% blasts, azurophilic granular, peroxidase + 
M3  Promyelocytic: intensely granular, variant form is microgranular, 
auer rods, peroxidase + 
M4  Myelomonocytic, peroxidase +++ 
M5  Monocytic, peroxidase +++ 
M6  Erythroid differentiation, > 50% of mononuclear cells are erythroid, 
peroxidase  
M7  Megakaryoblastic, peroxidase -/+, CD41+ and/or CD61+ 
 
Table 3: FAB classification of acute myeloid leukemia(Bennett et al., 1985)  
 
1.2.2  Chronic leukemia 
1.2.2.1  Chronic lymphocytic leukemia (CLL) 
Chronic leukemia results in an accumulation of mature granulocytes or lymphocytes. Chronic 
leukemia progresses slowly but can develop into an acute form. Major types include chronic 
lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML). 
Ninety percent of CLL cases are seen in people who are 50 years or older and is almost never 
seen in children. In CLL, lymphocytes accumulate in peripheral blood, bone marrow, lymph 
nodes, spleen, and liver (Kolyvanos et al., 2003). 
1.2.2.2  Chronic myelogenous leukemia (CML) 
Chronic myeloid leukemia is a clonal myeloproliferative disorder (MPD) that results from the 
neoplastic transformation of a hematopoietic stem cell  (Begemann  et al., 1998a). The 
leukemic cells of >95% of CML patients have a reciprocal translocation between the long 
arms of chromosomes 9 and 22, t(9;22). The derived chromosome 22 is termed the 
Philadelphia (Ph) chromosome (Faderl et al., 1999). 
The initial chronic phase of this biphasic disease is characterized by a massive expansion of 
the granulocytic cell lineage, even though most, if not all, hematopoietic lineages can be 
produced from the CML stem cell. The median duration of the chronic phase is 3–4 years. Introduction  19 
 
Acquisition of additional genetic and/or epigenetic abnormalities causes the progression of 
CML from chronic phase to blast phase. This phase is characterized by a block of cell 
differentiation that results in the presence of 30% or more myeloid or lymphoid blast cells in 
peripheral blood or bone marrow, or the presence of extramedullary infiltrates of blast cells 
(Hoelzer et al., 1998). 
Allogeneic stem-cell transplantation is the only known curative therapy for CML. However, 
most patients are not eligible for this therapy, because of advanced age which makes them 
unable to tolerate the serious side effects of the treatment or lack of a suitable stem-cell donor. 
The discovery that BCR/ABL is required for the pathogenesis of CML, and that the tyrosine-
kinase activity of ABL is essential for BCR–ABL mediated transformation, made the ABL 
kinase an attractive target for therapeutic intervention. Imatinib mesylate (Glivec, previously 
known as STI571), a potent inhibitor of the tyrosine kinases ABL, ARG, platelet-derived 
growth factor receptor and KIT, has been shown to selectively induce apoptosis of 
BCR/ABL+ cells, and is remarkably successful in treating patients with CML (Deininger et 
al., 2005).  In newly diagnosed patients with CML in chronic phase, imatinib induces 
complete cryptogenic response in more than 80% patients. Patients with more advanced 
phases of CML also respond to imatinib, but this occurs much less frequently and treatment is 
less durable. 
There are two major obstacles to imatinib-based therapies for patients with CML. One is the 
persistence of BCR/ABL-positive cells, this is known as ‘residual disease’, and is detected by 
a sensitive nested reverse-transcriptase PCR assay. Suppression of the disease therefore relies 
on continuous imatinib therapy. The other major problem is relapse of the disease due to the 
emergence of resistance to imatinib. Several mechanisms of resistance have been described, 
the most frequent of which are the appearance of point mutations in the BCR/ABL gene that 
impair the drug binding (Ren, 2005). 
The fact that the resistance to imatinib is most commonly associated with point mutations in 
the kinase domain of BCR/ABL further demonstrates the importance of this activity in the 
pathogenesis of CML. On the other hand, the persistence of BCR/ABL-positive cells in 
patients on imatinib therapy indicates that inhibition of the ABL kinase activity alone might 
not be sufficient to eradicate the leukemia cells. Identification of additional essential 
components in the pathogenesis of CML remains crucial for developing improved therapies 
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1.3  Cytogenetic abnormalities involved in leukemia 
The pathogenesis of leukemia is linked to oncogenic fusion proteins, generated as a 
consequence of primary chromosome translocations or inversions. About 80-85 % of AML 
and ALL patients and 98% of CML patients have chromosomal translocation (Begemann et 
al., 1998b; Faderl  et al., 1999). In most cases this chromosome translocations refer to 
reciprocal translocations between different chromosomes.  
1.3.1  The Philadelphia-Chromosome associated translocation products 
Over 95% of CML cases involve a balanced translocation of a fragment of the long arm of 
chromosome 9 to the long arm of chromosome 22: t(9;22) (Faderl et al., 1999). The shortened 
chromosome 22 was first described in 1960 by Peter Nowell and termed the Philadelphia 
chromosome. The Philadelphia chromosome also occurs in 10-20% of adult patients with 
acute lymphoblastic leukemia (ALL) (Faderl et al., 1999). 
The balanced reciprocal translocation t(9;22) creates a fusion between the BCR (breakpoint 
cluster region) gene on chromosome 22 and the ABL gene on chromosome 9 (Figure 5). The 
breakpoint in the abl gene locus is constantly found between exons 1 and 2 (a1 and a2). On 
chromosome 22, translocation t(9;22) involves three different breakpoints in the bcr locus : 
(minor) m-bcr, which maps in the first intron of bcr; (major) M-bcr, which spans between 
exons 12 to 16 (also referred to as b1 to b5) and (micro) μ-bcr which was found between exon 
e19 and e20 (Faderl et al., 1999). The translocation t(9;22) results in translocation of BCR 
exon 1, exons 1–12/13, or exons 1–19 , respectively, to the ABL exons 2 to 11 (also called a2 
to a11) on chromosome 9. These different oncogenes give rise to three distinct fusion proteins 
of molecular mass 190, 210, and 230 KD, which contain the same portion of the c-Abl 
tyrosine kinase in the COOH terminus but include different amounts of BCR sequence at the 
NH2 terminus. 
1.3.2  Chromosome 22q+: p185 
BCR/ABL and p210
 BCR/ABL 
The product of fusion between M-bcr and abl is a protein of 210KD, the p210
BCR/ABL, which is 
highly specific for CML. Different p210
BCR/ABL  has been found depending on the exon 
involved, for example: b2a2- p210
BCR/ABL or b3a3- p210
BCR/ABL. p210
BCR/ABL constructs were 
tested from many groups, but without paying special attention to the breakpoint of 
translocation. 
Due to the fact that in Ph+ ALL related p185
BCR/ABL the m-bcr breakpoint maps within an 
intron, the p185
BCR/ABL transcript is constant and appears in e1a2 form (Faderl et al., 1999). Introduction  21 
 
C-ABL kinase activity is in normal cells finely regulated in response to growth factors and 
other stimuli. By the fusion to BCR, ABL becomes constitutively activated. This leads to 
constitutive activation of the “down-stream” signal transduction pathways in particular to 
activation of RAS oncogene. 
 
 
 
Figure 2- The Translocation of t(9;22)(q34;q11) in CML. The Philadelphia (Ph) chromosome is a shortened 
chromosome 22 that results from the translocation of 3’ (toward the telomere) ABL segments on chromosome 9 
to 5’ BCR segments on chromosome 22. Breakpoints (arrowheads) on the ABL gene are located 5’ (toward the 
centromere) of exon a2 in most cases. Various breakpoint locations have been identified along the BCR gene on 
chromosome 22. Depending on which breakpoints are involved, different-sized segments from BCR are fused 
with the 3’ sequences of the ABL gene. This results in fusion messenger RNA molecules (e1a2, b2a2, b3a2, and 
e19a2) of different lengths that are transcribed into chimeric protein products (p190, p210, and p230) with varia-
ble molecular weights and presumably variable function. The abbreviation m-bcr denotes minor breakpoint clus-
ter region, M-bcr major breakpoint cluster region, and μ-bcr a third breakpoint location in the BCR gene that is 
downstream from the M-bcr region between exons e19 and e20 (Faderl et al., 1999).  
 
The suppression of constitutively active ABL kinase by the specific kinase inhibitor STI571 
(Novartis) induces apoptosis in BCR/ABL transformed cells (Gambacorti-Passerini  et al., 
1997).  JAK-STAT and PI-3 kinase are also among the signal transduction pathways induced Introduction  22 
 
by BCR/ABL translocation products. Furthermore the capacity of BCR/ABL to bind f-actin is 
indispensable for its transformation potential (Faderl et al., 1999). 
Noteworthy there seem to exist no differences between p185
BCR/ABL and p210
BCR/ABL regarding 
their biological functions. Studies with BCR/ABL infected bone marrow cells in mice proved 
the correlation between expression BCR/ABL in precursor cells and induction of leukemia 
(Huettner et al., 2000; Kelliher et al., 1990).  
1.4  The Philadelphia chromosome 
1.4.1  Breakpoint cluster region (BCR) 
The breakpoint cluster region protein, BCR, is a multidomain protein, of 160 kDa and is 
ubiquitously expressed (Laneuville, 1995) (Figure 3). The first N-terminal exon encodes a 
serine-threonine kinase (Maru and Witte, 1991), with substrates being Bap-1 and BCR itself. 
A coiled-coil domain at the N-terminus allows dimer formation in vivo (McWhirter et al., 
1993). The centre of the molecule contains a dbl-like pleckstrin-homology (PH) domain with 
guanine nucleotide exchange factor (GEF) function for Rho, which may activate the 
transcription factor NF-κB (Montaner, Perona et al. 1998). The C-terminus has a GTPase-
activating domain for Rac (regulates actin polymerisation) (Diekmann et al., 1991). BCR can 
be phosphorylated on Tyrosine-177. The Grb-2 adapter molecule involved in the activation of 
the Ras pathway, binds BCR on phosphorylated Tyrosine-177 (Ma et al., 1997).  
 
 
Figure 3 - Structure of the BCR protein (Deininger et al., 2000). The dimerization domain (DD) and the 
2 cyclic adenosine monophosphate kinase homologous domains are located at the N terminus. Y177 is the auto-
phosphorylation site crucial for binding to Grb-2. The center of the molecule contains a region homologous to 
Rho guanidine nucleotide exchange factors (Rho-GEF) as well as dbl-like and pleckstrin homology (PH) do-
mains. Toward the C-terminus a putative site for calcium-dependent lipid binding (CaLB) and a domain with 
activating function for Rac-GTPase (Rac-GAP) are found. Arrowheads indicate the position of the breakpoints in 
the BCR-ABL fusion protein.  Introduction  23 
 
ABL has been shown to reduce the activity of BCR by phosphorylation. The fact that BCR 
knockout mice are viable with no change in the incidence and biology of p190
BCR/ABL as com-
pared to wild-type mice, makes it difficult to discern the role of BCR in Ph+ leukemia 
(Voncken et al., 1998). 
1.4.2  Abelson murine leukemia virus homology gene (ABL) 
The Abl gene is the human homologue of the v-abl oncogene carried by the Abelson murine 
leukaemia virus (A-MuLV), and it encodes a non-receptor tyrosine kinase localized in the 
nucleus and cytoplasm (Deininger  et al., 2000; Ling  et al., 2003). Human ABL  is a 
ubiquitously expressed 145 kDa protein with two isoforms, arising from alternative splicing 
of the first exon (Laneuville, 1995). It contains several structural domains (Figure 4). Three 
Src homology domains (SH1-SH3) are located towards the NH2 terminus. The SH1 domain 
carries the tyrosine kinase function, whereas the SH2 and SH3 domains allow for interaction 
with other proteins (Cohen et al., 1995). Proline-rich sequences in the center of the molecule 
interact with the SH3 domains of other proteins such as Crk (Feller et al., 1994). Towards the 
3’ end, nuclear localization signals, DNA-binding and, actin-binding motifs are found 
(Deininger et al., 2000). 
 
 
 
Figure 4 - Structure of the Abl protein (Deininger et al., 2000)  
Type Ia isoform is slightly shorter than type Ib, which contains a myristylation (myr) site for attachment to the 
plasma membrane. Note the 3 SRC-homology (SH) domains situated toward the NH2 terminus. Y393 is the 
major site of autophosphorylation within the kinase domain, and Phenylalanine-401 (F401) is highly conserved 
in PTKs containing SH3 domains. The middle of each protein is dominated by proline-rich regions (PxxP) capa-
ble of binding to SH3 domains, and it harbors 1 of 3 nuclear localization signals (NLS). The carboxy terminus 
contains DNA as well as G- and F-actin-binding domains. Phosphorylation sites by Atm, cdc2, and PKC are 
shown. The arrowhead indicates the position of the breakpoint in the BCR-ABL fusion protein. 
 
The normal ABL protein serves a complex role as a cellular module that integrates signals 
from various extracellular and intracellular sources, thereby influencing cell cycle and 
apoptosis (Deininger et al., 2000). Introduction  24 
 
1.4.3  Breakpoint regions and fusion protein tyrosine kinase 
The breakpoints within the Abl gene on 9q34 occur at its 5’ end, either upstream of the first 
alternative exon 1b, downstream of the second alternative exon 1a, or more frequently, 
between the two (Melo, 1996) (Figure 5). Bcr sequences are always fused to Abl exon a2. In 
contrast to Abl, breakpoints within Bcr localize to 1 of 3 so-called breakpoint cluster regions 
(bcr). In most CML patients and in one third of ALL patients, the breakpoint spans Bcr exons 
b1-b5, defined as major breakpoint cluster region (M-bcr). Fusion transcripts with either b2a2 
or b3a2 junctions are formed, due to alternative splicing. A 210-kDa chimeric protein (p210 
BCR/ABL) is derived from this mRNA. In the remaining patients with ALL and rarely in 
patients with CML (with prominent monocytosis), (Ravandi et al., 1999), the breakpoint is 
between the alternative Bcr exons e2’ and e2 termed the minor breakpoint cluster region (m-
bcr). The resultant e1a2 mRNA is translated into a 190 kDa protein (p190
BCR/ABL). A third 
breakpoint cluster region (µ-BCR) has been identified downstream of exon 19, giving rise to 
p230 
BCR/ABL, a 230 kDa fusion protein, associated with the rare Ph+ chronic neutrophilic 
leukaemia (Pane, Frigeri et al. 1996), (Figure 5). In contrast to p190 and p210, transformation 
to growth factor independence by p230 is incomplete, consistent with the benign clinical 
course of p230- positive chronic neutrophilic leukaemia (Pane et al., 1996). Occasional cases 
with other junctions, such as b2a3, b3a3, e1a3, e6a2, or e2a2 have been reported in patients 
with ALL or CML.  
Based on the observation that the ABL part in the chimeric protein is constant, while the BCR 
portion varies, it can be concluded that ABL is likely to carry the transforming principle, 
whereas different sizes of the BCR sequence may determine the phenotype of the disease 
(Deininger et al., 2000). 
1.4.4  BCR-ABL signaling 
Features in the chimeric protein that are essential for cellular transformation include, the SH1, 
SH2 and actin binding domains in ABL (Figure 5), and; a coiled-coil motif contained in 
amino acids 1-63  (McWhirter  et al., 1993), the tyrosine at position 177, and the 
phosphoserine-threonine-rich sequence between amino 192-242 and 298-413 in BCR (Figure 
2).  
Under physiological conditions, Abl tyrosine kinase activity is tightly regulated. The SH3 
domain plays a critical role in this inhibitory process, because its deletion or positional 
alteration activates the kinase (Mayer and Baltimore, 1994). Other inhibitory mechanisms 
include binding of SH3 inhibitory proteins, conformational changes of the SH3 domain and Introduction  25 
 
mutations within the kinase domain (Dai  et al., 1998; Goga  et al., 1993; Mayer and 
Baltimore, 1994). 
 
 
 
Figure 5 - Locations of the breakpoints in the Abl and Bcr genes and structure of the chimeric mRNAs 
derived from the various breaks (Deininger et al., 2000). 
Fusion of the BCR sequence 5’ of the ABL SH3 domain abrogates the physiological suppression of the kinase. 
This is a consequence of homodimer formation by the N-terminal dimerization domain, in the BCR portion of 
the BCR/ABL protein. Autophosphorylation increases the phosphotyrosine on BCR/ABL itself which create 
binding sites for the SH2 domains of other proteins. Proliferation and survival pathways of BCR/ABL are shown 
in Figure 7. Effects of the BCR/ABL tyrosine kinase are regulated by tyrosine phosphatases. These include pro-
tein tyrosine phosphatase 1B (PTP1B) and receptor protein tyrosine phosphatase K (RPTP-K).  
1.4.4.1  Stat signaling 
STAT  (signal transducers and activators of transcription) are a seven member family of 
cellular proteins, that function as both cytoplasmic signaling molecules and nuclear 
transcription factors (reviewed in (Darnell, 1997).    Stats are phosphorylated by receptor 
tyrosine kinases, or various cytoplasmic kinases such as Jaks or SFKs, in response to 
numerous cytokines and growth factor signals (Wilson et al., 2002). 
BCR/ABL may also directly activate Stat1 and Stat5, and there seems to be specificity for 
Stat6 activation by p190
BCR-ABL, as opposed to p210
 BCR/ABL (Ilaria and Van Etten, 1996).  
Stat5 is activated by BCR/ABL via the SFK, Hck (Klejman et al., 2002). On interaction with 
the SH3 and SH2 domains of BCR/ABL, this kinase is activated and phosphorylates Stat5, 
leading to its translocation to the nucleus, where it functions as a transcription factor Introduction  26 
 
(Klejman et al., 2002). A Stat5 target gene involved in BCR/ABL leukemogenesis is the 
antiapoptotic Bcl-XL gene, whose level is down-modulated in Imatinib treated BCR/ABL -
expressing cells (Horita, Andreu et al. 2000). Two other Stat5 targets are the antiapoptotic 
proteins A1 (member of the Bcl-2 family) and pim-1 (it is a serine/threonine kinase and a 
proto-oncogene) (Calabretta and Perrotti, 2004). 
Evidence of Stat5 in BCR/ABL leukemogenesis is supported by the following observations: 
    (1) BCR/ABL mutants defective in Stat5 activation were less efficient than the wild-type form 
in transformation of myeloid precursor cells, and (2) a constitutively active Stat5 mutant 
rescued the leukemogenic potential of Stat5 activation-deficient  BCR/ABL  mutants 
(Nieborowska-Skorska et al., 1999). 
1.4.4.2  Ras/MAPK 
Autophosphorylation of Tyrosine-177 provides a docking site for the adaptor molecule Grb-2 
(Pendergast et al., 1993). Grb-2 then binds to Gab2, and the phosphorylation of SHC leads to 
enhanced activity of the guanosine diphosphate/guanosine triphosphate (GDP/GTP) exchange 
factor SOS, which promotes the accumulation of the active GTP bound form of Ras. Crkl 
which is a direct substrate of BCR/ABL can also activate Ras (Calabretta and Perrotti, 2004). 
Activation of Ras leads to the subsequent recruitment of the serine-threonine kinase Raf to the 
cell membrane. Raf initiates a signaling cascade through the serine-threonine kinases 
Mek1/Mek2 and Erk, which ultimately leads to activation of gene transcription (Deininger et 
al., 2000).  
Other pathways activated are the Jnk/Sapk, p38, Dok-1 (forms complexes with Crkl, Ras, 
Gab, and BCR/ABL). In any case, signals are transduced to the transcriptional machinery of 
the cell. The importance of Ras  dependent  signaling  for the phenotype of BCR/ABL  -
expressing cells is supported by observations that, down-regulation of these pathways by 
antisense strategies, expression of dominant negative molecules, or chemical inhibitors, 
suppresses proliferation and sensitizes cells to apoptotic stimuli  (Calabretta and Perrotti, 
2004). 
1.4.4.3  PI-3K/Akt 
BCR/ABL interacts indirectly with the p85 regulatory subunit of PI-3K via various adapter 
proteins including Grb-2/Gab2 and c-cbl (Figure 6). PI-3K activates the serine-threonine 
kinase Akt, triggering an Akt-dependent cascade, which regulates the subcellular localization 
or activity of several targets such as BAD, MDM2, IκB-kinase-α  and members of the 
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Phosphorylation of BAD by Akt suppresses its pro-apoptotic activity, because when 
phosphorylated, BAD is sequestered in the cytoplasm, in a complex with 14-3-3β. 
Phosphorylation of MDM2 enhances its nuclear-cytoplasmic export, inducing a more efficient 
degradation of p53 (transcription factor that regulates the cell cycle and functions as a tumor 
suppressor). 
Phosphorylation of IκB-kinase-α  enhances its activity towards its substrate IκB. On 
phosphorylation, IκB is subjected to ubiquitination and proteasome-depedent degradation 
allowing the translocation of nuclear factor κB (NF-κB) into the nucleus, where it functions as 
a transcription factor (Silverman and Maniatis, 2001). 
 
 
 
Figure 6 - Schematic representation of the main BCR-ABL -activated pathways. These pathways regulate 
proliferation and survival of BCR-ABL-transformed haematopoietic cells (Deininger et al., 2000).  
 
Phosphorylation of the transcription factor FKHRL1 prevents its translocation to the nucleus, 
and the transactivation of genes promoting apoptosis (for example TRAIL), or inhibiting cell 
cycle progression (for example p27) (Komatsu et al., 2003). 
Consistent with the effects of Akt, inhibition of the PI-3K/Akt pathway suppresses in vitro 
colony formation and in vivo leukemogenesis of BCR/ABL expressing cells (Skorski, 
Bellacosa et al. 1997). Marrow cells with inactivated PI-3K/Akt are resistant to BCR-ABL 
transformation (Calabretta and Perrotti, 2004). 
Other biological properties of BCR/ABL include: (1) altered adhesion to bone marrow 
stromal cells and extracellular matrix (which negatively regulates proliferation) by expression 
of an adhesion inhibitory variant of α1 integrin not found in normal progenitors, (2) 
Degradation of inhibitory proteins Abi-1 and Abi-2 in acute leukaemias (Lewis et al., 1996). Introduction  28 
 
1.5  Molecular therapy of Ph+ leukemia  
Given the fact that BCR/ABL is the causative agent for Ph+ leukemia it was obvious that 
targeting the function of the fusion protein itself would provide an excellent therapeutic 
approach. It was shown that the transforming capacity of BCR/ABL is strictly dependent on 
its TK activity(Lugo et al., 1990). Thus, a selective ABL-kinase inhibitor called Imatinib was 
developed, which competes with ATP for the binding to the TK domain and inhibits 
oncogenic ABL proteins like v-ABL, BCR/ABL and TEL/ABL  (Deininger  et al., 1997; 
Druker  et al., 1996; Weisberg and Griffin, 2000). Imatinib proved to be clinically very 
effective: 95% of CML-chronic phase patients achieve a complete hematologic and 
cytogenetic remission upon Imatinib treatment (O'Dwyer et al., 2003). 70% of CML blast 
crisis or Ph+ ALL patients achieve a transient complete remission, but relapse frequently 
within 4 – 6 months and become refractory towards further treatment with Imatinib. The most 
important resistance mechanisms towards Imatinib consist of the clonal selection of point 
BCR/ABL-mutants  (Ottmann and Hoelzer, 2002). These mutations concern amino acid 
residues that are critical for the binding of Imatinib to the kinase domain (Cowan-Jacob et al., 
2004; Deininger  et al., 2005). Other mechanisms that confer Imatinib resistance are the 
upregulation of BCR/ABL expression, upregulation of “multiple drug resistance” proteins and 
a functional inactivation of Imatinib through binding to the acidic glycoprotein “acute phase 
protein alpha 1” (Gambacorti-Passerini et al., 2000; Ottmann and Hoelzer, 2002). 
Recently, much effort has been undertaken to solve the problem of Imatinib resistance. In 
vitro, but not in patients, many point mutations are inhibited by increased doses of Imatinib, 
as the achievable serum levels of Imatinib are below the concentrations necessary to 
overcome resistance (O'Hare et al., 2005b; Weisberg et al., 2006; Weisberg et al., 2005). 
Therefore research focuses mainly on the development of second generation kinase inhibitors. 
Nilotinib (Novartis, Basle), like Imatinib, is a selective ABL-kinase inhibitor. Nilotinib 
inhibits many Imatinib-resistant point mutants because of its 20-fold higher affinity for the 
ABL kinase domain and achievable plasma levels for Nilotinib are sufficient for inhibition 
(O'Hare et al., 2005a). The dual SRC-ABL kinase inhibitor Dasatinib (Bristol-Myer-Squibb, 
New York) takes advantage of a characteristic difference between SRC- and  ABL-kinase 
domain conformations to inhibit Imatinib-resistant mutations: the inactive conformations of 
SRC and ABL are different, while the active conformations are closely related (Schindler, 
Bornmann et al. 2000). Dasatinib has a 325-fold higher affinity towards ABL than Imatinib 
(O'Hare et al., 2005a). Imatinib and Nilotinib bind to the inactive ABL-kinase conformation 
which is the reason for their selectivity, while Dasatinib binds to active ABL and active SRC. Introduction  29 
 
Therefore the binding of Dasatinib is dependent on another choice of aminoacid residues as 
Imatinib or Nilotinib (Schindler et al., 2000). Dasatinib inhibits most mutations identified in 
Imatinib resistant patients (O'Hare, Walters et al. 2005). Unfortunately, the mutation T315I, 
which clinically accounts for about 20% of Imatinib-resistant cases, is neither inhibited by 
Nilotinib nor Dasatinib (O'Hare et al., 2005b; von Bubnoff et al., 2006). 
1.5.1  Abl-kinase-inhibitor Imatinib Mesylate 
Imatinib (Gleevec, Norvatis, Basel, Switzerland) previously known as STI571 (signal 
transduction inhibitor 571) is an inhibitor of specific protein tyrosine kinases that is targeted 
to the constitutively active Philadelphia chromosome (of CML and Ph+ ALL), c-Kit (CD117) 
(overexpressed in gastrointestinal tumors), and the platelet derived growth factor (PDGF) 
receptor. Imatinib was approved by the Food and Drug Administration in May 2001 for the 
treatment of Ph+ leukemias, which does not respond to interferon therapy, and in February 
2002 for the treatment of gastrointestinal stromal tumors (Litzow, 2006; Savage and Antman, 
2002). Imatinib is a 2-phenyl-amino-pyrimidine and an orally available, therapeutic agent 
(Druker and Lydon, 2000). 
In June 1998, a phase 1 trial designed to determine the safety and efficacy of Imatinib in 
chronic-phase CML was initiated (Druker et al., 2001). Likewise, clinical trials of Imatinib 
were carried out in Ph+ ALL (Wassmann et al., 2003). The initial phase I study included 83 
CML patients in chronic phase (less than 15% blast), who had failed interferon-based therapy. 
With Imatinib having a terminal half-life of 14-16 hours, patients were treated with once-daily 
oral doses ranging from 25-1,000 mg. In this phase I study, no dose-limiting toxicity was 
encountered and toxicity at all dose levels was minimal (Mauro and Druker, 2001). Based on 
the effectiveness of Imatinib in chronic phase CML patients,  the phase I studies were 
expanded to include CML patients in myeloid and lymphoid blast crisis, and patients with 
relapsed Ph+ ALL (Talpaz et al., 1983). Patients were treated with Imatinib once daily, at 
doses of 300 to 1000 mg. 55% of patients with myeloid blast crisis responded to therapy 
(decrease in percentage of myeloid blast to less than 15%), and 70% of patients with CML in 
lymphoid blast crisis or Ph+ ALL responded with 55% having less than 5% of marrow blast. 
The success of the phase I study prompted phase II study. In a phase II study, an initial once-
daily oral dose of 400 mg and then 600 mg of Imatinib was used for the studies. Hematologic 
and cytogenetic responses were less common in patients with accelerated-  or blast-phase 
CML than in patients with chronic-phase CML, and adverse events were more common in 
advanced disease, but it was unclear whether this was due to the phase of the disease or to the 
higher dose of Imatinib that were used (Savage and Antman, 2002). In Ph+ ALL the initial Introduction  30 
 
overall response rates were 60-70%, but were almost invariably followed by relapse with very 
rapid kinetics (Schiffer et al., 2003). 
1.5.2  Resistance towards kinase inhibitors /Resistant BCR/ABL Mutations 
BCR/ABL is characterized by a deregulated and constitutively activated ABL tyrosine kinase 
(TK) activity which determines its transformation potential (Faderl et al., 1999). Cellular 
transformation and leukemogenesis are strictly dependent on the TK activity of BCR/ABL 
(Deininger et al., 1997; Druker et al., 1996; Lugo et al., 1990; Weisberg and Griffin, 2000). 
Molecular-targeted therapy with selective ABL-kinase inhibitors (AKI) such as Imatinib, 
Dasatinib or Nilotinib induces complete hematological and cytogenetic remissions in the 
majority of Ph+ leukemia patients (Ramirez and DiPersio, 2008). In advanced disease stages 
relapse frequently occurs and is accompanied by resistance to further treatment with the used 
compound. In the majority of the cases clones harboring point mutations in the ABL-portion 
of the fusion protein which interfere with the binding affinity for the inhibitors are selected 
upon exposure to AKI  (Cowan-Jacob  et al., 2004; Deininger, 2005). The most frequent 
mutations are the “P-loop” mutations Y253F and E255K, the “activation loop” mutation 
H396P, the “catalytic domain” mutation M351T, and the “gatekeeper” mutation T315I (Shah 
et al., 2002). The activity spectrum of actually available AKI covers 14/15 of these mutations. 
The T315I is the only mutation, which confers resistance against virtually all ATP 
competitors  (Druker, 2008). There is increasing evidence that these mutations not only 
interfere with the binding affinity to the kinase inhibitors, but modify biological functions of 
BCR/ABL. The observation that additional factors influence transformation potential of the 
AKI-resistant BCR/ABL T315I mutant was supported by our recent findings on the inhibition 
of tetramerization of BCR/ABL and its AK-resistant mutants. Tetramerization of ABL 
through the N-terminal coiled-coil region (CC) of BCR is essential for the aberrant ABL-
kinase activation. 
Targeting the CC-domain forces BCR/ABL into a monomeric conformation, abolishes its 
transformation potential by interfering with its kinase activity and increases the sensitivity for 
Imatinib  (Beissert  et al., 2008; Beissert  et al., 2003)  showed that factor dependent 
hematopoietic progenitors expressing BCR/ABL harboring the Y253F and E255K but not the 
T315I responded to the inhibition of tetramerization. Together with previous findings these 
results led to the hypothesis that BCR/ABL harboring the T315I mutation exhibits additional 
functions contributing to its leukemogenic potential, which are not present in the unmutated 
BCR/ABL. In fact it has been shown that the BCR/ABL mutants Y253F and E255K exhibited 
increased and the M351T and H396P reduced transformation potential, whereas that of T315I Introduction  31 
 
was assay dependent (Griswold et al., 2006). Interestingly the transformation potential of 
these BCR/ABL mutants is not constantly correlated with the intrinsic ABL-kinase activity.  
1.5.3  Mechanisms of Imatinib resistance 
Although Imatinib produces high rates of complete clinical and cytogenetic responses in the 
chronic phase, resistance, and clinical relapse develops rapidly in Ph+ ALL and in the 
advanced phases of CML (Litzow, 2006; Nimmanapalli and Bhalla, 2002).  
Two broad mechanisms of resistance have been characterized (Litzow, 2006). These include 
1.5.3.1  Imatinib-dependent mechanism 
1-  Mutations in the Abl kinase portion of the BCR/ABL gene affecting drug interaction 
or kinase activity.  
2-  Increased expression of BCR/ABL kinase from genomic amplification. 
1.5.3.2  Non-Imatinib-dependent mechanism 
1- Clonal evolutions involving survival signaling genes: SFKs, and MAP kinases  
2-  Decreased intracellular drug levels which result from, plasma binding by α-1 acid 
glycoprotein or drug efflux from P-glycoprotein (MDR-1) over expression. 
To predict the different mechanisms of Imatinib resistance, human cell lines that are 
BCR/ABL  positive and murine hematopoietic cells that have been transformed with 
BCR/ABL, have been exposed to Imatinib with subsequent development of resistance 
(Griswold et al., 2006). A mouse model has shown that although in vivo tumors were resistant 
to Imatinib, they retained in vitro sensitivity to Imatinib (Gambacorti-Passerini et al., 2000). 
The best studied mechanisms of resistance to Imatinib in patients are gene mutations in the 
Abl (tyrosine kinase) domain of the BCR/ABL gene. The first such mutation was described in 
2001, in which was a substitution of isoleucine (T315I) for threonine on positions 315, in the 
Abl tyrosine kinase domain of the BCR/ABL gene (Gorre et al., 2001). This substitution 
interfered with a critical hydrogen bond that forms between the Abl kinase and Imatinib, 
preventing Imatinib binding to BCR-ABL, and hence conferring resistance to Imatinib in 
vitro. This is a significant mechanism to Imatinib resistance, because the mutation T315I has 
been seen in many patients with Imatinib resistance. 
Some of the mutations in the Abl domain of BCR-ABL that are associated with Imatinib 
resistance. Both Abl and Src shift between an inactive or a closed conformation and a 
catalytically active or open conformation  (Litzow, 2006). It has also been shown that 
Imatinib binds BCR-ABL in an inactive state (Schindler et al., 2000). Mutations conferring Introduction  32 
 
Imatinib resistance fall into two groups; (1) those that change amino acids in direct contact 
with Imatinib, and (2) mutations that prevent BCR/ABL from achieving a conformational 
state that is inactive and required for Imatinib binding. The mutations in the second group will 
increase the ability to induce autophosphorylation, and a growth advantage to Ph+ cells even 
in the absence of Imatinib. Mutations within the P-loop are among the most common (Nardi 
et al., 2004). 
 
Figure 7 -  Proposed mechanisms of action of Imatinib-resistant mutations based upon the crystal 
structure of the Abl kinase domain complexed with Imatinib. Ribbon representation of the Abl kinase 
domain complexed with Imatinib (Nagar et al., 2002) 
Imatinib is depicted in gold. Amino-acid residues implicated in resistance are enumerated. Spheres 1–3 (red) 
represent mutations that directly affect Imatinib binding. All remaining spheres are likely to affect the ability of 
the kinase to adopt the conformation required for binding Imatinib, including those in the P-loop (4–8;green) and 
those in the vicinity of the activation loop (9–13; cyan). The activation loop is colored purple. The positions of 
amino acids are as follows: 1, F317L; 2, T315I; 3, F359; 4, M244; 5, G250; 6, Q252; 7, Y253; 8, E255; 9, 
M351; 10, E355; 11, V379; 12, L387; 13, H396. F311 is not depicted. V379I has been detected in a patient who 
failed to achieve a cytogenetic response, but has thus far not been implicated in acquired resistance to Imatinib.  
 
1.5.4  Strategies to overcome resistance towards kinase inhibitors 
As outlined above, the possibilities to overcome resistance towards a particular kinase 
inhibitor by choosing a second or third inhibitor might finally fail. Therefore, a closer look to 
other critical functions of the BCR/ABL fusion protein itself or to the BCR/ABL activated 
signaling pathways is now undertaken. Strategies under investigation include: the 
tetramerization interface (Beissert et al., 2008; Beissert et al., 2003), targeting the substrate 
binding site, the allosteric site and downstream pathways (for review (Quintas-Cardama et al., 
2007). Introduction  33 
 
Regarding the inhibition of T315I all these approaches show promising effects in preclinical 
trials. As BCR/ABL results in the simultaneous activation of various signaling pathways that 
contribute to the disease phenotype, the selective inhibition of singular downstream targets 
might be clinically disappointing, as it happened in the case of RAS inhibitors (Quintas-
Cardama  et al., 2007; Walz and Sattler, 2006). Therefore targets within the BCR/ABL 
molecule (upstream targets) might be more promising. 
1.5.5  Targeting the tetramerization domain of BCR/ABL 
From the point of view of c-ABL, the structurally most dramatic consequence of the fusion to 
BCR is the enforced tetramerization mediated by the BCR coiled-coil (CC), which leads to 
the constitutive activation of the ABL-TK domain (McWhirter et al., 1993; Tauchi et al., 
1997). The CC domain encompasses the N-terminal 72 amino acids (a.a.) of BCR. It consists 
of a short N-terminal Helix-alpha-1 (a.a. 5-15) followed by a flexible linker (a.a. 16-27) and 
subsequently by the larger Helix-alpha-2 (Helix-2) (a.a. 28-67). The interaction between BCR 
or BCR/ABL monomers is mediated basically by the direct interaction of Helix-2 (Zhao et al., 
2002). The importance of the CC is illustrated by the fact that its deletion reduces the 
BCR/ABL-TK-activity to such an extent that CC-deletion mutants (delta-CC-BCR/ABL) do 
no longer induce an MPD in mice. Delta-CC-BCR/ABL rather induces T-cell leukemia or 
lymphoma with a 5 to 6 fold longer mean latency than the MPD induced by BCR/ABL 
(Zhang et al., 2001). Although Delta-CC-BCR/ABL transduced murine hematopoietic cell 
lines acquire factor-independence the growth rates are greatly reduced (Beissert et al., 2003; 
Zhang  et al., 2001)  and fibroblasts expressing Delta-CC-BCR/ABL are not transformed 
(Beissert et al., 2003; Zhang et al., 2001). 
First indications that a competitive inhibition of the tetramerization is a promising approach 
were revealed in a study showing that the co expression of the first 160 a.a. of BCR (BCR1-
160) reduces the transformation potential of BCR/ABL (Guo et al., 1998). Furthermore it was 
shown that the hetero-oligomerization of BCR/ABL with over expressed BCR inhibits the 
TK-activity of the fusion protein (Lin et al., 2001). Our group has shown that the first 63 a.a. 
(BCR1-63) are sufficient for the hetero-oligomeric inhibition of BCR/ABL (Beissert et al., 
2003). Within the CC, the amino acid (a.a.) residues 5–15 and 28–67 form helices (Helix 
alpha 1 and alpha 2) separated by a flexible loop. The dimer interface is formed by the direct 
interaction of Helices-2 of both monomers, while Helix-1 from one monomer swings back 
and packs against the ‘‘outside’’ of the Helix-2 dimer and interacts with Helix-2 of the other 
monomer (Zhao et al., 2002). Helix-2 deletion leads to impaired oligomerization and reduced Introduction  34 
 
kinase activity (Smith et al., 2003), suggesting a fundamental role of Helix-2 for the biology 
of BCR/ABL. 
1.5.6  Targeting the Coiled coil (CC) enhances the effect of Imatinib 
and inhibits mutant BCR/ABL 
Upon CC deletion BCR/ABL is no longer forming tetramers (McWhirter  et al., 1993). 
Therefore the deletion of the CC could be regarded as an experimental monomerization of 
BCR/ABL. Delta-CC-BCR/ABL monomers show a severely reduced kinase activity (Zhang 
et al., 2001). Imatinib binds to the inactive conformation of the ABL-TK domain (Schindler 
et al., 2000). Accordingly, monomeric delta-CC-BCR/ABL is very sensitive towards Imatinib 
(Beissert et al., 2003). Hetero-oligomers of BCR/ABL and BCR1-63 peptides in a 1:3 ratio 
can be interpreted as BCR/ABL monomers. Consistent with this hypothesis BCR1-63 
significantly increases the sensitivity of BCR/ABL towards Imatinib (Beissert et al., 2003).  
The transformation potential of BCR/ABL is dependent on the ABL-kinase activity ((Lugo et 
al., 1990), which in turn is activated by and dependent on tetramerization (McWhirter et al., 
1993; Zhang et al., 2001). As it is known that Imatinib binds to the inactive conformation of 
the ABL-kinase domain (Schindler  et al., 2000), we hypothesized and proved that the 
experimental monomerization of BCR/ABL through the deletion of the CC-domain leads to a 
dramatic increase of the Imatinib-sensitivity of BCR/ABL(Beissert et al., 2003).  
It has been shown that the hetero-oligomerization of full length BCR or the first 160 a.a. of 
BCR (BCR1-160) with BCR/ABL inhibit the TK-activity and revert the BCR/ABL mediated 
transformation (Guo et al., 1998; Lin et al., 2001). We deduced from these data that the 
formation of hetero-oligomers of BCR/ABL with either BCR or the truncated construct is 
regarding the consequences for the ABL-part of the fusion protein similar to the experimental 
monomerization by CC deletion. Consequently it has been shown by our group that CC-
derived peptides (i.e. BCR1-63) that hetero-oligomerize with BCR/ABL are sufficient to 
inhibit the TK-activity of BCR/ABL and subsequently the transformation potential. 
Furthermore, consistent with the data obtained with the monomeric CC-deletion mutant. CC-
derived peptides increase the sensitivity of BCR/ABL towards Imatinib. It is clear that the 
CC-domain is a suitable target for the inhibition of BCR/ABL and that targeting the 
tetramerization represents a potential therapeutic option for the future (Beissert et al., 2003). 
1.5.7  Allosteric inhibition of BCR/ABL  
The activation status of wild-type c-ABL by autophosphorylation is finely regulated by 
several regulation signals. Myristoylation of the N-terminus of c-ABL is involved in Introduction  35 
 
regulation of the ABL kinase activity. The N-terminus of ABL is myristoylated, and the 
myristate residue binds to a hydrophobic pocket in the kinase domain (Myristoyl binding 
pocket, MBP), a process called “capping” (Hantschel et al., 2003). The “capping” leads to 
conformational changes, that allows the intra-molecular docking of the SH2 domain to the 
kinase domain. Hence, c-ABL takes on an auto-inhibited conformation. The N-terminal auto-
inhibitory ‘Cap’ region is absent in BCR/ABL, and the absence of this ‘Cap’ might allow the 
fusion protein to “escape” auto-inhibition (Hantschel and Superti-Furga, 2004). This lack of 
auto-inhibition mainly contributes to the constitutive activation of BCR/ABL (Hantschel and 
Superti-Furga, 2004). The absence of an N-terminal myristoylated domain activates c-ABL, 
consistent with its auto-regulatory role (Franz et al., 1989). 
In order to discover agents capable of targeting the BCR/ABL kinase via a mechanism 
distinct from ATP competition, an unbiased differential cytotoxicity screen of a combinatorial 
kinase-directed heterocyclic library led to the identification of a new class of BCR/ABL 
inhibitors. One of these compounds, GNF-2, (Figure 8) is a cell-permeable pyrimidine 
compound that binds to MBP and acts as an allosteric, non-ATP-competitive inhibitor of 
BCR/ABL. It possesses exclusive anti-proliferative activity against BCR/ABL-expressing 
factor-independent cells (Adrian et al., 2006). It inhibits BCR/ABL phosphorylation with an 
IC50 of 267 nM, but does not inhibit a panel of 63 other kinases, including native c-Abl, and 
shows complete lack of toxicity towards cells not expressing Bcr-Abl. Unfortunately; GNF-2 
is unable to overcome the resistance of BCR/ABL harboring the T315I mutation (Adrian et 
al., 2006). 
   
 
Figure 8: Structure of GNF-2 
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1.6  Dissertation Hypothesis and Aims 
The major oncogenes of Philadelphia chromosome positive (Ph1) leukemia is the BCR/ABL 
fusion protein. BCR/ABL is characterized by a deregulated and constitutively activated ABL 
tyrosine kinase (TK) activity (Faderl et al., 1999). Multiple downstream signaling pathways 
activated by BCR/ABL including RAS, JAK/STAT, phosphatidylinositol-3-kinase (PI3K) 
and MYC (Deininger et al., 2000; Faderl et al., 1999; Sattler et al., 1996) contribute to the 
transformation potential of BCR/ABL. The expression of BCR/ABL alone is sufficient to 
induce a leukemic phenotype in mice (Huettner et al., 2000; Kelliher et al., 1990). Cellular 
transformation and leukemogenesis are strictly dependent on the TK activity of BCR/ABL 
(Deininger et al., 1997; Druker et al., 1996; Lugo et al., 1990; Weisberg and Griffin, 2000). 
Molecular targeted therapy with the ABL-kinase inhibitor Imatinib Mesylate (Imatinib) 
induces complete hematological and cytogenetic remissions in the majority of Ph+ leukemia 
patients (O'Dwyer et al., 2003). A growing concern is that during advanced disease stages, 
Imatinib-resistant relapse frequently occurs mainly because of point mutations in the ABL-
kinase domain that interfere with the binding affinity of Imatinib (Cowan-Jacob et al., 2004; 
Deininger et al., 2005). 
Recently, we have shown that a peptide, representing the CC (a.a 1-63), interferes  with 
BCR/ABL tetramerization and counteracts the kinase activity and transformation potential of 
BCR/ABL accompanied by an increased sensitivity for Imatinib (Beissert et al., 2003).  
Peptide-based molecular targeting is emerging as an important therapeutic approach for 
treating human cancers (Selivanova et al., 1997). The obvious limitations of using peptides as 
therapeutics are poor permeability and low selectivity. A potential strategy to overcome these 
limitations is the peptide transduction (PT) system, which involves conjugating the peptide of 
interest to a protein transduction domain (PTD), conferring the capacity to pass through the 
cell membrane of living cells (Fawell et al., 1994). An example of a PTD is HIV-TAT, which 
is derived from the human immunodeficiency viral protein TAT, and contains an arginine-
rich sequence of 11 a.a. (Asoh  et al., 2002; Schwarze  et al., 1999).  Rapid receptor-
independent uptake of TAT-conjugated peptides occurs in many cell types and animals (Cao 
et al., 2002; Denicourt and Dowdy, 2003; Sugioka et al., 2003). 
There is increasing evidence that Imatinib-resistant mutations not only interfere with binding 
affinity to the kinase inhibitors, but also modify the biological functions of BCR/ABL. The 
observation that additional factors influence the transformation potential of the AKI-resistant 
BCR/ABL T315I mutant was supported by our recent findings on the inhibition of 
tetramerization of BCR/ABL and its AKI-resistant mutants. Tetramerization of ABL through Introduction  37 
 
the N-terminal coiled-coil region (CC) of BCR is essential for aberrant ABL-kinase 
activation. Targeting the CC-domain forces BCR/ABL into a monomeric conformation, 
abolishes its transformation potential by interfering with its kinase activity, and increases 
sensitivity to Imatinib (Beissert et al., 2008; Beissert et al., 2003). We showed that factor-
dependent hematopoietic progenitors expressing BCR/ABL harboring the Y253F and E255K 
mutations but not the T315I mutation responded to the inhibition of tetramerization. Together 
with previous findings, these results led to the hypothesis that BCR/ABL harboring the T315I 
mutation exhibits additional functions contributing to its leukemogenic potential that are not 
present in the unmutated BCR/ABL. 
Myristoylation of the N-terminus of c-ABL is involved in regulation of the ABL kinase 
activity. The N-terminus of ABL is myristoylated, and the myristate residue binds to a 
hydrophobic pocket in the kinase domain (Myristoyl binding pocket, MBP), a process called 
“capping” (Hantschel et al., 2003; Hantschel and Superti-Furga, 2004). The “capping” leads 
to conformational changes that allow the intra-molecular docking of the SH2 domain to the 
kinase domain. Hence, c-ABL takes on an auto-inhibited conformation. The N-terminal auto-
inhibitory 'Cap' region is absent in BCR/ABL, and the absence of this 'Cap' might allow the 
fusion protein to “escape” auto-inhibition (Hantschel and Superti-Furga, 2004). This lack of 
auto-inhibition mainly contributes to the constitutive activation of BCR/ABL (Hantschel and 
Superti-Furga, 2004).  The absence of an N-terminal myristoylated domain activates c-ABL, 
consistent with its auto-regulatory role (Franz et al., 1989). 
GNF-2 is a cell-permeable pyrimidine compound that binds to MBP and acts as an allosteric, 
non-ATP-competitive inhibitor of BCR/ABL. It possesses exclusive anti-proliferative activity 
against BCR/ABL-expressing factor-independent cells (Adrian et al., 2006) . Unfortunately, 
GNF-2 is unable to overcome the resistance of BCR/ABL harboring the T315I mutation 
(Adrian et al., 2006). 
 
The aims of the study: 
1-  To further develop the CC targeting peptide for effective inhibition 
 
2-  To determine how the inhibition of oligomerization interferes with the transformation   
potential of BCR/ABL and its Imatinib-resistant mutants. 
 
3-    To develop a novel cell based in vivo peptides delivery system 
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4-  To investigate that why inhibition of oligomerization is ineffective in the case of cells  
expressing the BCR/ABL-T315I mutant. 
 
5-  To find Whether T315I confers additional features to the leukemogenic activities of  
BCR/ABL. 
 
6-  To investigated whether it is possible to overcome the resistance of the BCR/ABL-
T315I mutant against molecular therapeutic approaches by combining the allosteric 
inhibition of GNF-2 with  the competitive peptide Helix-2 to inhibit BCR/ABL 
oligomerization. 
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2  Materials   
2.1  Instruments and apparatus 
3MM Whatman paper    Whatman, Dassel, Germany 
Autoclave    Integra Biosciences, Baar, Switzland 
Benchtop gyroory incubator        New Brunswick Scientific, Edison 
 shaker for bacterium         N.J. USA         
Bacteria incubator          Heraeus, Hanau, Germany 
Bandelin Sonopuls HD 2070       South Yorkshire, England 
Cell culture flasks/dishes        Greiner, Heidelberg, Germany 
Cell culture incubator         Heraeus, Hanau, Germany 
CELL locate glass cover slips with grids,    Eppendorf, Hamburg, Germany 
- Grid size 55 μm 
Cell scraper            Corning, Wiesbaden, Germany 
Cell strainer (40μm)          Becton Dickinson, Heidelberg, Germany 
FACS (Fluorescence-activated cell sorting)   FACScan, Beckton Dickinson, Heidelberg 
Centrifuge 
Cytocentrifuge          Thermo Shandon, Pittsburgh, USA 
Rotina 48 RS Table top centrifuge      Hettich, Tuttlingen, Germany 
-Sorvall RC- 5B refrigerated superspeed 
centifuge and Biofuge 13R        Heraeus, Hanau, Germany 
Table top centrifuge 5415C        Eppendorf, Hamburg, Germany 
Megafuge 1.0 with Rotor BS4402/A     Heraeus, Hanau, Germany 
Chemiluminescence detection 
-Film BioMax           Eastman-Kodak, Rochester, USA 
Corning 125 pH meter        Fisher Scientific, Shwerte, Germany 
Cryotubes            Nalgene, Rochester, NY , USA 
Cytofunnel            Shandon, Pittsburgh, USA 
Electroporation: 
Gene Pulser System with electroporation    Bio-Rad Laboratories, Munich, Germany 
Cuvette 0.4 cm           
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-Circular parallel plate  GlycoTech, Maryland, U.S.A 
Gel electrophoresis system 
-DNA-sub cell and Mini-Sub cell System    Gibco, Betheseida, USA 
 
Power PAC 2000          BioRad, Munich, Germany 
Irradiation of mice 
-Betatron 500A          Siemens, Munich, Germany 
Lumat LB 9507          Berthold, Bad Wildbad, Germany 
Magnetic cell separation 
-MiniMACS separator        Miltenyi, Bergisch Gladbach, Germany 
-MidiMACS separator        Miltenyi, Bergisch Gladbach, Germany 
-MACS separation columns: LD and LS    Miltenyi, Bergisch Gladbach, Germany 
Microscope 
-SZ40 Zoom Stereo Microscope      Olympus, Munich, Germany 
Axioplan II-imaging Fluorescence microscope  Zeiss, Goettingen, Germany 
Leitz Labovert inverted Microscope     Leitz, Wetzlar, Germany 
Zeiss ID03 inverted microscope      Zeiss, Goettingen, Germany 
Nitrocellulose membrane (0.45 μm)     Bio-Rad Laboratories, Munich, Germany 
PCR 
-Techne TC-312          Kisker , Steinfurt, Germany 
Protein transfer 
-Trans-Blot SD Semi-dry Transfer cell    BioRad, Munich, Germany 
Spectrohotometer 
-Gene Quant II          Pharmacia Biotech, Freiburg, 
-Ultraspec® 2000          Germany 
Steril bank            Heraeus, Hanau, Germany 
Steril filter 
-0.22μM            Millipore, Eschborn, Germany 
-0.45μM            Millipore, Eschborn, Germany 
Vortex             Eppendorf, Hamburg, Germany 
Water bath            Julabo Labortechnik, Seelbach, Germany 
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2.2  Chemicals 
Acetic acid glacia     Sigma, Steinheim, Germany 
Acetone     Roth, Karlsruhe, Germany 
Ammonium persulfate        Fluky, Deisenhofen, Germany 
Ampicillin            Sigma, Steinheim, Germany 
Anti-Sca-1 Microbeads        Miltenyi, Bergisch Gladbach, Germany 
Biorad protein dye          Biorad, Munich, Germany 
Borax              Sigma, Steinheim, Germany 
BrdU     Sigma, Steinheim, Germany 
β-Mercaptoethanol       Fluka , Deisenhofen, Germany 
Bromophenol blue          Sigma, Steinheim, Germany 
Calcium chloride          Sigma, Steinheim, Germany 
Chlorofor     Fluka , Deisenhofen, Germany 
Cumaric acid            Sigma, Steinheim, Germany 
ddH2O             Sigma, Steinheim, Germany 
DEPC     Sigma, Steinheim, Germany 
DMSO             Sigma, Steinheim, Germany 
EDTA, disodium, dihydrate        Sigma, Steinheim, Germany 
Ethanol            Merck, Darmstadt, Germany 
Ethidiumbromid          Sigma, Steinheim, Germany 
Formaldehyd            Merck, Darmstadt, Germany 
Forene (Isofluran)          Abbott GmbH, Wiesbaden, Germany 
Glucose            Sigma, Steinheim, Germany 
Glutathione sepharose
TM  Amersham/Pharmacia  Biotech, Freiburg, 
Germany 
Glycerol            Sigma, Steinheim, Germany 
Glycin             Merck, Darmstadt, Germany 
Isopropylthio-β-D-Galactoside (IPTG)    Sigma, Steinheim, Germany 
HCL              Merck, Darmstadt, Germany 
Isobutanol            Sigma, Steinheim, Germany 
Isopropanol            Fluka , Deisenhofen, Germany 
Kanamycin            Sigma, Steinheim, Germany 
Lineage cell depletion kit        Miltenyi, Bergisch Gladbach, Germany 
Luminol            Fluka , Deisenhofen, Germany Materials  42 
 
Methanol            Merck, Darmstadt, Germany 
Methylenbla   Sigma, Steinheim, Germany 
MgSO4            Fluka , Deisenhofen, Germany 
NaN3              Sigma, Steinheim, Germany 
NaCl              Merck, Darmstadt, Germany 
NaH2PO4            Sigma, Steinheim, Germany 
NaOH             Roth GmbH, Karlsruhe, Germany 
Natriumacetat      Fluka , Deisenhofen, Germany 
Paraformaldehyd          Merck, Darmstadt, Germany 
p-Coumaric acid          Sigma, Steinheim, Germany 
PD-10 columns  Amersham/Pharmacia Biotec, Freiburg, 
Germany 
Phenol             Fluka , Deisenhofen, Germany 
PKH26 Red fluorescence kit       Sigma, Steinheim, Germany 
Polybrene            Sigma, Steinheim, Germany 
Ponceau S            Sigma, Steinheim, Germany 
Propedium iodide          Sigma, Steinheim, Germany 
Protease-inhibitors           Roche Basel, Switzerland 
Pre-stained SDS-PAGE standards 
-Broad range            Bio-Rad Laboratories, Munich, Germany 
Retronectin
®             Takara Bio Inc., Otsu, Japan 
Sca-1 Isolation Kit          Miltenyi, Bergisch Gladbach, Germany 
SDS              Sigma, Steinheim, Germany 
STREPtactin sepharose
TM        IBA, Goettingen, Germany 
Protein elution buffer         IBA, Goettingen, Germany 
TEMED            Sigma, Steinheim, Germany 
Tritriplex III, 1,1%            University teaching hospital Frankfurt 
Trizma HCl            Sigma, Steinheim, Germany 
Triton X-100            Sigma, Steinheim, Germany 
Tween20            Sigma, Steinheim, Germany 
Vivapore (For concentrating protein)    VivaScience, Stonehouse, UK 
Xylencyanol            Sigma, Steinheim, Germany Materials  43 
 
2.3  Special reagents and materials 
2.3.1  Cell culture medium and reagents 
7-aminoactinomycin D (7-AAD)      Sigma, Steinheim, Germany 
BSA, V solution          Sigma, Steinheim, Germany 
Chloroquine            Sigma, Steinheim, Germany 
DMEM, -High glucose (4.5g/l)      Invitrogen, Karlsruhe, Germany 
DMSO             Sigma, Steinheim, Germany 
FBS              Gibco BRL, Paisley, Schottland 
Ficoll separating solution        Biochrom (# L-6115), Berlin, Germany 
Gelatin              Sigma, Steinheim, Germany 
GNF-2             Sigma, Steinheim, Germany 
HBSS             Gibco, Karlsruhe, Germany 
HEPES solution          Gibco, Karlsruhe, Germany 
Horse serum            Gibco, Karlsruhe, Germany 
Imatinib            Novartis, Basel Switzerland 
IMD              Gibco, Karlsruhe, Germany 
L-Glutamine            Gibco, Karlsruhe, Germany 
Methoculttm GF M3434  StemCell Technologies, Vancouver, 
Canada 
Mycosa            Gibco, Karlsruhe, Germany     
PBS              Gibco, Karlsruhe, Germany 
Penicillin-Streptomycin solution      Gibco, Karlsruhe, Germany 
Retinoic acid            Sigma, Steinheim, Germany 
Retronectin            Takara, Shiga, Japan 
RPMI 1640            Gibco, Karlsruhe, Germany 
Trypan blue stain (0.4%)        Gibco, Karlsruhe, Germany 
Trypsin EDTA, 0.25% solution      Gibco, Karlsruhe, Germany 
2.3.2  Chemokines and cytokines 
rmG-CSF            Peprotech, Offenbach, Germany 
rmSCF             Peprotech, Offenbach, Germany 
rmIL-6             Peprotech, Offenbach, Germany 
rmIL-3             Peprotech, Offenbach, Germany 
rmGM-CSF            Peprotech, Offenbach, Germany Materials  44 
 
2.3.3  Enzymes 
Calf intestinal phosphatase (CIP)   NEB, Frankfurt, Germany                                    
Gateway LR clonase enzyme mix      Invitrogen, Karslruhe, Germany 
Klenow-Fragment DNA-polymerase I   NEB, Frankfurt, Germany             
Restriction endonucleases  NEB, Frankfurt, Germany           
RNAse              Sigma, Steinheim, Germany 
Superscript II           Invitrogen, Karlsruhe, Germany 
T4 DNA-ligase    NEB, Frankfurt, Germany 
Taq-DNA-polymerase      Biosystems, Weiterstadt, Germany 
Proteinase K       Stratagene, La Jolla, USA 
2.3.4  Polymerase Chain Reaction (PCR) 
Taq-DNA-polymerase        Biosystems, Weiterstadt, Germany 
DNTPs            Fermentas, St. Leon-Rot, Germany 
PCR Buffer            Fermentas, St. Leon-Rot, Germany 
MgCl2             Fermentas, St. Leon-Rot, Germany 
PfU turbo polymerase          Stratagene, La Jolla, USA 
 Primers            Sigma, Steinheim, Germany      
2.3.5  Antibodies 
2.3.5.1    Primary antibodies used for western blotting 
Mouse anti-β  tubulin (Ab-4)        Neo Markers, Asbach, Germany 
Mouse lineage panel          Pharmingen, San Diego, CA, USA 
Rabbit anti-c-ABL (11/24)      Santa Cruz, Heidelberg, Germany 
Rabbit anti-p-ABL-Tyr-245    Upstate-Biotechnology, Lake Placid, NY, 
USA 
Rabbit anti-p-ABL-Tyr-412    Cell Signalling, Boston, USA 
Rabbit anti-p-BCR-Tyr-177    Cell Signalling, Boston, USA 
Rabbit anti-BCR(C-20)        Santa Cruz, Heidelberg, Germany 
Mouse anti- GFP   Upstate-Biotechnology, Lake Placid, NY, 
USA 
Mouse anti-phospho-STAT5       Cell Signalling, Boston, USA 
Rabbit anti -STAT5          Cell Signalling, Boston, USA 
Rabbit anti-phospho-CrkL (Tyr207)     Cell Signalling, Boston, USA Materials  45 
 
Mouse anti-CrkL    Cell Signalling, Boston, USA 
Mouse anti-phosphotyrosine (clone 4G10)    Upstate-Biotechnology, Lake Placid, NY, 
USA 
2.3.5.2  Secondary antibodies 
Anti-mouse IgG-HRP          Santa Cruz, Heidelberg, Germany 
Anti-rabbit IgG-HRP         Santa Cruz, Heidelberg, Germany 
2.3.5.3  FACS antibodies 
Mouse-anti-human-PE-LNGFR      BD, San Jose, CA, USA 
Rat-anti- mouse-PE-Gr-1        BD, San Jose, CA, USA 
Rat-anti- mouse-PE-Mac-1        BD, San Jose, CA, USA 
Rat-anti- mouse-PE-B220        BD, San Jose, CA, USA 
Mouse-anti-PE-IgG 2a, K        BD, San Jose, CA, USA 
Mouse-anti-PE-IgG 2b, K        BD, San Jose, CA, USA 
Rat –anti-Mouse FITC-Sca-1       BD, San Jose, CA, USA 
Rat-anti- mouse-PE-Sca-1        BD, San Jose, CA, USA 
2.3.6  Buffers 
MACS buffer 
20% (w/v) BSA      12.5 ml 
EDTA         1mmol 
Penicillin/Streptomycin    5ml 
Add PBS up to       500ml 
2M CaCl2 solution 
The component was dissolved in ddH2O and sterile filtered with 0.22 μm filter and stored at -
20°C in aliquots until use. 
2X HBS solution 
Na2HPO4        0.315g (1.5 mM final) 
HEPES        19.5g (0.05M final) 
NaC          24g (0.28M final) 
Water added up to 1200ml, three clean bottles were filled with exactly 400 ml of the solution, 
the pH to 6,95/ 7,0 / 7,05 was adjusted respectively, each bottle was filled to 500 ml, pH was 
controlled again. The buffer was filter-sterilized and stored at -20°C in aliquots. Materials  46 
 
1x TAE Electrophoresis buffer 
Tris-Acetate        0,04M 
EDTA            1 mM 
Buffer W for lysis of bacteria 
Tris-HCl pH 8.0       100 mM 
NaCl           150 mM  
EDTA          1 mM  
Tween         0.1%  
Protease inhibitor      1x 
1X SDS gel-loading buffer 
Tris-HCl, pH 6.8       50mM 
SDS          2 % (w/v) 
Glycerol        10% (v/v) 
β-mercaptoethanol      100mM 
Bromophenol blue      0.1 %( v/v) 
1X SDS gel-loading buffer lacking dithiothretitol was stored at room temperature. β-
mercaptoethanol from a 14 M stock was added just before the buffer is used. 
For protein electrophoresis   (Invitrogen life technologies, Germany)  
NuPAGE Novex Bis-Tris       
Tris-Acetate Pre-Cast Gels 
NuPAGE Novex MES and Tris-Acetate SDS Running Buffers 
NuPAGE Transfer Buffer  
Precision plus protein (PPP) 
NuPAGE LSD Sample Buffer 
NuPAGE Reducing Agent 
NuPAGE Antioxidant 
10X TBS 
Trizma HCl, pH 7.5      24.23 g 
NaCl          80.06 g 
Above materials were mixed in 800 ml water, and pH was adjusted to 7.6 with pure HCL. The 
volume was adjusted to 1 L with wate. 
TBST 
1X TBS+ 0.05% Tween 20 
Blocking Buffer for immunoblot Materials  47 
 
5% Carnation non-fat dry milk in TBST 
Protein transfer buffer 
TrisHCl        48 mM 
Glycine        39 mM 
SDS          0,038 % (w/v) 
Methanol        20 % (v/v) 
Coomassie staining solution 
Coomassie brilliant blue R250   0.1 % (w/v) 
Methanol        50 % (v/v) 
Glacial acetic acid      10 % (v/v) 
Coomassie destaining Solution 
Methanol        50 % (v/v) 
Glacial acetic acid      10 % (v/v) 
Ponceau S staining solution 
Ponceau S        2 % (w/v) 
Trichloroacetic acid      30 % (v/v) 
Sulfosalicylic acid.      30 % (v/v) 
ECLsolution I: 
1 M TrisHCl, pH 8,5      10ml 
90mM p-Coumaric acid (in DMSO) 0.44ml 
250mM Luminol (in DMSO)      1ml 
Water was dded up to 100ml; aliquots were made and stored in the dark at -20°C. 
ECLsolution II: 
30 % H2O2        64μl 
1 M TrisHCl, pH 8,5      10 ml 
Water was added up to 100ml, aliquat solution and store in the dark at -20°C. 
Stripping buffer 
Tris-HCl, pH8.0      62.5 mM 
2-mercaproethanol      100 mM 
SDS          2 % (w/v) 
FACS Wash Buffer 
PBS + 1%FCS + 1% NaN3 
FACS Fixative Solution 
PBS + 2% formaldehyde solution Materials  48 
 
Phosphate-Buffered Saline (PBS) 
NaCl          137 mM 
KCl          2.7 mM 
Na2HPO4        10 mM 
KH2PO4  2 mM 
The above components were dissoolved in water and adjusted pH to 7.4 with HCl. 
Tris-HCl (1M) 
121.1g of Tris base was dissolved in 800ml of water. The pH was adjusted to the desired 
value by adding concentrated HCl as follows: 
pH          HCl 
7.4          70 ml     
7.6          60 ml 
8.0          42 ml 
The solution was allowed to cool to room temperature before making final adjustments to the 
pH. The volume of the solution was adjusted to 1 liter with water. 
10X Tris EDTA (TE) 
pH 7.4         100 mM Tris-Cl (pH 7.4) 
           10 mM EDTA (pH 8.0) 
pH 7.6 
           100 mM Tris-Cl (pH 7.6) 
           10 mM EDTA (pH 8.0) 
pH 8.0 
           100 mM Tris-Cl (pH 8.0) 
           10 mM EDTA (pH 8.0) 
SDS (20% w/v) 
200 g of electrophoresis-grade SDS was dissolved in 900 ml of water. The mixture was 
heated to 68°C and stirred with a magnetic stirrer to assist dissolution. The pH was adjusted to 
7.2 by adding a few drops of concentrated HCl. The volume was adjusted to 1 liter with 
water. 
EDTA (0.5 M, pH 8.0) 
186.1 g of disodium EDTA was added to 800 ml of H2O. The mixture was stired vigorously 
on a magnetic stirrer. The pH was adjusted to 8.0 with NaOH. The disodium salt of EDTA did 
not go into solution until the pH of the solution was adjusted to ～ 8.0 by the addition of 
NaOH. Materials  49 
 
 
Solutions for plasmid minipreparation 
Resuspension solution (Sol I) 
Glucose          50 mM 
Tris-HCl pH 8.0        25 mM 
EDTA pH 8.0         10 mM 
Autoclaved and stored the solution at 4°C 
Alkaline lysis solution (Sol II) 
NaOH           0.2 M 
SDS            1 % (w/v) 
Sol II was prepared fresh and used at room temperature 
Neutralization solution (Sol III) 
5 M Potassium acetate      60 ml 
Glacial acetic acid        11.5 ml 
ddH2O 28.5 ml 
The solution was stored at 4°C and transferred to ice before use 
0.1% Diethylpyrocarbonate (DEPC) 
1 g DEPC was dissolved in 1 L water and mixed it vigiously. It let stand with loose lid 
overnight at room temperature or at 37°C for 1h and autoclaved for 15 minutes at 15 psi on 
liquid cycle. DEPC cannot be used to treat Tris buffer. 
2.3.7  Plasmids and vectors 
pCDNA 3.1 vector  Invitrogen GmbH, Karlsruhe, Germany 
pEntr1A  Invitrogen GmbH, Karlsruhe, Germany 
PINCO  Retroviral hybrid vector with LTR derived from Moloney 
murine Leukemia virus. The main characteristics of  this vector 
is the presence of the EBV origin of replication  and the EBNA-
1 gene and the presence of the cDNAs that  encodes for the 
EGFP, controlled by a cytomegalovirus promoter.This vector 
allows high-efficiency gene transfer  (Grignani et al., 1998). 
PAULO  This vector is a modified pinco vector in which GFP is replaced 
by LNGFR 
PIDE  This vector is based on pinco vector in which GFP is deleted and 
Hind III site can be used for cloning gene instead of GFP 
Pinco∆CMV  Retroviral pinco based vector without any reporter gene Materials  50 
 
pPRIBA2    IBA, Gottingen , Germany 
pGEX4T3    Amersham Biosciences, Freiburg, Germany 
2.3.8  Bacterial E.Coli Strain and genotype 
E. coli – HB101, BL21, JM83, DB 3.1,  Invitrogen, Karlsruhe, Germany 
2.3.9  Medium for bacterium 
LB medium 
Bacto-Tryptone      1 % (w/v) 
Bacto-Yeast-Extrac      0.5 % (w/v) 
NaCl          1.5 % (w/v) 
Adjuted pH to 7.4 with NaOH and autoclaved 
 
LB agar plates 
Bacto-Agar        1.5 % (w/v) 
 
Bacterium freezing solution 
Glycerin        65 % (v/v) 
MgSO4        0.1 M 
TrisHCl, pH 8.0      0.025M 
SOC  Invitrogen, Karlsruhe, Germany 
2.3.10  Cell lines 
2.3.10.1 Ph+ cells 
CML blast cell lines 
In CML cells, the translocation product encodes for p210
BCR/ABL. 
BV173: Human B cell precursor leukaemia cell line, established from the peripheral blood of 
a patient with chronic myeloid leukaemia (CML) in lymphoid blast crisis. Contains the t(9;22) 
b2-a2 fusion gene. Obtained from DSMZ, Germany 
K562: Established from the pleural effusion of a patient with chronic myeloid leukaemia 
(CML) in myeloid blast crisis. Cells carry the Ph chromosome with the Bcr-Abl b3-a2 fusion 
gene. Obtained from DSMZ, Germany 
Ph+ ALL 
In Ph+ cells, the translocation product encodes for p185
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Sup-B15: Human B cell precursor leukemia cell line, established from the bone marrow of a          
patient with acute lymphoblastic leukemia, carrying the ALL-variant (m-bcr) of the 
BCR/ABL fusion gene (e1-a2). Obtained from DSMZ, Germany 
Tom-1: human B cell precursor leukemia. Established from the bone marrow of a patient with 
refractory Ph chromosome acute lymphoblastic leukemia (ALL); described to carry the ALL-
variant (m-BCR) of the BCR/ABL fusion gene (e1-a2) obtained from DSMZ, Germany. 
2.3.10.2 Other Cell lines 
Nalm-6: Human lymphoblastic B cell line; Ph- 
Ba/F3: IL-3 dependent murine pro B cell line established from peripheral blood; apparently 
derived from BALB/c mouse. 
32D: IL-3 dependent murine myeloid cell line established from peripheral blood. 
Rat-1: Rat fibroblast cells line 
293T: Transformed human embryonal kidney cell line 
Phoenix: Based on the 293T cell line (transformed human embryonal kidney cell line). 
Expresses the retroviral structural genes gag, pol und env. It is also known as a packaging cell 
line. The ecotropic packaging cell line delivers genes only to dividing murine or rat cells. 
All cells were obtained from the “Deutsche Sammlung von Mikroorganismen und 
Zellkulturen GmbH” (DSMZ) (German Collection of Microorganisms and Cell Cultures), 
with the exception of the ecotrophic Phoenix cells which were obtained from Nolan lab, 
Standford, USA. 
2.3.11  Medium for Cell culture 
L-glutamine        1 % (v/v) 
FBS          10 % (v/v) 
Penicillin/Streptomycin    1 % (v/v) 
Added to DMEM and RPMI medium for adherent and suspension cells respectively 
Medium for 32D/Baf3 cells 
L-glutamine        1 % (v/v) 
FBS          10 % (v/v) 
Penicillin/Streptomycin    1 % (v/v) 
mIL-3         10 ng /ml 
Added the above to RPMI medium 
Medium for Nalm-6, BV-173 and K562 
L-glutamine        1 % (v/v) Materials  52 
 
FBS          10 % (v/v) 
Penicillin/Streptomycin    1 % (v/v 
Added the above to RPMI medium 
Medium for Tom-1 
L-glutamine        1 % (v/v) 
FBS          20 % (v/v) 
Penicillin/Streptomycin    1 % (v/v 
Added the above to RPMI medium 
Medium for Sup-B15 
L-glutamine        1 % (v/v) 
FBS          20 % (v/v) 
Penicillin/Streptomycin    1 % (v/v 
Added the above to Mycosa medium  
Medium for Sca1+/lin- mouse BM cells 
L-glutamine        1 % (v/v) 
FBS(Hyclon)        10 % (v/v) 
Penicillin/Streptomycin    1 % (v/v) 
mIL-3         20 ng /ml 
mIL-6         20 ng /ml 
mSCF         100 ng /ml 
Added the above to ISCOVE medium 
Cell freezing medium 
Solution I 
RPMI/DMEM       70 % (v/v) 
FBS          30 % (v/v) 
Solution II 
RPMI/DMEM       80 % (v/v) 
DMSO         20 % (v/v) 
2.3.12  Materials for animal experiments 
2.3.12.1 Mice 
The C57BL/6N mice (age between 6-8 weeks, all female) were purchased from Charles River 
Laboratories GmbH in Munich, Germany and served as the recipient mice for all the animal 
experiments. Materials  53 
 
2.4  Miscellaneous 
Nucleospin
R Mini plasmid DNA isolation Kit  Macherey-Nagel, Dueren Germany   
Nucleospin
R Maxi plasmid isolation kit     Macherey-Nagel, Dueren Germany 
Gel cleaning kit          Macherey-Nagel, Dueren Germany 
PCR cleaning kit          Macherey-Nagel, Dueren Germany 
Qiagen gel extraction Kit        Qiagen, Duesseldorf, Germany 
Qiagen Plasmid kit Mini, Midi and Maxi    Qiagen, Duesseldorf, Germany 
Qiagen PCR purification Kit       Qiagen, Duesseldorf, Germany 
Quick change site mutagenesis kit      Stratagene, La Jolla, USA  
Endo Toxin removal kit        Profos AG, Regensburg, Germany 
Cell proliferation (XTT) kit    Amersham/Pharmacia Biotech, Freiburg, 
Germany 
Protein concentrator (Vivapore)  VivaScience, Hannover, Germany   Methods  54 
 
3  Methods 
3.1  Preparation of plasmid DNA 
3.1.1  Transformation of E.coli 
A frozen vial of competent E.coli bacteria was thawed on ice. The transforming DNA (up to 
25ng per 50ul competent bacterium or 10ul ligation product) was pipetted directly to 
competent E.coli bacteria and mixed by swirling the tubes gently several time. Bacteria were 
left on ice for 30 minutes and then exposed to 42°C heat shock for exactly 2 minutes. The vial 
was removed from 42°C immediately and put on ice for 2min, 500μl of SOC  medium 
(without antibiotic) was added and the tube was transferred to a shaking incubator set at 37°C. 
The culture was incubated for 45min to allow the bacterium to recover and express antibiotic 
resistant marker encoded by plasmid. 1/10 of the transformed cells were spread on a LB agar 
plate containing antibiotics. The plate was incubated for 16 hours at 37°C and individual 
colonies were identified. 
3.1.2  Bacterium growth in liquid media 
3.1.2.1  Growing an overnight culture 
To make an overnight saturated culture of E. coli, inoculate 2ml liquid LB medium containing 
antibiotics with a single colony quickly to minimize contact of the tube with the possibly 
contaminated air. Grow the culture at 37°C with vigorous agitation (～220 rpm) until the 
culture is freshly saturated which normally takes at least 6 hours. 
3.1.2.2  Growing larger cultures 
Larger cultures are generally inoculated with overnight cultures diluted 1:100. Use an 
Erlenmeyer or baffle flask whose volume is at least 5 times the volume of the culture. Grow 
the culture at 37°C with vigorous agitation (～300 rpm) to ensure proper aeration. 
3.1.3  Miniprep: a small scale preparation of plasmid DNA 
Mini preparation of the plasmids was performed with Nucleobond® AX Mini preparation kit 
according to the manufacturer’s instructions. The Nucleobond® AX Miniprep procedure are 
based on a modified alkaline lyses  procedure, followed by binding of plasmid DNA to 
Nucleobond Anion-Exchange Resin under appropriate salt concentrations and pH conditions. Methods  55 
 
3.1.4  Maxi prep: a large scale preparation of plasmid DNA 
Maxi preparation of the plasmids was performed with Nucleobond® AX Maxi preparation kit 
according to the manufacturer’s instructions. The Nucleobond® AX Maxiprep procedure are 
based on a modified alkaline lysis procedure, followed by binding of plasmid DNA to 
Nucleobond Anion-Exchange Resin under appropriate salt concentrations and pH conditions. 
3.1.5  Determining of DNA yield and quality 
Plasmid yield is measured by UV spectroscopy using the following relationship:1 OD at 260 
nm (1 cm path length) is equivalent to 50 μg plasmid DNA/ml. Plasmid quality is checked 
initially by running a 1% agarose gel. This will give information on percentage of super 
coiled form of isolated plasmid DNA.Plasmid quality is further checked by UV spectroscopy 
(quotient 260 nm/ 280 nm). A ratio of 1.80-1.90 is an indication for pure plasmid DNA. 
3.1.6  Enzymatic Modification of Nucleotide Acids 
3.1.6.1  Restriction digestion of Plasmid DNA 
The restriction endonucleases used for restriction of plasmid DNA belong to the type II 
endonucleases, which can recognize short DNA sequences and cleave double stranded DNA 
at specific sites. Thereby either blunt ends or sticky ends can be obtained. Restriction 
endonuclease cleavage is accomplished simply by incubating the enzymes with DNA in the 
appropriate reaction conditions. 0.5 μg – 1 μg plasmid-DNA was used for one restriction 
reaction. The DNA was incubated together with 5-fold excess of enzyme (5-10U enzyme/μg 
DNA) and appropriate restriction buffer for 1-2 hours at 37° C. 
3.1.6.2 Dephosphorylation of Linear Plasmid-DNA by Alkaline Phosphatase CIP (Calf 
Intestinal Phosphatase) 
This method was used to decrease self-ligation of the cut plasmid DNA. The CIP-treated 
fragments lack the 5’ phosphoryl-termini, which are required by ligases for proper ligation. 
The reaction was performed by incubating cut plasmid DNA with CIP-buffer and 1 μl (0.5 
U/μg vector) CIP at 37° C for 1 hour. The following phenol-chloroform extraction or gel 
extraction was performed to purify the DNA fragments. 
3.1.6.3  Fill-in of 5’-Overhangs to form blunt ends by Klenow-Reaction 
The 5’overhang of DNA ends were filled up by Klenow-fragment, a large subunit of the DNA 
polymerase I of E. coli. The enzyme is active in all the NEB buffers and was incubated with 
the restricted DNA (1 U/μg DNA) and dNTPs for 15 minutes at 25° C. The enzyme activity Methods  56 
 
was stopped by adding EDTA to a final concentration of 10 mM and heating at 75° C for 20 
minutes. 
3.1.6.4  Ligation of DNA Fragments 
DNA fragments and vector were ligated with T4 DNA ligase. T4 DNA ligase catalyses the 
formation of a phosphor-diester bonds between juxtaposed 5’ phosphate and 3’ hydroxyl 
termini in duplex DNA. 15 μl reaction was done with 25-50 ng vector, 3-5 fold molar excess 
of insert, 1.5 μl 10x ligase buffer and 1 U T4 DNA ligase overnight at 16°C and 7,5 μl of the 
reaction was used for the transformation with chemically competent E.Coli .To control for the 
self-ligation an additionally vector-only ligation reaction was included. 
3.1.6.5  Quick change site-directed mutagenesis  
The in vitro site-directed mutagenesis protocol used is a modification of Stratagene’s Quick-
change site-directed mutagenesis Kit protocol. This technique  was  used for vector 
modifications. With this technique, point mutations were introduced. The mutagenic 
polymerase chain reactions were performed using PfuTurbo DNA polymerase. 
3.1.6.6  Recombination („gateway LR clonase enzyme kit“from Invitrogen) 
This technique is based on the recombination reactions of the bacteriophage λ vector and 
makes use of a special Enzyme Mix (Integrase and Excisionase of the bacteriophage λ; and 
Integration Host Factor from E. coli). The Gateway cloning mechanism includes a BP 
Reaction (PCR fragment (contains attB sites) + Donor vector (contains attP sites) = Entry 
Clone (gene of interest flanked by attL sites), followed by an LR reaction (Entry Clone ,gene 
of interest flanked by attL sites) + Destination Vector (contains attR sites) = Expression 
Clone). Sequences known as attachment sites (att sites) are the points were excision and 
integration occurs.  
The recombination reaction generates two molecules. One molecule contains the DNA 
segment of interest, the other molecule is a by-product. 
The Recombination reactions are carried out with the Gateway LR-clonase enzyme kit 
(Invitrogen, Karslruhe, Germany). 4 µl  of LR-reaction buffer was pipetted (composition not 
mentioned by manufacturer), 300 ng Entry clone DNA (pEp185
BCR/ABL or mutant plasmids), 
300 ng Destination vector DNA (PINCO) and made up to 16µl with TE-buffer (10 mM Tris-
HCl, pH7,4; 1 mM EDTA, pH8,0), mixed by pipetting.4 µl LR-Clonase Enzyme Mix was 
added, mixe and incubated for 1 hour at room temperature. Finally, E. coli HB101 competent 
cells were transformed using 4µl of the reaction mixture and plasmid DNA was prepared for 
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3.1.6.7  Cloning of Gateway Destination vector 
For the recombination reaction, the pinco, paulo, PIDE, pPRIBA2 or pGEX4T3 vectors were 
converted into a Destination vector using the gateway reading frame cassettes i.e. RFA, RFB 
or RFC (Invitrogen, Karlsruhe, Germany). 
3.1.7  Electrophoretic separation of DNA 
DNA was separated electrophoretically on agarose gels for the following reasons: to control 
the progression of a restriction enzyme digestion, determine the yield and purity of the DNA 
preparation, check the products of the PCR reaction, or purify the DNA fragments. 
Concentration of agarose gels ranged from 0.5% to 3%, depending on the size of a desired 
fragment. Agarose was mixed with 1X TAE buffer and heated in a microwave until 
completely dissolved. This solution was cooled down to 50°C, added ethidium bromide to a 
final concentration of 1 μg/ml, and poured into a gel tray. Samples were mixed with 6X DNA 
loading buffer and electrophoresis was carried out in 1X TAE buffer at 5 V/cm. Following 
electrophoresis, gel was exposed to UV light (λ=320nm) to visualize the ethidium bromide-
stained DNA fragments, and fragment length determined by comparing to DNA marker 
(Sambrook and Russel, 1989). 
3.1.8  Cloning of the used Plasmids 
3.1.8.1  Cloning of Eukaryotic expression plasmids 
All cDNAs encoding p210
BCR/ABL as well as p185
BCR/ABL and its mutants have been described 
previously (Beissert et al., 2008; Beissert et al., 2003; Puccetti et al., 2000). All retroviral 
expression vectors used in this study were based on the bi-cistronic vectors PINCO or 
PAULO converted into Gateway
®-destination vectors by the introduction of a Gateway
® 
cassette according to the manufacturer’s instructions (Invitrogen, Karlsruhe, Germany). All 
related inserts were available in the Gateway
® entry-vector (pENTR1A) for recombination 
into the destination vectors using the “LR-clonase” enzyme kit (Invitrogen).  The mutant 
constructs were prepared using the following strategies and the modular organization of these 
constructs is shown in figure 9. 
ΔCC constructs 
 ΔCCp185-Y253F,  ΔCCp185-E255K,  ΔCCp185-T315I,  ΔCCp185-T315I,  ΔCCp210 and 
ΔCCp210-T315I were generated by substituting the sequence encoding the first 63 aa of 
p185
BCR/ABL  by a Kozak-consensus by using the following primers: 5‘-
ATCTACCTGCAGACGACGATGGCCAAG-3‘ and 5‘-ATGGCCCTTGCGGATCCGCTCG-3‘ (the Kozak Methods  58 
 
consensus at the start codon and the BamHI site are underlined). The resulting fragments were 
cloned into BamHI-digested p185-Y253F, p185-E255K, and p185-T315I and p210BCR
/ABL 
sequences.   
BCC/ABL-T315I 
BCC/ABL-T315I was cloned by “megaprimer” PCR. First, PCR was performed with the 
primers Pr1 5‘-CCACCATGGTGGACCCGGTGGGCTTC-3‘ (start-codon underlined) and Pr2 5‘-
CGCTGAAGGGCTTCTTCCAGCAACGTCTGCAGGT-3‘ (ABL sequences,  BCR-sequences). The 
resulting “megaprimer” and the primer Pr3 -5‘-AGGCCCATGGTACCAGGAGTG-3‘ were used in a 
second PCR round, and the resulting fragment was cloned into a KpnI-digested pEp185-
T315I.  
#ABL and #ABL-T315I  
For constructing the ABL part of BCR-ABL (#ABL and #ABL-T315I), the start codon and 
Kpn1 sites were introduced at the ABL-part by PCR using the primers Pr4 5‘-
AAGGTACCACCATGGAAGCCCTTCAGCGGCCAGTAGCATCTGACTTTGAGC-3‘(Start-codon and 
Kpn1 underlined) and Pr3 5‘-AGGCCCATGGTACCAGGAGTG-3‘ (Kpn1 site underlined). The 
resulting PCR products were controlled by sequencing and cloned into the KpnI-digested 
p185 and p185-T315I sequences, respectively.  
ΔSH3-ABL and ΔSH3-ABL-T315I  
ΔSH3-ABL and ΔSH3-ABL-T315I were constructed by digesting the constructs pEΔCCp185 
and pEΔCCp185  -T315I with HincII followed by recircularization. Linker 5‘-
gaccaccatggagaaacactcctggtac was ligated to the recircularized plasmids with Kpn1 and 
HincII to introduce a Kozak consensus sequence. 
BCR (1-196)/ABL and BCR(1-196)/ABL-T315I  
In order to construct BCR(1-196)/ABL and BCR(1-196)/ABL-T315I, two PCR rounds were 
performed, first with primers pr5 5‘-TTCTAAAGCTTCACCTCTTTGTCGTTGACC-3‘ and pr6 5‘-
AAATGGATCCGGTACCATGGTGGACCCGGTGG-3‘ and then with pr7 5‘-
ATCATGAAGCTTGAAGAAGCCCTTCAGCGG-3` and Pr3 5‘-AGGCCCATGG
In order to construct p185Y177F and p185Y177F-T315I, three PCR rounds were performed: 
first with the primers pr8 5‘-CCTGTTAGTTAGTTACTTAAGCTCG-3‘ and pr9 5‘-
TGAAACTCGACGTTCACGAAGAAGGGCTTCTCG-3‘, second with the primers pr10 5‘-
AGAAGCCCTTCTTCGTGAACGTCGAGTTTCACC -3‘ and Pr3 -5‘-AGGCCCATGGTACCAGGAGTG-3‘, 
TACCAGGAGTG-3‘ (Kpn1 
site underlined). The resulting products were controlled by sequencing and ligated and 
subcloned into KpnI-digested pEp185 and pEp185-T315I.  
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and finally, PCR products 1 and 2 were used as primers without a template. The full-length 
p185Y177F and p185Y177F-T315I products were completed by ligating the third PCR 
products using the KpnI-site of p185
BCR/ABL p185-T315I cDNA.  
 
 
Figure 9 – Different constructs used in the study: A Modular organization of the p185
BCR/ABL and p210
BCR/ABL 
and their mutants lacking different functional domains. B Schematic presentation of different retroviral con-
structs 
 
ΔCCp185-Y177F and ΔCCp185 Y177F-T315I 
To construct double mutant ΔCCp185-Y177F and ΔCCp185 Y177F-T315I, pEΔCC p185 was 
cloned into BamHI-digested p185Y177F and p185Y177F-T315I. All other constructs have 
been described previously (Beissert et al., 2008; Beissert et al., 2003). 
3.1.8.2  Cloning of prokaryotic expression plasmids 
All expression vectors used in this study were based on pPRIBA2, which provides an in-
frame Strep Tag as well as a His-tag  (IBA  -  BioTAGnology, Goettingen, Germany). 
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Gateway® cassette, according to the manufacturer’s instructions (Invitrogen, Karlsruhe, 
Germany). All related inserts were available in the Gateway® entry-vector (pENTR1A), and 
were shuttled into the destination vectors using the “LR-clonase” enzyme kit (Invitrogen). 
The pENTR1A with GFP and the Hfelix-2-GFP fusion peptide (pE-GFP and pE-H2-GFP, 
respectively) have been previously described [13]. For the generation of the HIV-TAT-
H2GFP fusion peptides (here referred to as MPH-2), the following linkers were used 5‘- 
GCGCCTACGGCCGCAAGAAGCGACGTCAGAGACGACGCGTCAAC-3‘ and 5‘- 
TATCGTTGACGCGTCGTCTCTGACGTCGCTTCTTGCGGCCGTAG-3‘. Retro-HIV-TAT-H2GFP fusion 
peptides were generated using the linkers 5‘- 
GCGCCCGAAGACGCCAACGAAGGAAGAAACGGGTCAAC-3‘and  5-
‘TATCGTTGACCCGTTTCTTCCTTCGTTGGCGTCTTCGG -3‘. The resulting PCR products were all 
confirmed by sequencing, and were cloned into the pPRIBA2 vector using a BsaI site, and 
recombined with pE-GFP and pE-H2GFP. The pPRIBA2-GFP and pPRIBA2-H2-GFP 
vectors were constructed by directly shuttling pE-GFP and pE-H2GFP into the pRIBA2 
vector. 
3.2  Immunoblot 
3.2.1  Lysis of cells (Sambrook et al., 1989) 
Cells were washed twice with cold PBS, collected by centrifugation (2000 x g for 10 minutes 
at 4°C) and lysed by adding approximately 100μl of SDS lyses buffer per million cells. In the 
case of primary mouse bone marrow cells, SDS lysis buffer at 80°C can be used. After 10 
minutes incubation on ice, lysates were cleared by centrifugation at 14000 x g for 15 minutes 
at 4°C. The supernatants were transferred to the fresh tubes and stored by –80°C. 
3.2.2  Determining of protein concentration 
Protein concentrations were determined by Bradford-assay with Bio-Rad protein detection kit 
according to the manufacturer’s instruction and quantified with a spectrophotometer at 595 
nm. The standards for protein concentration were prepared with different concentrations of 
BSA (0.5 to 10mg/ml). 
3.2.3  SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
A very common method for separating proteins by electrophoresis uses a discontinuous 
polyacrylamide gel as a support medium and SDS to denature the proteins. The method is 
called sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). SDS is an 
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molecular mass. The negative charges on SDS destroy most of the complex structure of 
proteins, and are strongly attracted toward an anode (positively-charged electrode) in an 
electric field. Their net migration through gel is determined not by the electrical charge but by 
molecular weight, 
Mini Protean II® (8.5cm X 6.5cm) apparatus was assembled by using two glass plates and 
side spacers. The resolving gel was mixed in acrylamide-bisacrylamide concentration that 
matches protein weight (Sambrook et al., 1989), and poured between the two glasses. 
Isobutanol saturated with ddH2O was laid over to ensure a flat surface and prevent trapping of 
air bubbles. After the gel has polymerized, isobutanol was washed out and stacking gel laid 
over. Samples were prepared by mixing 50μg of total protein with sample buffer in the 25μl 
end volume, heated for 5 minutes at 80
0C and briefly collected to the bottom. 
Electrophoresis was run for approximately 1 hour, at a constant voltage of 150V. After the 
electrophoresis, gel was stained in Coomassie-blue for visualizing separated proteins. 
3.2.4  Transfer of proteins onto a nitrocellulose membrane (Western blot) 
Following electrophoresis, proteins were transferred to the 0.2μm nitrocellulose membranes 
in a process called Western blotting. This transfer was carried out between the two horizontal 
metal plates in a Semidry System (Bio-Rad). The membrane was soaked in a transfer buffer 
for 10 minutes, placed on top of the 3MM 
Whatman® paper immersed in the same buffer, and laid the gel over. This was covered by 
another sheet of wet 3MM Whatman® paper, all dimensions being slightly brighter then the 
gel. Transfer was carried out in excess of blotting buffer for 2 hour, by electric density of 
0.3mA/cm2 and a 300- 400 mA current (45 V). Following Western blotting, membranes were 
usually stained with Ponceau-S for 5 minutes and protein bands were visualized. The dye was 
removed by washing with TBST, and membrane stored at 4°C until further analysis. 
3.2.5  Immunodetection of specific proteins 
Proteins immobilized on a membrane were identified by using highly specific antibodies. The 
membrane was first incubated in TBS-T containing 5% (w/v) Carnation milk in order to 
saturate nonspecific protein binding sites, and after one hour or overnight incubation  by 4°C 
on a rocking platform the membrane was washed three times for 5 minutes in TBS-T. Primary 
antibody was diluted to appropriate concentration (1:200-1:10000) in TBS-T and membrane 
was incubated for 3 hours to overnight. Incubation was followed by three washing steps for 
10 minutes  in TBS-T and secondary antibody added (as recommended). After one hour, 
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Signals  were detected in the dark by rinsing the membrane shortly in water and then 
incubating with ECL (enhanced chemo luminescence system) I and II solutions in 1:1 ratio 
for one minute. Membranes were exposed to X-OMAT film for 30 seconds to 5 minutes 
depending on the intensity of the signal detected and antibody-bound proteins visualized. 
3.3  Characterization of high molecular weight complexes (HPLC) 
 The formation of HMW was detected as previously described (Minucci et al., 2000). Both 
COS-1 cells expressing p185
BCR/ABL  and GFP or Helix-2-  GFP, respectively, and IL-3-
independent Ba/F3 cells expressing p185
BCR/ABL  and GFP or Helix-2-GFP were used. 
Cytosolic extracts were prepared from 1 to 5 X 10
8 cells and fractionated at 4
0C by HPLC 
using a Superose 6 HR 10/30 size exclusion column (Amersham/Pharmacia Biotech). The 
flow rate was 0.4 ml/min. Fractions of 0.4 ml were pulled, concentrated and analyzed by 
Western blotting as described above. 
3.4  Production of GST-Fussion protein in bakteria 
3.4.1  Protein mini preparation 
E. coli JM-83 cells were transformed with the required PGEX4T3 fusion protein constructs 
and PGEX empty vector as control.  The transformed bacteria were plated on Agar/Amp 
plates and incubated over night at 37
0C. Single colony was inoculated into 2 mL LB/Amp 
liquid medium and shaked at 37
0C over night. The culture was diluted as 1:10 in LB/Amp 
medium and shaked for 3 hours. Finally the protein induced with 0.1 mM IPTG shaked for 
more 3 hours. The bacteria were centrifuged at 3000 rpm for 2 mints. The pallet was lysed in 
200 µl E1A buffer (150mM) and sonicated. 10 µl of lysate was mixed with10 µl 2X 
SDS/PAGE sample buffer and separated the lysates with SDS-PAGE. The gel was stained in 
coomassie solution for 3 hours. The gel was destained by incubation over night in distilled 
water. The expression was observed by comparing the bands with un-induced samples and 
empty vector.  
3.4.2  Protein maxi preparation 
E. coli JM-83 cells were transformed with the required PGEX4T3 fusion protein constructs 
and PGEX empty vector as control.  The transformed bacteria were plated on Agar/Amp 
plates and incubated over night at 37
0C. Single colony was inoculated into 2 mL LB/Amp 
liquid medium and shaked at 37
oC over night. The culture was diluted as 1:10 in LB/Amp 
medium and shaked for 3 hours. Finally the protein induced with 0.1 mM IPTG shaked for 
more 3 hours. Bacterial growth was stopped by incubation the culture on ice for 10 mints. The Methods  63 
 
bacteria were centrifuged on 4
oC at 4000 rpm for 15 mints. The pallet was lysed in 20 ml E1A 
buffer (150 mM NaCl, 1% Triton X-100) and sonicated. Th elysates were centrifuged at 
1000g on 4°C for 10 minutes. The supernatant was collected. 1 ml of GST sepharose beads 
were mixed with 10 ml of lysate and rotated on 4
oC at low speed for 3 hours or more. The 
mixture was centrifuged for 1 minute at 4000 rpm and the protein bound sepharose were 
collected. The sepharose were washed 4 times with 10 ml E1A buffer (150 mM without 
detergents). At the end the sepharose beads were resuspended in E1A buffer (50 mM NaCl, 
0.1% NP-40) and stored at 4°C .10 µl of lysate was mixed with10 µl 2X SDS/PAGE sample 
buffer and separated the proteins with SDS-PAGE. The gel was stained in coomassie solution 
for 3 hours. The gel was destained by incubation over night in distilled water. The expression 
was observed by comparing the bands with empty vector. 
3.5  GST “Pull-down” assays 
The glutathione S-transferase (GST)–BCC, Helix-2 and Helix-1  fusion proteins were 
expressed in Escherichia coli BL21 cells by induction with isopropyl thiogalactoside (IPTG) 
for 3 hours at 37°C. Extracts were prepared after cell lysis by sonication/detergent treatment. 
Cell lysates were cleared by centrifugation (10 minutes at 10 000g) and incubated for 2 hours 
at 4°C with glutathione-  Sepharose beads (Amersham/Pharmacia Biotech, Freiburg, 
Germany). The beads were washed twice with E1A buffer (HEPES 50 mM, pH 7.8, NaCl 150 
mM, EDTA 5 mM, DTT [dithiothreitol] 1 mM, NP40 0.1%) and quantified on sodium 
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) by comparison to a 
standard curve of bovine serum albumin (BSA). For the pull-down experiments cells were 
resuspended in E1A buffer (NaCl, 150 mM). Cell extracts were prepared after cell lyses by 
sonication and clarification by centrifugation (10 minutes at 10 000g). Total protein (1 mg) 
was then incubated with GST or GST-Helix-2 fusion protein (approximately 10µg) bound to 
glutathione Sepharose for 1 hour at 4°C. The bound proteins were eluted by boiling in 30 µL 
2 X SDS-PAGE loading buffer, resolved by SDS-PAGE, and visualized by Western blotting 
with the α-ABL antibody described earlier. 
3.6  Cell biology techniques 
3.6.1  Cell cultures 
Eukaryotic cells were grown in culture flasks in a humidified atmosphere at 37°C and by 5% 
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3.6.1.1  Used Cell lines 
Nalm-6, BV-173 and K562 suspension cells were cultivated in RPMI 1640, supplemented 
with 10% FCS (Gibco), 2mM L-glutamine, 40μg/ml penicillin and 40μg/ml streptomycin 
medium, cultures were seed out in 1:4 to 1:10 ratio every 2-3 days in order to keep constant 
log phase population growth at about 1 x 10
6 cells/ml. 
Sup-B15 were cultivated in Mycosa medium, supplemented with 10% FCS (Gibco), 2mM L-
glutamine, 40μg/ml penicillin and 40μg/ml streptomycin medium, cultures were seed out in 
1:3 to 1:5 ratio every 2-3 days in order to keep constant log phase population growth at about 
1 x 10
6 cells/ml. 
Tom-1  were cultivated in RPMI 1640, supplemented with 20% FCS (Gibco), 2mM L-
glutamine, 40μg/ml penicillin ,40μg/ml streptomycin medium . 
BaF/3 and 32D cells were cultivated in RPMI 1640, supplemented with 10% FCS (Gibco), 
2mM L-glutamine, 40μg/ml  penicillin,  40μg/ml  streptomycin  medium  and  10  ng/ml  of 
recombinant murine–interleukin 3 
Adherent Rat-1, Phoenix and 293T cells were grown in DMEM medium supplemented with 
10% FCS (Hyclone), 2mM L-glutamine, 40U/ml Penicillin and 40μg/ml Streptomycin. Upon 
reaching sub confluent state (~80% surface occupied), cells were washed with PBS and 1ml 
of trypsin-EDTA (PAN Biotech) added. After 1-2 minutes, trypsin was inactivated by 
addition of FCS-containing medium and detached cells reseeded in the fresh plates at 
approximately 1:7 ratios. 
3.6.1.2  Cell counting and determination of cell viability 
Cell number and viability were controlled by trypan blue exclusion. 10μl cell suspension was 
mixed with 40μl of 0.4% trypan blue in 0.9% NaCl. Only unstained cells were considered 
viable, and their number was calculated as follows: Cell concentration [10
6/ml] = Number of 
counted cells in 5 quadrants X 10
4 / ml 
3.6.1.3  Freezing and thawing 
Freezing 
For storing in liquid nitrogen, approximately 1 X 10
7 cells were collected at 1200 x g for 5 
minutes and washed with PBS. After centrifugation, the cells were resuspended in 0.9 ml 
freezing Solution I, transferred into cryovials, and mixed with drop wise added 0.9 ml of 
freezing Solution II. This suspension was immediately placed in cryobox containing 
isoproponol at -80°C, and after 3-5 hours stored in a liquid nitrogen freezer. 
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Thawing 
Cryo-preserved cells were taken out of the liquid nitrogen, thawed rapidly in a 37°C incubator 
and resuspended in a 5 ml culture medium. Following one washing step to remove residual 
DMSO, cells were transferred into culture flasks and resuspended with fresh medium. 
3.6.2  Genetic modification of mammalian cell 
3.6.2.1  Transfection of mammalian cells 
A day prior to transfection, Phoenix cells were plated in fresh medium. After 14-16 hours, 
cells were sub confluent (70-80% of plate occupied), which is the stage when they are most 
transfectable and give the highest possible virus titre. 
For transfection, following premix was made: 
2M CaCl 62 μl 
DNA 5 μg 
Add H2O to make final volume as 500μl 
While vortexing the premix, 0.5 ml of 2xHBS were added drop wise.  The mix was kept for 
10-20 minutes at room temperature. Next, medium was aspired, DNA/HBS solution was 
gently spread across the cell layer and plates were transferred to 37°C incubator. After 30 
minutes, fresh pre-warmed medium with 25 μM chloroquine was added, and incubation 
continued for the next 8-12 hours (DNA delivered by CaCl2 transfection is believed to transit 
through lysosomes, and chloroquine acts as to inhibit lysosomal DNases by neutralizing 
vesicle pH). Following this time, medium was replaced and cells were left overnight. Next 
day medium was changed and incubated the cells for nex 24 hours. Transfection efficiency 
was estimated according to the level of expression of green fluorescence protein (GFP) on 
FACS (Fluorescence Activated Cell Sorter). Only after reaching the transfection efficiency of 
at least 80%, experiment was preceded and retroviral supernatant were collected, filtered and 
cry frozen in liquid nitrogen. Next day again the virus supernatant was collected, stored and 
used for further infection of target cells. 
3.6.2.2  Retroviral infection  
For infection of target cells, retronectin1 (Takara Bio, Otsu, Japan) was used to enhance 
infection efficiencies following the manufacturer’s instructions. Non tissue culture 24-well 
plates were coated with 0.2mg retronectin per well in 100µL volume. The plate was incubated 
at 4
0C overnight. Retronectin were removed, washed with PBS and blocked with 0.2% BSA 
for 30 minutes. 200µL of viral supernatant were plated in each well and centrifuged at 4000 
rpm for 15 minutes on 15
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times. The wells were washed with PBS and Ba/F3, 32D or Rat-1 target cells (100 000 
cells/ml) were plated in the viral coated plate. Infection efficiency was measured by 
fluorescence-activated cell sorting (FACS) analysis of GFP-positive cells after 48 hours. 
3.6.3  Cell growth and proliferation assay 
Cell growth was assessed by dye exclusion using Trypan-blue. Ba/F3, 32D harboring p185 
and p185 T315I and loss of function mutants of BCR/ABL were plated at10
5 cells/ml. IL3 
independent growth was monitored for 4 days with dye exclusion assay.
 Proliferation was 
assessed with proliferation kit XTT (Amersham) according to the manufacture instructions. 
Similarly, cells growth and proliferation was measured for human Philadelphia chromosome 
positive and negative cell lines like Nalm-  6, BV-173, Sup-B15, Tom-1 and K562 ether 
retrovirally transduced or with cell permeable TAT-fusion peptides.  
3.6.4  Proliferation-competition assays (PCA) 
For modified proliferation-competition assays (PCA) (Griswold et al., 2006)), Ba/F3 and 32D 
cells were infected with PAULO vectors harboring unmutated and mutant p185
BCR/ABL. IL-3 
was removed from the media of infected Ba/F3 cells by washing the cells twice with 
phosphate buffered saline (PBS). The cells were continuously cultivated in absence of IL-3 
and superinfected with GFP and Helix-2-GFP. Day 4 GFP-expression levels were used to 
normalize the expression levels of different GFP expression. Proliferation-  competition 
between single and double infected cell fractions was monitored by FACS analysis of the 
GFP expression (Fig. 12A). 
Similarly, GFP expression was followed in Nalm-6, SupB15 and BV173 cells infected with 
GFP, and Helix-2-GFP. 
3.6.5  Apoptosis measurement by 7-aminoactinomycin D (7-AAD) 
7-AAD is used in the staining of apoptotic cells, whereby it binds to the DNA. The 7AAD 
staining was carried out as described elsewhere (Schmid et al., 1994). Briefly, 2.5 to 5 x 10
5 
cells were taken in 1 ml FACS buffer an centrifuged for 5 minutes at 1500 rpm. Supernatant 
was completely discarded. The pellet resuspended in 200 µl of 7AAD solution (diluted in 
PBS at a ratio of 1: 10 to have a final concentration of 20 µg/ml). The cells were then 
incubated in the dark for 20 minutes at 4°C. The Tubes were filled with PBS and pelleted 
cells by centrifugation. Supernatant  was discarded, and cells  were resuspended  in an 
appropriate volume (200 to 500 µl) of FACS fixing solution. Cells  were  analyzed 
immediately by FACS scanning. 
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3.6.6  Transformation assays 
3.6.6.1  Focus formation assay 
For focus-formation assays in a 24-well plate format 40,000 per well infected Rat-1 cells were 
plated. Foci were stained after 15 days using 1% crystal violet (Sigma-Aldrich, Steinheim, 
Germany) and photographed. 
3.6.6.2  Soft agar anchorage-independent growth assay 
For soft-agar assays Rat-1 fibroblasts were co-transduced with GFP or Helix-2-GFP and 
PAULO vectors harbouring unmutated and mutant p185(BCR/ABL). Six-well-plates were 
filled with 2ml/well DMEM/10%FCS/0.5% bactoagar (DIFCO Laboratories, Detroit, USA). 
5000 Rat-1 cells were plated in 1 ml/well topagar (DMEM/10% FCS/ 0.25% bactoagar). Rat-
1 colonies were counted after 15 days incubation at 37
0C, 5% CO2.  
3.7  Production of recombinant TAT- fusion proteins 
The strep-tagged H2-GFP, TAT-GFP and MPH-2 peptides were produced in E.coli BL21 
using  pPRIBA2 vectors upon induction with 0.5 mM isopropyl thiogalactoside (IPTG) 
overnight at 25°C. Bacterial lysates were prepared in buffer W (100 mM Tris-HCl pH 8.0, 
150 mM NaCl, 1 mM EDTA, 0.1% Tween) containing a complete protease inhibitor cocktail 
(Roche Basel Switzerland), sonicated, and cleared by centrifugation (10.000 g for 10 min.). 
Further purification of the STREP-tagged peptides was performed using a STREPtactin 
Matrix (IBA, Gottingen, Germany). The beads were washed 4 times with buffer W, and the 
proteins were eluted with elution buffer at room temperature for 15 min. The buffer was 
exchanged with PBS using PD-10 columns (Amersham/Pharmacia Biotec, Freiburg, 
Germany), and the endotoxin was removed using endotoxin free columns (Profos AG, 
Regensburg, Germany). The amount of protein was quantified by comparing the samples to a 
bovine serum albumin (BSA) standard curve. Samples were stored at -20°C  in  15-20% 
glycerol for further use. Quantification of proteins was performed using SDS-PAGE followed 
by coomassie-staining. 
3.8  Determination of TAT-fusion protein uptake  
To determine the uptake efficiency of the fusion proteins, 1x 105 cells/well of 293T, Rat-1, 
Nalm-6, BV-173, K562 and Tom-1  were plated in a 12-well plate for 12-16 hr. Cells were 
then incubated with H2-GFP, TAT-GFP or MPH-2 (1 μM each) for 3 hours. The cells were 
washed with PBS, harvested, and the uptake efficiency was measured by quantification of the 
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3.9  „Pull-down-assays“for TAT-fusion protein 
BV173 cells were exposed to 1μM H2-GFP, TAT-GFP and MPH-2. After 3 hr, the cells were 
washed, trypsinized and lysed in E1a buffer. The cell lysates were clarified by centrifugation 
(10 min at 10.000g). An aliquot of total protein (1 µg) was incubated with 10 µL STREPtactin 
Matrix (IBA) overnight at 4° C. The mixture of sepharose and protein was washed 4 times 
with E1A buffer (150 mM, NaCl, 5mM, HEPES 50 mM pH 7.0, EDTA 5mM pH 8.0, 1% 
Triton, NaVO4 2 mM and 1X protease inhibitor cocktail Roche, Mannheim, Germany).  The 
bound protein was eluted with elution buffer (IBA), resolved by SDS-PAGE, and visualized 
by staining the blots with an α-ABL antibody. 
3.10  Animal experiments 
3.10.1  In vivo peptide transduction 
3.10.1.1 Raring of mices 
C57 BL/6N female mice (Harlan Winkelmann, Borchen, Germany) 6 to 8 weeks old were 
kept on sterile bedding in filter-top cages. They were provided with sterile food and water ad 
libitum.  
3.10.1.2 Delivery of peptides to the mices  
Membrane permeable Helix-2 (MPH-2) peptides dissolved in PBS at a dosage of 2.5 mg/kg 
were inoculated i.v. into recipient mice. Negative control mice received the same volume of 
phosphate-buffered saline (PBS).  
3.10.1.3 Analysis of the mices 
Animals were sacrificed by CO2-asphyxiation after 15 min, 2 hr, 6 hr, and 24 hr of treatment. 
Peripheral blood (PB) was obtained from the heart, and bone marrow (BM) was harvested 
from the femur and tibiae by flushing the bones with a syringe and 26-gauge needle. Spleen 
cells were isolated by passing the tissue through a 40 µM Nylon cell strainer (Beckton-
Dickinson, Le Pont de Claix, France). For analysis of GFP expression, the mono nucleic cells 
(MNCs) were enriched using a Ficoll density gradient and GFP expression was measured by 
fluorescence activated cells sorting (FACS). 
3.11  Statistical  Analyses 
All statistical analyses were performed using Student-t-Tests and p ≤ 0.05 was considered as 
significant. The data were presented as mean values from three independent experiments with 
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4  Results 
4.1  Targeting of the N-terminal coiled-coil (CC) oligomerization interface by a Helix-
2 peptide inhibits BCR/ABL 
4.1.1  The Helix-2 but not Helix-1 of coiled-coil (CC) interacts with 185 
BCR/ABL 
It is previously shown by our group that a peptide of the amino acid (a.a. = 1-63 representing 
the N-terminal BCR coiled-coil oligomerization interface (CC) interacts with p185
  BCR/ABL. 
This CC inhibits kinase activity and growth of p185 
BCR/ABL (Beissert et al., 2003). The CC 
domain is composed of two α-helices, Helix-1 and 2 (Figure 10A). Previous data on deletion 
mutants and crystal structures suggest that Helix-2 mediates the protein-protein interaction by 
the CC domain (Smith et al., 2003; Zhao et al., 2002). To definitively determine the relevant 
protein-protein interaction interface in the CC domain, we investigated the capacity of 
peptides encompassing Helix-1 (a.a.1–17) and Helix-2 (a.a. 23–72), respectively, to bind with 
p185
BCR/ABL. Therefore, recombinant GST-Helix-1 and GST-Helix-2 fusion proteins were 
purified from E.coli  JM-83 by high affinity chromatography (Figure 10B). These 
Immobilized peptides on glutathione-sepharose beads were used as a bait to precipitate 
p185
BCR/ABL from lysates of Ba/F3 cells expressing p185
 BCR/ABL. GST alone and the previously 
described GST-CC  (Beissert  et al., 2003)  were used as a negative and positive control, 
respectively. 
Sepharose-bound protein complexes were separated by SDS-PAGE and analyzed by α-ABL 
Western blotting. As depicted in figure 10C, only GST-Helix-2 was able to precipitate 
p185
BCR/ABL from the cell lysates to the same extent as GST-CC. 
These data indicate that Helix-2 represents the oligomerization interface of BCR and thus 
mediates the interaction between p185
BCR/ABL monomers. 
4.1.2  Co-expression of Helix-2 disrupts p185
BCR/ABL tetramers 
The tetramerization of p185
BCR/ABL  is reflected by the formation of intracellular HMW 
complexes. In fact, the size of complexes formed by a deletion mutant lacking the N-terminal 
CC domain is markedly reduced as compared to unmutated p185
  BCR/ABL  (Beissert  et al., 
2003). 
To investigate whether it is possible to disrupt the p185
BCR/ABL  HMW-complexes by the 
presence of Helix-2, we co-expressed p185
 BCR/ABL with either GFP or Helix-2-GFP in Cos-1 
cells (Figure 11A). Cell lysates were separated by size-exclusion-HPLC. The single HPLC-
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with GFP, p185
BCR/ABL was found in complexes with an apparent MW between 670 and 1,070 
kDa (Figure 11B), whereas the presence of Helix-2 led to the detection of p185
  BCR/ABL 
complexes with apparent MW between 440 and 1,070, with a marked peak at 670 kDa.  
 
 
 
Figure 10- Interaction of Coiled-Coil Subdomains with p185 BCR/ABL .(A) Modular organization of the 
BCR-coiled-coil domain adapted from Zhao et al. Helix-1 spans from a.a.5-15, Helix-2 spans from a.a. 28-67 
19. 
(B) Expression of recombinant proteins in E. coli and ‘pull-down’ experiment: the coomassie staining (left side) 
shows the purity and integrity of the indicated constructs expressed in E. coli BL21. Lysates from p185
BCR/ABL 
expressing Ba/F3 cells were incubated with the indicated GST-fusion constructs immobilized on GST-sepharose 
beads. The precipitation of interacting p185
BCR/ABL was detected by Western blotting using an α-ABL antibody. 
 
Endogenous c-ABL complexes displayed an apparent MW of 440–670 kDa, which was not 
influenced by the presence of GFP or Helix-2-GFP (Figure 11B).   
In summary, these data suggest that binding to Helix-2 interferes with the oligomerization of 
p18
 BCR/ABL as revealed by the reduction of the size of its HMW-complexes. 
4.1.3  Helix-2 reduces the autophosphorylation of p185
BCR/ABL  
The fact that Helix-2 interact with p185
 BCR/ABL disrupts  the p185
 BCR/ABL HMW-complexes 
prompted us to investigate whether the Helix-2 peptides have inhibitory effects on p185
BCR/ABL 
expressing cells as compared to the known effects of the CC-peptides (Beissert et al., 2003). 
Hence, we investigated the autophosphorylation of p185
BCR/ABL in the presence of CC-GFP 
and Helix-2-GFP. Therefore, we analyzed Ba/F3 cells stably co-expressing p185
BCR/ABL in the 
presence of GFP, CC-GFP or Helix-2-GFP  by  Western  blotting  with  an  α-phospho-ABL 
antibody (α-P-ABL-Y245) and an α-ABL antibody. As depicted in Figure 11C the presence 
of Helix-2 reduced the level of p185
BCR/ABL autophosphorylation to the same extent as CC. 
Taken together, these results show that the Helix-2 peptide inhibits the p185
 BCR/ABL kinase 
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Figure 11-  Disruption of p185BCR/ABL High Molecular Weight Complexes and Reduction of p185 
BCR/ABL autophosphorylation by Helix-2. (A) Western blot analysis of cytoplasmic extracts of transfected 
Cos-1 cells. The cells were co-transfected as indicated either with GFP and p185
 BCR/ABL or Helix-2-GFP and 
p185
 BCR/ABL. The expression of the transgenes was determined by α-GFP and α-ABL antibodies. (B) The cytop-
lasmic extracts of co-transfected Cos-1 cells were fractionated by size-exclusion HPLC. p185
BCR/ABL was de-
tected in the fractions by an α-ABL Western blot. The blots show the presence of p185
BCR/ABL in fractions corres-
ponding to the molecular weight (MW) indicated at the top. (C) Ba/F3 cells stably expressing the indicated 
transgenes were lysed and phosphorylation at ABL-tyrosine residue 245 was analyzed by Western blot using an 
α-ABL(Tyr-245) specific antibody. The membrane was repeatedly stripped and probed with the indicated anti-
bodies. One representative experiment out of three is given. 
4.1.4  Helix-2 inhibits growth of p185BCR/ABL positive cells and increases its 
sensitivity towards Imatinib 
To assess whether the inhibited autophosphorylation of p185
BCR/ABL by Helix-2 interferes with 
the survival of cells transformed by p185
 BCR/ABL, we performed proliferation competition ex-
periments on p185
 BCR/ABL expressing Ba/F3 cells. The principle of the assay is depicted in 
Figure 12A. Ba/F3 cells transduced with the retroviral vector PAULOp185
 BCR/ABL were se-
lected by IL- 3 withdrawal for 7 days, resulting in bulk populations that uniformly coexpress 
p185
BCR/ABL and ∆LNGFR. Thereafter, these cells were transduced with retroviral vectors har-
boring GFP, CC-GFP or Helix-2-GFP. The resulting double infected cell populations were 
then exposed to a sub-apoptotic Imatinib concentration (0.4 µM) for p185
 BCR/ABL expressing 
Ba/F3 cells. The effect of the transduced peptides was assessed by the detection of GFP posi-
tive cells for 1 week by FACS. The GFP-expression on day 4 was taken as a reference for 
normalization. 
As shown in Figure 12B, the expression of GFP did not alter the proliferation of p185
 BCR/ABL 
expressing Ba/F3 cells as revealed by the constant percentage of GFP positive cells. In con-
trast, CC and Helix-2 inhibited the growth of p185
 BCR/ABL expressing Ba/F3 cells as shown by 
the fact that the percentage of CC-GFP or Helix-2-GFP expressing cells decreased over time 
with comparable kinetics (Fig. 12B). The addition of Imatinib accelerated the decrease of CC-Results  72 
 
GFP- or Helix-2-GFP expressing cells, but had no influence on GFP controls (Fig. 12B). To 
exclude effects of the peptides not related to their binding to p185
BCR/ABL and to prove the spe-
cificity of their effects, we performed the same experiments with Ba/F3 cells expressing a 
constitutively activated murine c-Kit, the mutant c-KitD814H.21 The c-KitD814H mediates 
factor independence to the same extent as p185
BCR/ABL, which was also reverted by 2 µM Im-
atinib (Zheng et al., 2009). The co-expression of Helix-2- or CC-GFP-fusion peptides did not 
inhibit the growth of c-KitD814H-expressing IL-3 independent cells either in the absence or 
presence of Imatinib (Figure 12C). 
Taken together, these results show that the Helix-2 peptide inhibits the p185
BCR/ABL kinase 
activity to the same extent as the previously described CC-peptide inducing both growth sup-
pression of p185
 BCR/ABL-dependent cells and an increased sensitivity for Imatinib. 
4.1.5  Helix-2 specifically inhibits Ph+ human cell lines 
To confirm the effects of Helix-2 on human Ph+ patient derived cells, we performed the 
proliferation competition experiments on human Ph+ cell lines derived from ALL or CML 
patients. We used SupB15 (Ph+ ALL) expressing p185
 BCR/ABL, BV-173 (lymphatic CML blast 
crisis) expressing p210
  BCR/ABL and as a BCR/ABL-negative control the Ph- Nalm-6 cells, 
because all these cells exhibited a nearly identical  pre-B lymphatic differentiation level 
(Puccetti et al., 2000). These cells were retrovirally infected with GFP, CC-GFP or Helix-2-
GFP. The GFP-expression was determined for 12 days after infection with the day 4 
expression as a reference. In contrast to the Ph- Nalm-6 cells  which exhibited a constant 
GFP, CC-GFP or Helix-2 expression, in the Ph+ SupB15 and BV173 cells the percentages of 
CC-GFP and Helix-2-GFP positive cells decreased over time, whereas the GFP expression 
was constant. The kinetics of the outgrowth of Helix-2-GFP positive cells was accelerated 
with respect to that of CC-GFP positive cells (Figure 12D). 
To obtain 100% infected human cells, we sorted CC-GFP and Helix-2-GFP expressing cells. 
While Nalm-6 cells transduced with GFP, Helix-2-GFP or CC-GFP rapidly proliferated after 
sorting, BV173 and SupB15 cells only infected with GFP but not with CC-GFP or Helix-2- 
GFP grew up after sorting.  
Taken together these data show that patient derived Ph+ cell lines are specifically inhibited by 
peptides targeting the N-terminal oligomerization interface of BCR/ABL and that Helix-2 
seems to be more effective than CC in the inhibition of BCR/ABL. Results  73 
 
 
 
Figure 12- Growth Inhibition of p185BCR/ABL Expressing Ba/F3 Cells and Philadelphia Chromosome 
positive human cell lines. (A) Schematic representation of a proliferation-competition assay. Factor indepen-
dent cells (e.g. p185
BCR/ABL expressing Ba/F3 cells) are retrovirally infected with inert control peptides (GFP) or 
inhibitory peptide-GFP fusions (CC-GFP or Helix-2-GFP). In the case of the inert GFP control the percentage of 
GFP-positive cells remains constant from day 4 to day 12. In contrast, the expression of inhibitory peptides re-
sults in an outgrowth of peptide expressing cells revealed by a progressive loss of Helix-2-GFP expression. (B 
and C) For proliferation-competition experiments p185
 BCR/ABL or c-Kit
D814H transduced Ba/F3 cells adapted to 
factor independence were infected with GFP, CC-GFP or Helix-2-GFP expressing retroviruses and replated 4 
days after infection in the presence or absence of sub-apoptotic Imatinib (Ima) concentrations (0,4 µM). The 
proportion of the GFP-positive cell fraction was followed by flow cytometry for 10 days and normalized to the 
GFP expression at day 4. Graphs show mean values ± SD of three independent experiments. (D) Proliferation 
competition assays were performed with the human B-cell precursor cell lines Nalm-6 (Ph-), SupB15 (Ph+) and 
BV173 (Ph+). These cells were infected with GFP, CC-GFP or Helix-2-GFP expressing retroviruses. The pro-
portion of GFP-positive cell fraction was followed by FACS for 10 days and normalized to the GFP expression 
at day 4. Graphs show mean values ± SD of three independent experiments. 
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Based on our present results, Helix-2 efficiently inhibits BCR/ABL positive cells. The next 
goal was to establish an efficient method for the delivery of Helix-2 peptides to Ph+ cells. 
4.2  Targeting the oligomerization of BCR/ABL by membrane permeable competitive 
peptides inhibits the proliferation of Philadelphia chromosome positive leukemic cells 
4.2.1  HIV-TAT-fusion peptides were efficiently delivered to fibroblasts 
To determine the most efficient peptide transduction system, we compared the HIV-TAT with 
the Retro-HIV-TAT-sequences fused to Helix-2. We created fusion peptides containing a 
Strep-tag (for efficient immunoprecipitation), HIV-TAT or Retro-HIV-TAT as the peptide 
transduction tag, the Helix-2 sequence, and GFP as reporter (Figure 13A). A construct lacking 
the  Helix-2 sequence (TAT-GFP) was used as the control in experiments. These fusion 
peptides were expressed in the E.coli  strain BL21, and purified by high affinity 
chromatography (Figure 13B). Peptide transduction was performed in the presence/absence of 
chloroquine, which facilitates the up-take of membrane permeable peptides. Here, we show a 
higher efficiency of peptide transduction of Helix-2 upon fusion with the HIV-TAT (MPH-2), 
as compared to Retro-HIV-TAT in untransformed Rat-1 fibroblasts (Figure 13C). Due to its 
high efficiency, HIV-TAT was used as transduction tag for the remaining studies. 
4.2.2  HIV-TAT mediates the efficient cellular uptake of Helix-2 fusion proteins 
To confirm that the HIV-TAT fused membrane permeable Helix-2 (now referred to as MPH-
2) is able to enter leukemic cells, we exposed Ph+ (Tom-1, BV173 and K562) and Ph- (Nalm-
6) leukemic cells to the HIV-TAT-fusion peptides. Peptides without the TAT-domain (H2-
GFP) or TAT-GFP were used as controls. The uptake rate was assessed by determining the 
percentage of GFP-positive cells by FACS. As reported in figure 14A, both the Ph+ and Ph- 
leukemic cell populations were nearly 100% positive for GFP in the presence of the 
transduction tag, whereas the cells incubated with control peptides were completely negative. 
Interestingly, the uptake of MPH-2 was more efficient than the TAT-GFP peptide. To exclude 
that the GFP-positivity was due to peptides binding to the outer side of the cell membrane 
without penetrating the cell, we exposed Nalm-6 and BV-173 to H2-GFP, TAT-GFP or MPH-
2, and performed immunoblots on cell lysates that excluded the membrane fraction. Both of 
the cell lines expressed the peptides corresponding to the HIV-TAT tag, which clearly 
confirmed greater uptake of MPH-2 compared to the TAT-GFP control (Figure 14B). 
To determine the stability of MPH-2, Rat-1 fibroblasts were exposed to TAT-GFP, MPH-2 
and H2-GFP for 3 hr. Then the cells were extensively washed, trypsinized, and seeded in 
fresh media. GFP expression was measured after 30, 60 and 120 min, 6 hr and 24 hr. As Results  75 
 
depicted in figure 14C, GFP was detectable for at least 6 hr, showing that the TAT-fusion 
peptides were stable for at least 6 hr.  
 
 
Figure 13 - Recombinant membrane permeable peptides. (A) Schematic representation of the fusion peptides 
used in this study with the indicated tags. (B) Recombinant peptides on a coomassie-stained SDS-PAGE Gel. 
(C) Peptide transduction efficiency with the indicated peptide transduction tag fused to Helix-2 in Rat-1 fibrob-
lasts, provided as percentage of GFP-positive cells. The data represent the mean of 3 independent experiments 
with SD. 
 
Taken together, these data provide evidence that MPH-2 transduces several different cell 
types with high efficiency, and remains stable for several hours. 
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Figure 14 - Uptake of HIV-TAT fusion peptides by leukemic cell lines and primary stem cells. (A) Ph+ cell 
lines; Tom-1 (Ph+ ALL), BV173 (CML lymphatic blast crisis) and K562 (CML - myeloid blast crisis), and the 
Ph- Nalm-6 cells (ALL) were exposed to 1 µM of the indicated peptides. GFP expression was determined using 
FACS. (A) one representative of 3 independent experiments is provided, as all yielded nearly identical results. 
(B) Intracellular uptake of MPH-2. Western blot analysis of the cell lysates cleared from the membrane fraction, 
and probed with an α-GFP-antibody. D Stability of MPH-2. Rat-1 cells were exposed to 1 µM of the indicated 
peptides. GFP expression was determined using FACS at indicated time points. 
 
4.2.3  MPH-2 interacts with BCR/ABL 
To be therapeutically effective, MPH-2 has to inhibit the oligomerization of BCR/ABL by 
competing for the binding to the N-terminal CC-domain of BCR/ABL. We investigated 
whether MPH-2 could bind BCR/ABL. We exposed Ph+ BV173 cells to MPH-2, and to H2-
GFP and TAT-GFP, which were negative  controls. As shown in Figure 13A, all of the 
recombinant peptides used in the experiments had a Strep-tag. Lysates were incubated with 
strep-tactin sepharose to pull down the strep-tagged peptides. Strep-tactin sepharose-bound 
protein complexes were separated by SDS-PAGE, and blotted on a methyl cellulose 
membrane, which was probed with an α-ABL antibody (Figure 15).  
Here, we show that MPH-2 was able to precipitate BCR/ABL from the cell lysates, which 
confirms that MPH-2 and BCR/ABL directly interact. 
 Results  77 
 
 
 
Figure 15 - Interaction between MPH-2 and BCR/ABL. Pull-down of BCR/ABL from BV173 cells exposed 
to TAT fusion proteins. BV173 were exposed for 3 hr to 1 µM of MPH-2 or the indicated control peptides. All 
fusion peptides harbored the Strep-tag (Figure 1A) and were pulled down by the STREPtactin Matrix. They were 
analyzed for the presence of bound BCR/ABL by probing with the α-ABL antibody. As a control, 10% of the 
inputs are shown. 
 
4.2.4  MPH-2 efficiently reduces the autophosphorylation of BCR/ABL 
The capacity of MPH-2 to interact with BCR/ABL in vivo prompted us to study its inhibitory 
effects on the aberrant BCR/ABL kinase-expressing cells.  We investigated the 
autophosphorylation status of BCR/ABL at the phospho-tyrosine residue Y245, which is 
critical for ABL-kinase activation  in the Ph+ cell lines, Tom-1 (Ph+ ALL) and BV-173 
(lymphatic CML blast crisis), upon exposure to MPH-2.  Tom-1 and BV-173 cells were 
transduced with MPH-2 and TAT-GFP as negative controls. After 3 hr, cells were lysed, and 
a western blot was performed with antibodies directed against the c-ABL and phosphorylated 
ABL (Y245). As depicted in Figure 16, in contrast to TAT-GFP, MPH-2 inhibited the 
autophosphorylation of BCR/ABL, showing that MPH-2 targets BCR/ABL in patient derived 
Ph+ leukemic cell lines. 
4.2.5  MPH-2 selectively inhibits Ph+ leukemic cell lines 
To definitively establish the inhibitory effects of MPH-2 on the transformation potential of 
BCR/ABL, we assessed the growth of human Ph+ patient derived cells. We exposed Tom-1, 
BV-173, and K562 (myeloid CML blast crisis), and the BCR/ABL negative Nalm-6 cells to 1 
µM of MPH-2, and the negative controls, TAT-GFP and Helix-2-GFP. Cell viability was 
monitored by Trypan blue dye exclusion. As shown in Figure 17A, the growth of Tom-1, BV-
173 and K562 were inhibited by MPH-2 in comparison to the controls, but MPH-2 did not 
exert any influence on the growth of Nalm-6 cells. The inhibitory effects of MPH-2 on the 
growth of Ph+ leukemic cell lines were confirmed by XTT-proliferation assays. The human 
Ph+ cell lines Tom-1, BV-173, K562, and the Ph- cell line Nalm-6 were transduced with 1 
μM of MPH-2, and the proliferation rate was measured after 48 hr of exposure. As depicted in 
Figure 36B, the proliferation of Tom-1 and BV-173 BCR/ABL expressing cells was Results  78 
 
significantly inhibited by MPH-2, whereas the proliferation of K562 was only slightly 
reduced. No non-specific activity of MPH-2 on Nalm-6 cells was observed (Figure 17B).  
Taken together, these data indicate that MPH-2 specifically inhibits Ph+ human cell lines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16 - MPH-2 inhibits the autophosphorylation of BCR/ABL. TOM-1 and BV173 cells were exposed 
for 3 hr to 1 µM of MPH-2. Autophosphorylation was assessed by Western blotting with the α-ABL and α-p-
ABL antibodies directed against whole and phophsorylated ABL, repsectively. 
4.2.6  TAT-fusion protein are efficiently delivered in vivo 
To investigate whether the MPH-2 is efficiently transduced into primary cells we exposed 
primary Sca1+/lin- murine hematopoietic stem cells (HSCs) to MPH-2 for 3 hr. We found that 
these cells were transduced to a similar extent than the above described leukemic cell lines 
(Figure 18A). To determine to what extent the TAT fusion peptides are actively transduced in 
vivo and to assess their in vivo stability, we inoculated i.v. 250 μg of TAT-GFP and MPH-2 
peptides into recipient mice. MNCs from the peripheral blood and bone marrow and spleen 
cells were isolated after 15 mints, 2 hr, 6 hr and 24 hr of treatment. GFP expression was 
measured using FACS. As shown in figure 18B, the GFP expression level peaked at 15 mints, 
was maintained until 6 hr, and was completely abolished after 24 hr in the peripheral blood 
and bone marrow cells. Consistent with peripheral blood, the GFP expression was maximal 
after 15 min and maintained until 24 hr in the bone marrow cells (Figure 18B). In contrast, the 
spleen cells exhibited maximal GFP expression after 6 hr of treatment, which was completely 
lost after 24 hr (Figure 18B). Control mice had no detectable GFP expression in any organ. 
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Figure 17 - Growth inhibition of Ph+ leukemic cell lines upon exposure to MPH-2. Ph+ cell lines; Tom-1 
(Ph+ ALL), BV173 (CML lymphatic blast crisis) and K562 (CML - myeloid blast crisis), and the Ph- Nalm-6 
cells (ALL) were exposed to 1 µM of the indicated peptides. A Proliferation was assessed by either the Trypan 
blue dye exclusion (A) or XTT (B) assay. 
 
In summary, these results demonstrate that TAT-fusion proteins are efficiently delivered to 
the hematopoietic organs and are pharmacologically stable for a pharmacologically 
reasonable period of time. 
Ph+ cell lines are specifically inhibited by Helix-2 peptides targeting the N-terminal 
oligomerization interface of BCR/ABL and these peptides were efficiently delivered to Ph+ 
cell lines. 
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Figure 18 - In vivo transduction of MPH-2. (A)Transduction efficiency in primary Sca1
+
/lin
-
 murine hemato-
poietic stem cells. (B) Transduction efficiency in vivo. 25 µg/kg of body weight of MPH-2 were injected i.v., and 
after the indicated time points, 3 mice/group were sacrificed. GFP expression was determined in the MNCs from 
PB, spleen and BM. 
 
The most  frequent and clinical important resistant BCR/ABL mutations are the “P-loop” 
mutations Y253F and E255K, the “activation loop” mutation H396P, the “catalytic domain” 
mutation M351T, and the “gatekeeper” mutation T315I (Shah et al., 2002). The aim was to 
find out strategies for overcoming resistance towards kinase inhibitors by targeting the 
tetramerization domain of BCR/ABL. 
4.3  Mechanism of the resistance of “gatekeeper” mutation T315I and strategies to 
overcome this sresistance 
4.3.1  Helix-2 interacts with mutant p185
BCR/ABL and disrupts the HMW-complexes of 
these mutants 
The acquisition of point mutations, which decrease the affinity of competitive TK-inhibitors 
such as Imatinib, Dasatinib or Nilotinib to the ATP-binding site of BCR/ABL, is the best 
studied mechanism for resistance against kinase inhibitors (Hantschel and Superti-Furga, 
2004; O'Hare et al., 2005a; von Bubnoff et al., 2005). To assess whether the inhibition of 
tetramerization by Helix-2-peptides is able to inhibit Imatinib-resistant p185
BCR/ABL  we 
evaluated the effects of Helix-2 on three clinically relevant mutations responsible for Imatinib 
resistance - two P-loop mutations Y253H and E255K, and the “gatekeeper” T315I mutation.  
As the interaction of Helix-2 with mutant p185
BCR/ABL  and its capacity to disrupt the 
p185
BCR/ABL tetramerization are required for its inhibitory effects, we first investigated whether  
Helix-2 interacts with mutant p185
BCR/ABL  and disrupts the HMW-complexes of mutant 
p185
BCR/ABL. Therefore, lysates of IL-3 independent Ba/F3 cells co-expressing either WT Results  81 
 
p185
BCR/ABL  or its mutants together with GFP or Helix2-GFP were used for co-
immunoprecipitation as well as for size-exclusion HPLC as described above. 
 
 
 
 
Figure 19 - Helix-2 Interacts with Mutant p185 BCR/ABL, Disrupts HMW-Complexes and Inhibits Auto-
phosphorylation of  WT and Mutant p185 BCR/ABL.(A) A GFP specific antibody was used to co-precipitate 
WT or mutant p185
  BCR/ABL  from lysates of IL-3 independent Ba/F3 cells co-expressing WT or mutant 
p185
BCR/ABL and either GFP or Helix-2-GFP. Co-precipitated p185
 BCR/ABL was detected by Western blot with an 
α-ABL antibody. 5% of the protein amount used is given as input. (B) Cytoplasmic extracts of IL-3 independent 
Ba/F3 cells coexpressing the indicated p185
 BCR/ABL constructs and either GFP or Helix-2-GFP were fractionated 
by size-exclusion HPLC. p185
 BCR/ABL was detected in the fractions by an α-ABL Western blot. (C) Autophos-
phorylation of Mutant p185
 BCR/ABL in presence of Helix-2 peptides. Lysates of GFP or Helix-2-GFP Ba/F3 cell 
clones infected with WT of mutant p185
(BCR/ABL) were blotted and probed with an α-ABL(Tyr-245) specific 
antibody, stripped and re-probed with an α-ABL(Tyr-412) specific antibody. The membrane was repeatedly 
stripped and probed with the indicated antibodies. One representative experiment out of three is given. 
 
The co-immunoprecipitation by an α-GFP antibody and subsequent α-ABL Western blotting 
showed that the p185
BCR/ABL mutants bind to Helix-2 like wt p185
BCR/ABL (Figure 20A) 
Noteworthy, in contrast to GFP, the presence of Helix-2 in these factor-independent cell 
populations seemed to select high expression of p185
BCR/ABL, p185
BCR/ABL-Y253F  and 
p185
BCR/ABL-E255K, but not p185
BCR/ABL-T315I (Figures 19A). Results  82 
 
The analysis of p185
BCR/ABL HMW-complex formation by size-exclusion-HPLC revealed no 
differences between WT p185
 BCR/ABL, and the mutants p185
BCR/ABL-Y253F and p185
BCR/ABL-E255K, 
in the presence of GFP. In fact, all these p185
 BCR/ABL forms were found in HMW fractions 
corresponding to an apparent MW between 670 and 1070 kDa (Figure 19B). In general 
p185
BCR/ABL-T315I forms HMW-complexes of similar sizes as WT p185
BCR/ABL. In addition to 
this p185
BCR/ABL-T315I predominantly forms a complex of about 1070 kDa (fraction no. 25). In 
the presence of Helix-2-GFP we observed a similar size reduction of the HMW-complexes of 
WT p185
BCR/ABL, p185
BCR/ABL-Y253F and p185
BCR/ABL-E255K as observed before in transfected Cos-
1 cells (Figure 11B). Similarly, Helix-2 influenced the HMW-complex pattern of p185
BCR/ABL-
T315I. Helix-2 led to the elution of p185
BCR/ABL-T315I in fractions corresponding to lower MWs 
than GFP. In contrast, the predominant 1070 kDa fraction (no. 25) formed by the mutant 
T315I was not influenced by Helix-2 (Figure 19B).  
In summary, these data suggest that Helix-2 interacts with p185
BCR/ABL, notwithstanding the 
presence of point mutations related to the resistance against kinase inhibitors. Contrary to this, 
the presence of T315I mutations seems to interfere with the capacity of Helix-2 to disrupt 
HMW-complexes of p185
BCR/ABL. 
4.3.2  Helix-2 inhibits the factor independence and overcomes Imatinib resistance of 
hematopoietic cells expressing mutant p185
BCR/ABL with exception of T315I  
To assess whether the interaction of Helix-2 peptides withp185
BCR/ABL is able to overcome 
p185
BCR/ABL- mediated factor independence of hematopoietic cells and the Imatinib- resistance 
conferred by point mutations, we performed proliferation competition assay (PCAs) as 
described earlier. Retrovirally transduced IL-3 independent Ba/F3 bulk populations 
expressing either ΔLNGFR and unmutated p185
  BCR/ABL or ΔLNGFR and p185
  BCR/ABL “P-
loop” mutants Y253H, E255K and “gatekeeper” mutant T315I were super infected with GFP 
or Helix-2-GFP. GFP and Helix-2-GFP expression levels were followed for 8 days and 
expression at day 4 was taken as a reference. Half of the cells were exposed to sub-apoptotic 
Imatinib concentrations (0.4 µM for unmutated p185
BCR/ABL, 3 µM for mutant p185
 BCR/ABL. As 
shown in Figure20A, the growth of cells expressing unmutated p185
BCR/ABL, p185
BCR/ABL-Y253F 
or p185
BCR/ABL-E255K, but not p185
BCR/ABL-T315I was inhibited by Helix-2-GFP, whereas no effect 
of GFP was seen. This effect was enhanced by Imatinib with the exception of p185
BCR/ABL-T315I 
(Figure 20A). To exclude cell line specific effects we extended the on the IL-3 dependent 
murine myeloid cell line 32D with identical results (Figure 20B). 
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Figure 20 - Effect of Helix-2 on BCR/ABL mutants resistant to Imatinib. For proliferation competition expe-
riment WT or mutant p185
BCR/ABL transduced Ba/F3 cells (A) or 32D cells (B) adapted to factor independence 
were infected with GFP or Helix-2-GFP expressing retroviruses. The cells were replated 4 days after infection in 
the presence or absence of sub-apoptotic Imatinib (Ima) concentrations (0.4 µM for WT and 3 µM for mutant 
p185
 BCR/ABL. The proportion of the GFP-positive cell fraction was followed by FACS for 10 days and normalized 
to the GFP expression at day 4. Graphs show mean values ± SD of three independent experiments. 
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In summary, these results demonstrated that Helix-2 is able to inhibit the proliferation of 
Ba/F3 and 32D cells expressing p185
BCR/ABL-E255K and p185
BCR/ABL-Y253F, but not p185
BCR/ABL-
T315I. Except for p185
  BCR/ABL 
-T315I the co-expression of Helix-2 increases the sensitivity of 
mutant p185
 BCR/ABL towards Imatinib. 
4.3.3  Helix-2 reduces the transforming activity of unmutated and mutant p185
BCR/ABL 
We have shown before that the BCC-GFP peptides inhibit the transformation potential of 
BCR/ABL, as revealed by the inhibition of the anchorage independent growth of p185
BCR/ABL - 
expressing Rat-1 fibroblasts (Beissert et al., 2003). To investigate whether Helix-2 peptides 
exhibit similar inhibitory effects on the transformation potential of mutant p185
BCR/ABL we co-
expressed GFP or Helix-2-GFP and unmutated or mutant p185
  BCR/ABL in Rat-1 cells. The 
transduction efficiency was assessed by the detection of GFP and ΔLNGFR, respectively. For 
each construct triplicates of 5,000 double infected Rat-1 cells were plated in soft agar and the 
colonies were counted after 15 days. As shown in Figure 21A Helix-2 inhibited the colony 
formation of Rat-1 cells that express either unmutated or mutant p185
BCR/ABL. To assess 
whether Helix-2 restores the contact inhibition of Rat-1 fibroblasts expressing unmutated or 
mutant p185
 BCR/ABL we performed focus-formation assays with these double-infected Rat-1 
bulks in the presence and absence of Imatinib. At day 15, foci were stained with crystal violet. 
The expression of Helix-2 restored the contact inhibition of unmutated and less pronounced 
that of mutant p185
 BCR/ABL. With the exception of the mutant T315I, the addition of Imatinib 
to the growth medium enhanced the restoration of the contact inhibition (Figure 21B). 
These data indicate that Helix-2 peptides inhibit the transforming capacity of Imatinib-
resistant p185
BCR/ABL  mutants and increase the sensitivity towards Imatinib except for the 
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Figure 21 - Fibroblast Transformation Assays. Rat-1 cells were retrovirally transduced with GFP or Helix-2-
GFP and overinfected with retroviruses encoding WT or Mutant p185
BCR/ABLas indicated. (A) 5000 double in-
fected Rat-1 cells per well were plated in soft-agar in 6-well-plates as described in the material and methods 
section. After 15 days incubation at 5% CO2 and 37°C the colonies were counted. Means ±SD of triplicates of 
two representative experiments are given. (B) Triplicates of 40000 double infected Rat-1 cells per well were 
plated in 24-well-plates. 72h later cells reached confluency and were subsequently incubated for additional 12 
days in absence or presence of the indicated concentrations of Imatinib. Thereafter the adherent cells were 
washed twice with PBS, dried and stained with 1% crystal violet. One represenative experiment of three is given 
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4.3.4  ABL kinase inhibitor (AKI)-resistance mutations restore both transformation  
potential and the capacity to mediate factor independence of oligomerization-deficient 
p185
BCR/ABL 
Targeting the oligomerization interface of p185
BCR/ABL using competitive peptides reduced the 
factor independence of hematopoietic progenitors expressing either unmutated p185
BCR/ABL or 
p185
BCR/ABL harboring the Y253F or E255K but not the T315I mutations. Furthermore, it 
restored Imatinib-sensitivity to p185
BCR/ABL harboring the Y253F and E255K mutations but 
not to p185
BCR/ABL-T315I (Beissert et al., 2008). To determine whether T315I and the other two 
most clinically relevant mutations Y253F and E255K influence the leukemogenic potential of 
p185
BCR/ABL,  we created oligomerization-deficient p185
BCR/ABL  lacking the N-terminal CC-
domain (ΔCCp185) (Beissert et al., 2003) and harboring the Y253F, the E255K, or the T315I 
mutations. The aberrant kinase activity of unmutated BCR/ABL induces signaling pathways 
able to replace factor-induced survival signaling of hematopoietic precursors such as the IL-3 
signaling in the Ba/F3 cell line. We first investigated the capacity of the mutated ΔCCp185 to 
mediate factor independence of Ba/F3 cells. Therefore we retrovirally expressed the indicated 
constructs (Figure 22A) in Ba/F3 cells and controlled the transgene expression by Western 
blotting (Figure 22B). As reported in figure 22C, “unmutated” ΔCCp185 did not grow upon 
factor withdrawal, in contrast to ΔCCp185 harboring Y253F and T315I, which exhibited 
growth curves identical to unmutated p185
BCR/ABL. The ΔCCp185-E255Y cells showed a delay 
in growth of two days (Figure 22C). To avoid cell specific effect we did the same experiments 
using myeloid hematopoietic cells (32D). As shown in figure 22D, in “unmutated” 
p185
BCR/ABL deletion of the coiled-coil domain completely inhibited the growth of p185
BCR/ABL 
after factor withdrawl but ΔCCp185 harboring T315I exhibited growth curves identical to 
unmutated p185
BCR/ABL. The ΔCCp185-E255Y and ΔCCp185-Y253F cells showed a delay in 
growth (Figure 22D).   
To investigate the influence of the mutations on the transformation potential of p185
BCR/ABL, 
we performed classical transformation assays: focus formation assays for the determination of 
contact inhibition and colony assays in semi-solid medium for the determination of Results  87 
 
 
 
 
Figure 22 - The influence of the resistance mutations on the transformation potential of oligomerization-
deficient p185BCR/ABL. (A) Modular organization of the p185
BCR/ABL mutants lacking the CC oligomerization 
interface. (B) Expression of the transgenes in Ba/F3 cells. Tubulin was used as a loading control. (C) Factor-
independent growth of Ba/F3 cells expressing the indicated transgenes; the graph shows the means +/- SDs 
(standard deviations) of three independent experiments. (D) Factor-independent growth of 32D cells expressing 
the indicated transgenes; the graph shows the means +/- SDs (standard deviations) of three independent experi-
ments. (E) Focus formation assay - 4x10
4 infected Rat-1 cells/well were plated in 24-well-plates, grown for 72h 
to conﬂuence, and incubated for additional 12 days. The plates were then washed, dried, and stained with crystal 
violet. One representative of each of 3 experiments performed in triplicate is given (34x magnification). (F) 
Colony formation - Rat-1 cells were retrovirally transduced with the indicated constructs and seeded at 5x10
3 
cells/well in soft-agar in 6-well-plates. After 15 days, the colonies were counted and the means +/- SDS of tripli-
cates of 2 representative experiments are given. 
 
anchorage-dependent growth. We retrovirally transduced Rat-1 fibroblasts with the constructs 
indicated in figure 22A. As shown in Figure 22 E and F, the inhibition of the oligomerization 
by the deletion of the CC-domain completely abolished both focus and colony formation of 
p185
BCR/ABL, whereas the presence of Y253F, E255K, or T315I restored the transformation Results  88 
 
potential of ΔCCp185 as shown by the formation of foci and colonies, respectively (Figure 
22E and F). 
Taken together, these data indicate that the ”p-loop mutations“ Y253F and E255K and the 
“gatekeeper“ mutation T315I are  not only responsible for AKI-resistance but also confer 
additional properties to the oligomerization-deficient  ΔCCp185, which allow the 
transformation potential and the capacity to mediate factor independence to be restored. 
Notably, the T315I mutation exhibited the most prominent effects. We focused our study on 
the “gatekeeper” mutation T315I which confers resistance against virtually all ATP 
competitors and oligomerization inhibition. 
4.3.5  The “gatekeeper” mutation T315I restores the capacity to mediate factor  
independence of oligomerization-deficient CML-associated p210
BCR/ABL 
T315I confer additional properties to the oligomerization-deficient ΔCCp185, which allow the 
transformation potential and the capacity to mediate factor independence.  
To determine whether T315I influences the leukemogenic potential of p210
BCR/ABLalso, we 
created oligomerization-deficient p210
BCR/ABL lacking the N-terminal CC-domain (ΔCCp210) 
and harboring the T315I mutation. The aberrant kinase activity of unmutated BCR/ABL 
induces signaling pathways able to replace factor-induced survival signaling of hematopoietic 
precursors such as the IL-3 signaling in the Ba/F3 cell line. We first investigated the capacity 
of the mutated ΔCCp210 to mediate factor independence of Ba/F3 cells. Therefore we 
retrovirally expressed the indicated constructs (Figure 23A) in Ba/F3 cells and controlled the 
transgene expression by Western blotting (Figure 23B). As reported in Figure 23C, 
“unmutated”  ΔCCp210 did not grow upon factor withdrawal, in contrast to ΔCCp185 
harboring T315I, which exhibited growth curves identical to unmutated p185
BCR/ABL.  
Collectively these data show that in CML-associated p210
BCR/ABL, T315I restored the factor 
independent growth of the oligomerization deficient ΔCCp210 in similar way as p185
BCR/ABL. 
Therefore, we focused our study on the Ph+ ALL-associated p185
BCR/ABL because there is no 
difference in the response to oligomerization inhibition between CML-associated p210
BCR/ABL 
and p185
BCR/ABL. 
4.3.6  Deletion of BCR AA 64-412 (BCC/ABL) sensitizes T315I towards inhibitory  
peptides 
To determine the mechanisms i.) of the resistance of T315I mutants against the inhibition of 
oligomerization and ii.) of how the T315I mutation influences the biology of BCR/ABL itself, 
we investigated the effects of T315I on BCR/ABL mutants that have no capacity or a reduced  Results  89 
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Figure 23 - The influence of the resistance mutations on the transformation potential of oligomerization-
deficient p210BCR/ABL. (A) Modular organization of the p210
BCR/ABL and its T315I mutant lacking the CC 
oligomerization interface. (B) Expression of the transgenes in Ba/F3 cells in comparison to p185
BCR/ABL and p185-
T315. The detection of endogenous ABL allows us to evaluate equal loading. C Factor-independent growth of 
Ba/F3 cells expressing the indicated transgenes; the graph shows the means +/- SDs of three independent experi-
ments. 
 
capacity to mediate factor-independent growth of hematopoietic progenitors. First we focused 
on mutations interfering with functional domains in the BCR-portion of the fusion protein. We 
investigated the effects of T315I on BCC/ABL, in which the CC-domain is directly fused to the 
ABL-portion of the fusion protein (Beissert  et al., 2003).Thus; we retrovirally transduced 
Ba/F3 and 32D cells with the indicated constructs (Figure 24A) and the expression of the 
transgenes was controlled by Western blotting (Figure 24B). We investigated cell growth upon 
factor withdrawal (Figure 24C-F). As shown in Figure 24C, T315I strongly improved the 
capacity of BCC/ABL to mediate factor-independent growth of Ba/F3. In fact, BCC/ABL-
T315I grew to the same extent as unmutated p185
BCR/ABL, whereas BCC/ABL showed the 
expected delay in growth (Figure 24C). To study the response of these mutants to the inhibition 
of the oligomerization, we performed proliferation competition assays upon exposure to either 
the Helix-2 peptide fused to GFP or to GFP alone as a control as described previously (Beissert 
et al., 2008). Results  90 
 
 
 
Figure 24 - Role of serine/threonine and Grb-2 binding domains in the resistance of T315I mutants against 
the oligomerization inhibition by Helix-2. For the determination of factor-independent growth and for the 
proliferation competition assays (CPAs) and transformation assays, Ba/F3, 32D and Rat-1 cells were retrovirally 
transduced with the indicated constructs. (A) BCC/ABL - the N-terminal CC-domain of BCR/ABL directly 
fused to the ABL-portion of the fusion protein +/- T315I. (B) Transgene expression was confirmed by Western 
blotting with the indicated antibodies. Molecular mass references (KDa) are given, and α-Tubulin was used as a 
loading control. (C) factor-independent growth Ba/F3 cells and (D) factor-independent growth 32D cells. The 
number of viable cells was daily determined by Trypan blue dye-exclusion. (E) CPAs for Ba/F3 and (F) for 32D 
cells. The cells were adapted to factor independence, infected with GFP or Helix-2-GFP, and seeded. The pro-
portion of the GFP-positive cell fraction was followed by FACS for 10 days and normalized to the GFP expres-
sion at day 4 (rel. GFP expression). The graphs show the means +/- SD of three independent experiments. (G) 
Focus formation assay -  4x10
4  infected Rat-1 cells/well were plated in 24-well-plates, grown for 72h to 
conﬂuence, and incubated for additional 12 days. The plates were then washed, dried, and stained with crystal 
violet. One representative of each of 3 experiments performed in triplicate is given (34x magnification). (H) 
Colony formation - Rat-1 cells were retrovirally transduced with the indicated constructs and seeded at 5x10
3 
cells/well in soft-agar in 6-well-plates. After 15 days, the colonies were counted and the means +/- SDS of tripli-
cates of 2 representative experiments are given. 
 
The capacity of both BCC/ABL and BCC/ABL-T315I to mediate factor-independent growth 
was completely abolished by the inhibition of the BCC-mediated oligomerization through the Results  91 
 
competitive Helix-2 peptide (Figure 24E). Similar results were obtained in 32D cells (Figure 
24D and F) 
Regarding the transformation potential of p185
BCR/ABL, we performed focus formation assays 
for the determination of contact inhibition and colony assays in semi-solid medium for the 
determination of anchorage-dependent growth. We retrovirally transduced Rat-1 fibroblasts 
with the constructs indicated in figure 24A. As shown in figure 24G and H, deletion of the 
S/T and Grb-2 binding (Y177) domains completely abolished both focus and colony 
formation of p185
BCR/ABL and p185
BCR/ABL-T315I. 
Collectively these data show that deletion of serine/threonine and Grb-2 binding domains 
sensitize T315I towards inhibitory peptides and the cells are no more transformed. 
4.3.7  In case of ΔS/T (BCR 1-196ABL) construct: T315I enhances factor independence 
while transformation of fibroblast is not changed 
Further we constructed mutants BCR(1-196) ABL and BCR(1-196) ABL-T315I, in which the 
Y177 phosphorylation is present in addition to the CC-domain. We retrovirally transduced 
Ba/F3 cells with the indicated constructs (Figure 25A) and controlled the expression of 
transgene by western blotting  (Figure 25B).We investigated cell growth upon factor 
withdrawal by dye exclusion using Trypan-blue (Figure 25C). As show in (Figure 26B) the 
T315I mutation improved the capacity to mediate factor-independent growth to the level of 
unmutated p185
BCR/ABL, while unmutated BCR/ABL showed a delay in growth.  
To study the response of the above mutants to the inhibition of the oligomerization, we 
performed proliferation competition assays upon exposure to either the Helix-2 peptide fused 
to GFP or to GFP alone as a control as described previously(Beissert et al., 2008). Notably, 
the presence of T315I rendered the BCR (1-196)/ABL resistant against the inhibition of 
oligomerization by Helix-2 (Figure 25D). 
To determine transformation potential, focus formation assay and colony formation in semi-
solid medium were performed with retrovirally transduced Rat-1 cells. As depicted in figure 
25E and F deletion of serine/threonine domain did not change the transformation potential of 
fibroblast. 
Take together these data show that serine/ threonine domain has no important role in 
transformation of fibroblast and the resistance of T315I towards inhibitory peptides.  Results  92 
 
 
 
Figure 25 - Role of serine/threonine domain in the resistance of T315I mutants against the oligomerization 
inhibition by Helix-2. For the determination of factor-independent growth and for the proliferation competition 
assays (CPAs) and transformation assays, Ba/F3 and Rat-1 cells were retrovirally transduced with the indicated 
constructs. (A)  ∆S/T-ABL or BCR(1-196)/ABL - the N-terminal CC-domain to Grb-binding sites of BCR/ABL 
directly fused to the ABL-portion of the fusion protein +/- T315I. (B) Transgene expression was confirmed by 
Western blotting with the indicated antibodies. Molecular mass references (KDa) are given, and α-Tubulin was 
used as a loading control. (C) factor-independent growth Ba/F3 cells. The number of viable cells was daily de-
termined by Trypan blue dye-exclusion. (D) CPAs for Ba/F3 cells. The cells were adapted to factor indepen-
dence, infected with GFP or Helix-2-GFP, and seeded. The proportion of the GFP-positive cell fraction was 
followed by FACS for 10 days and normalized to the GFP expression at day 4 (rel. GFP expression). The graphs 
show the means +/- SD of three independent experiments. (E) Focus formation assay - 4x104 infected Rat-1 
cells/well were plated in 24-well-plates, grown for 72h to conﬂuence, and incubated for additional 12 days. The 
plates were then washed, dried, and stained with crystal violet. One representative of each of 3 experiments per-
formed in triplicate is given (34x magnification). (F) Colony formation - Rat-1 cells were retrovirally transduced 
with the indicated constructs and seeded at 5x103 cells/well in soft-agar in 6-well-plates. After 15 days, the co-
lonies were counted and the means +/- SDS of triplicates of 2 representative experiments are given. 
 
4.3.8  Resistance of p185
BCR/ABL-T315I  against inhibition of the 
oligomerization depends on the phosphorylation at Y177 
To confirm the hypothesis that the phosphorylation of Y177 is indispensable for the resistance 
of p185
BCR/ABL harboring the T315I mutation against the Helix-2, we studied a p185-T315I 
mutant in which phosphorylation at Y177 was abolished by a point mutation to phenylalanine 
(p185-Y177F-T315I). We retrovirally transduced Ba/F3 cells with the indicated constructs Results  93 
 
and confirmed the expression of transgene by western blotting (Figure 26A and B). We 
investigated cell growth upon factor withdrawal by dye exclusion using trypan-blue. As 
shown in figure 26C, the absence of phosphorylation at Y177 strongly delayed growth upon 
factor withdrawal, which was completely restored by the presence of T315I. To study the 
response of these mutants to the inhibition of the oligomerization, we performed proliferation 
competition assays upon exposure to either the Helix-2 peptide fused to GFP or to GFP alone 
as a control as described previously(Beissert  et al., 2008).  Factor-independent growth of 
p185
BCR/ABL which was reduced by mutating Y177 to Y177F was completely abolished by the 
inhibition of oligomerization through the competitive Helix-2 peptides. Furthermore, the 
p185-Y177F-T315I turned sensitive to the  oligomerization inhibition by Helix-2 (Figure 
26D). 
To study transformation potential of the fibroblast, focus formation and semi-solid colony 
formation assays were performed. As shown in figure 26E,  mutation of Y177 to 
phenylalanine impaired colony formation in unmutated BCR/ABL but not in T315I, while no 
difference was observed foci formation (Figure 26E and F).  
In summary, our results show that i.) the phosphorylation of Y177 is critical for the resistance 
of p185
BCR/ABL against the inhibition of the oligomerization ii.) the phosphorylation of Y177 is 
for colony formation but has no role in foci framation iii.) the effects of the T315I mutation 
are not limited to oligomerization-deficient p185
BCR/ABL mutants. 
4.3.9  Autophosphorylation at Y177 is not affected by the oligomerization inhibition, 
but  phosphorylation at Y177 of endogenous BCR parallels the effects of T315I 
The differences between unmutated p185
BCR/ABL  and p185-T315I regarding the apparent 
importance of the phosphorylation at Y177  for the resistance against the inhibition of 
oligomerization  prompted us to investigate the tyrosine phosphorylation at Y177 in the 
presence/absence of T315I. We used a specific antibody directed against BCR phosphorylated 
at Y177 on lysates of Ba/F3 cells expressing the different p185
BCR/ABL mutants with or without 
the T315I mutation. To avoid the interference of stress signalling induced by the selection 
factor withdrawal, we performed these experiments on newly transduced cells in the presence 
of IL-3. We showed that unmutated p185
BCR/ABL and all mutants in which Y177 was present 
(ΔCCp185,  ΔCCp185-T315I, BCR(1-196)/ABL, BCR(1-196)/ABL-T315I) were fully 
phosphorylated at the Y177  (Figure 27A-C) independently of the inhibition of 
oligomerization through either the Helix-2 or the  deletion of the CC-domain (Figure 27A and 
B). Results  94 
 
 
 
Figure 26 - Role of Y177 in the resistance of T315I mutants against the oligomerization inhibition by He-
lix-2. For the determination of factor-independent growth and for the proliferation competition assays (CPAs) 
and transformation assays, Ba/F3 and Rat-1 cells were retrovirally transduced with the indicated constructs. (A)  
Grb-2-binding site Y177 of BCR/ABL was mutated to phenylalanine +/- T315I. (B) Transgene expression was 
confirmed by Western blotting with the indicated antibodies. Molecular mass references (KDa) are given, and α-
Tubulin was used as a loading control. (C) factor-independent growth Ba/F3 cells. The number of viable cells 
was daily determined by Trypan blue dye-exclusion. (D) CPAs for Ba/F3 cells. The cells were adapted to factor 
independence, infected with GFP or Helix-2-GFP, and seeded. The proportion of the GFP-positive cell fraction 
was followed by FACS for 10 days and normalized to the GFP expression at day 4 (rel. GFP expression). The 
graphs show the means +/- SD of three independent experiments. (E) Focus formation assay - 4x10
4 infected 
Rat-1 cells/well were plated in 24-well-plates, grown for 72h to conﬂuence, and incubated for additional 12 days. 
The plates were then washed, dried, and stained with crystal violet. One representative of each of 3 experiments 
performed in triplicate is given (34x magnification). (F) Colony formation - Rat-1 cells were retrovirally trans-
duced with the indicated constructs and seeded at 5x10
3 cells/well in soft-agar in 6-well-plates. After 15 days, 
the colonies were counted and the means +/- SDS of triplicates of 2 representative experiments are given. 
 
 The antibody also revealed the Y177-phosphorylation of endogenous BCR. The inhibition of 
oligomerization either by the deletion of the CC-domain or by the competitive Helix-2 
peptides reduced or abolished Y177 phosphorylation of endogenous BCR in cells expressing  Results  95 
 
 
 
Figure 27 - Y177-phosphorylation in the autophosphorylation of p185BCR/ABL and its mutants and the 
transphosphorylation of endogenous BCR in relationship to the presence of T315I upon the inhibition of 
oligomerization. Western blotting using antibodies directed against BCR (which did not detect BCR/ABL) (α-
BCR) and BCR phosphorylated at Y177 (α-p-BCRY177). p185
BCR/ABL and its mutants were detected by an α-
ABL-antibody. Molecular mass references (KDa) are given. Tubulin or endogenous ABL was used as a loading 
control. (A) Ba/F3 cells expressing p185
BCR/ABL or p185-T315I in the presence of either Helix-2 (H2) or control 
GFP. (B) Ba/F3 cells expressing p185
BCR/ABL p185-T315I lacking the N-terminal CC-oligomerization interface 
(ΔCCBCR/ABL) in the presence of either Helix-2 (H2) or control GFP. (C) Ba/F3 cells expressing BCC/ABL 
+/- T315I in the presence of either Helix-2 (H2) or control GFP.  (D) Ba/F3 cells expressing BCR(1-196)/ABL 
+/- T315I.  
  
unmutated p185
BCR/ABL, BCR(1-196)/ABL, or BCC/ABL (Figure 27A-C). Notably, in all 
mutants, the T315I mutation restored the phosphorylation of BCR at Y177 independently of 
targeting the oligomerization (Figure 27A-C and D). Results  96 
 
Taken together, these data indicate that the biological effects of the T315I mutation may be 
mediated through an aberrant trans-phosphorylation of endogenous BCR as an expression of a 
restored or increased substrate phosphorylation by the ABL-kinase in the presence of the 
T315I mutation. 
4.3.10  The effects of T315I are associated with an intact ABL-kinase activity 
Our data suggest a direct relationship between positive effects of T315I on p185
BCR/ABL-
mutants and the phosphorylation of endogenous BCR. To confirm this hypothesis and to 
disclose whether the effects of T315I depend on an intact ABL-kinase activity, we first 
explored the effects of T315I on the isolated ABL portion of the BCR/ABL fusion proteins 
(#ABL) regarding factor-independent growth. Ba/F3 cells were retrovirally transduced with 
the indicated constructs the expression of the transgenes was controlled by Western blotting 
(Figure 28A and B). As shown in Figure 28C, T315I was unable to confer to #ABL the 
capacity to induce factor-independence. To investigate transformation potential of fibroblast 
of #ABL constructs, we performed focus formation and semi-solid colony assay using 
retrovirally transduced RAT-1 cells. As show in figure 28E and F, T315I could not confer 
transformation potential to the deleted construct #ABL. In these cells, endogenous BCR was 
not phosphorylated (Figure 28B). Same results were obtained from 32D cells (Figure 28D). 
These data show that T315I exerts its effects in the presence of an intact ABL-kinase activity 
and confirm the relationship between the phosphorylation of endogenous BCR and the 
capacity of BCR/ABL and ABL-mutants to mediate factor-independent growth induced by 
the presence of T315I. 
4.3.11  Deletion of regulatory SH3 domain (∆SH3-ABL) restores 
factor-independent growth of T315I 
In the past, it has been described that the deletion or inactivation of the SH3 domain of ABL 
by point mutations confers transformation potential  to c-ABL  (Barila and Superti-Furga, 
1998; Zheng  et al., 2004). The SH3 domain seems to be responsible for the functional 
inactivity of the ABL-portion of BCR/ABL. Hence, we created a mutant that lacks a 
functional  SH3 domain (ΔSH3-ABL) alone and in combination with the T315I and 
retrovirally transduced Ba/F3 cells with these constructs (Figure 29A). As shown in Figure 
29C, upon factor-withdrawal, ΔSH3-ABL allowed the survival of the cells but the cells did 
not proliferate. In contrast, cells expressing ΔSH3-ABL-T315I proliferated to the same extent 
as p185
BCR/ABL. In both ΔSH3-ABL-  and  ΔSH3-ABL-T315I-expressing cells, endogenous 
BCR was phosphorylated (Figure 29B). Results  97 
 
 
 
Figure 28 - Role of the ABL-kinase in the activity of T315I in p185BCR/ABL and its mutants. For the de-
termination of factor-independent growth and transformation assay, Ba/F3 and Rat-1 cells were retrovirally 
transduced with the indicated constructs and grown upon factor withdrawal. (A) Constructs #ABL - the ABL-
portion of the BCR/ABL fusion protein +/- T315I. (B) Transgene expression was confirmed by Western blotting 
with the indicated antibodies against ABL and BCR and BCR phosphorylated at Y177. α-Tubulin was used as a 
loading control. (C) factor-independent growth Ba/F3 cells. The number of viable cells was daily determined by 
Trypan blue dye-exclusion. (D) CPAs for Ba/F3 cells. The cells were adapted to factor independence, infected 
with GFP or Helix-2-GFP, and seeded. The proportion of the GFP-positive cell fraction was followed by FACS 
for 10 days and normalized to the GFP expression at day 4 (rel. GFP expression). The graphs show the means +/- 
SD of three independent experiments. (E) Focus formation assay - 4x10
4 infected Rat-1 cells/well were plated in 
24-well-plates, grown for 72h to conﬂuence, and incubated for additional 12 days. The plates were then washed, 
dried, and stained with crystal violet. One representative of each of 3 experiments performed in triplicate is given 
(34x magnification). (F) Colony formation - Rat-1 cells were retrovirally transduced with the indicated con-
structs and seeded at 5x10
3 cells/well in soft-agar in 6-well-plates. After 15 days, the colonies were counted and 
the means +/- SDS of triplicates of 2 representative experiments are given. 
 
Collectively these data show that deletion of SH3 domain restores factor-independent growth 
of T315I which is accompanied with endogenous BCR phosphorylation. 
4.3.12  Oligomerization domain & GRB-2 binding site double deletions (ΔCCp185- 
Y177F): T315I enhances factor-independence  
To definitively prove the effects of T315I on functionally completely inactive BCR/ABL 
mutants, we created an oligomerization-deficient mutant lacking the phosphorylation site at Results  98 
 
Y177 (ΔCCp185-Y177F). We  retrovirally transduced Ba/F3 cells for factor-independent 
growth and Rat-1 for transformation potential with the indicated constructs (Figure 30A). 
 
 
 
Figure 29 - Role of the SH3 domain in the activity of T315I in p185BCR/ABL. For the determination of 
factor-independent growth, Ba/F3 cells were retrovirally transduced with the indicated constructs and grown 
upon factor withdrawal. (A) ConstructsΔSH3-ABL - ABL lacking the N-terminal SH3 domain +/-T315I. (B) 
Transgene expression was confirmed by Western blotting with the indicated antibodies against ABL and BCR 
and BCR phosphorylated at Y177. α-Tubulin was used as a loading control. (C) factor-independent growth 
Ba/F3 cells. The number of viable cells was daily determined by Trypan blue dye-exclusion. 
 
Interestingly, even in this mutant, which lacks two functions considered indispensable for the 
activity of BCR/ABL, in the presence of T315I the capacity to mediate factor independent 
growth was almost completely restored (Figure 30B). The same results were observed for 
transformation potential of fibroblast (Figure 30D and E).  Also, the presence of T315I was 
accompanied by the Y177 phosphorylation of endogenous BCR (Figure 30C).  
These data show that T315I exerts its effects in the presence of an intact ABL-kinase activity 
and confirm the relationship between the phosphorylation of endogenous BCR and the 
capacity of BCR/ABL and ABL-mutants to mediate factor-independent growth induced by 
the presence of T315I. Furthermore, it seems that activation of the ABL-kinase activity is 
enough to ensure survival of cells upon factor withdrawal but not to make them proliferate. 
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Figure 30 - The influence of the resistance mutations on the transformation potential of oligomerization-
deficient & GRB-2 binding site (Y177F) double muatatin BCR/ABL.  (A)  Modular organization of the 
p185
BCR/ABL mutants lacking the CC oligomerization interface and point muation in the Grb-2 binding site Y177. 
(B) Factor-independent growth of Ba/F3 cells expressing the indicated transgenes; the graph shows the means 
+/- SDs (standard deviations) of three independent experiments. . (C) Transgene expression was confirmed by 
Western blotting with the indicated antibodies against ABL and BCR and BCR phosphorylated at Y177. α-
Tubulin was used as a loading control. (D) Focus formation assay - 4x10
4 infected Rat-1 cells/well were plated 
in 24-well-plates, grown for 72h to conﬂuence, and incubated for additional 12 days. The plates were then 
washed, dried, and stained with crystal violet. One representative of each of 3 experiments performed in tripli-
cate is given (34 x magnifications). (E) Colony formation - Rat-1 cells were retrovirally transduced with the 
indicated constructs and seeded at 5x10
3 cells/well in soft-agar in 6-well-plates. After 15 days, the colonies were 
counted and the means +/- SDS of triplicates of 2 representative experiments are given. 
 
4.3.13  The presence of T315I is associated with increased ABL-kinase activity also in  
mutants unable to induce Y177 phosphorylation of endogenous BCR 
To determine whether the Y177 phosphorylation in the presence of T315I is due to increased 
substrate phosphorylation of the ABL-kinase, we investigated whether the T315I was able to 
interfere with the ABL-kinase activity. Therefore, we studied the autophosphorylation at 
Y245 in the different mutants used in this study. As shown in Figure 31, T315I increased the 
autophosphorylation in all mutants as revealed by the specific antibody. Interestingly, T315I 
induced a slight increase in kinase activity in the #ABL mutant, which was unable to rescue Results  100 
 
the capacity of this mutant to mediate factor independent growth or the Y177 phosphorylation 
of endogenous BCR (32 A and B). 
 
 
Figure 31 - Influence of T315I on the kinase activity p185
BCR/ABL and its mutants – autophosphorylation. 
Western blotting on lysates of Ba/F3 cells expressing the indicated transgenes using antibodies directed against 
c-ABL and ABL Y245 (α-p-ABLY245). Molecular mass references (KDa) are given and Tubulin was used as a 
loading control. 
 
These data show that T315I induces increased ABL-kinase activity, an effect that is probably 
masked in the unmutated forms of BCR/ABL. Interestingly; there is no direct relationship 
between the ABL-kinase activity and the capacity to mediate factor-independence as revealed 
by the #ABL-T315I mutant, which was unable to induce Y177 phosphorylation of BCR.  
Oligomerization inhibition and allosteric inhibition  (GNF-2) are unable to overcome the 
resistance of BCR/ABL harboring the T315I mutation (Beissert et al., 2008). we investigated 
whether it was possible to overcome the resistance of the BCR/ABL-T315I mutant against 
molecular therapeutic approaches by combining the allosteric inhibition of GNF-2 with the 
competitive peptide Helix-2 to inhibit BCR/ABL oligomerization. 
 
4.4  Oligomerization inhibition combined with allosteric inhibition abrogates the  
transformation potential of T315I-positive BCR/ABL   
4.4.1  Targeting the oligomerization of BCR/ABL increases the efficacy of GNF-2 
against unmutated p185
BCR/ABL and p185
BCR/ABL harboring the T315I mutation 
In order to determine whether or not the inhibition of oligomerization improved the response 
to allosteric inhibition of cells that depend on the functionality of BCR/ABL for their 
survival,  we performed proliferation competition assay (PCA) on p185
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Ba/F3 cells. The principle of the assay is depicted in Figure 32A: Ba/F3 cells transduced with 
the retroviral vector PAULOp185. The resulting in bulk populations that uniformly coexpress 
p185
BCR/ABL and ΔLNGFR, were transduced with retroviral vectors harboring GFP and Helix-
2-GFP. The resulting double infected cell populations were then exposed to GNF-2 at a 
concentration of 2 µM, which was the IC50 for growth inhibition in our system. The effect of 
the transduced peptides was assessed by the detection of GFP positive cells for 10 days by 
FACS. The GFP-expression on day 2 was taken as a reference for normalization. As shown in 
figure 32B, the expression of GFP did not alter the proliferation of p185
BCR/ABL expressing 
Ba/F3 cells as revealed by the constant percentage of GFP positive cells. In contrast, Helix-2 
inhibited the growth of p185
BCR/ABL expressing Ba/F3 cells as shown by the fact that the 
percentage of Helix-2-GFP expressing cells decreased over time with comparable kinetics 
(Figure 32B). The addition of GNF-2 accelerated and intensified the decrease of Helix-2-GFP 
expressing cells, but had no influence on GFP controls, suggesting a reciprocal interaction 
between the two compounds in blocking the BCR/ABL-dependent survival signaling upon 
factor withdrawal in these cells (Figure 32B). 
Given the fact that PCA cannot reveal the effects of GNF-2 alone, we investigated the effects 
of GNF-2 alone or in combination with Helix-2 in comparison to the effects of Helix-2 on the 
proliferation of p185
BCR/ABL-expressing Ba/F3 cells by measuring the reduction of the 
tetrazolium salt XTT to formazan (XTT-assay). As a control, the cells were exposed to 0.5 
µM Imatinib. Imatinib and GNF-2 reduced the metabolic activity of the p185
BCR/ABL-
expressing Ba/F3 cells to the same extent independently of the presence of helix-2 (Figure 
32C). 
Both GNF-2 and Helix-2 are known to have no effect on cells that express p185-T315I 
(Adrian et al., 2006; Beissert et al., 2008). To investigate whether the combination of these 
two approaches are able to inhibit p185-T315I, the experiments described above were 
repeated using Ba/F3 cells that express p185-T315I. The known resistance of these cells 
against GNF-2 and Helix-2 alone was confirmed in the PCA and the XTT assay (Figure 32D 
and E). Interestingly, in combination, the two compounds were nearly able to completely 
abolish the capacity of the p185-T315I mutant to mediate factor-independent growth (Figure 
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Figure 32  -  Effects of  the oligomerization inhibitor Helix-2 on the response of p185BCR/ABL and 
p185BCR/ABLT315I towards allosteric inhibition by GNF-2 (A) Schematic representation of the prolifera-
tion-competition assay.(B) Proliferation-competition assay (PCA) forBaF/3 cells expressing p185
BCR/ABL. Factor-
independent cells (i.e. p185
BCR/ABL expressing Ba/F3 cells) were retrovirally infected with inert control peptides 
(GFP) or Helix-2-GFP. In the case of the inert GFP control, the percentage of GFP-positive cells remained con-
stant from day 2 to day 10. In contrast, the expression of inhibitory peptides resulted in an outgrowth of peptide-
expressing cells, which was revealed by progressive loss of Helix-2-GFP expression. (C) XTT assay for Ba/F3 
cells expressing p185
BCR/ABL upon exposure to 0.5 µM Imatininb and/or 2 µM GNF-2 in the absence/presence of 
Helix-2, as indicated. Proliferation status was revealed by determination of the metabolic activity of cells given 
by the reduction rate of XTT to formazan. The means +/- SD of triplicates from one representative experiment 
out of three performed are given. (D)  Proliferation-competition assay (PCA) forBaF/3 cells expressing 
p185
BCR/ABL-T315I. E XTT assay for Ba/F3 cells expressing p185
BCR/ABL upon exposure to 0.5 µM Imatininb and/or 
2 µM GNF-2 in the absence/presence of Helix-2, as indicated. (E) Proliferation status was revealed by determi-
nation of the metabolic activity of cells given by the reduction rate of XTT to formazan. The means +/- SD of 
triplicates from one representative experiment out of three performed are given.  
 
Taken together, these data suggest that the effect of GFN-2 may be enhanced by the 
monomerization of BCR/ABL and the combination of the two molecular approaches 
overcomes the resistance of BCR/ABL-T315I against the oligomerization inhibition of Helix-
2 and the allosteric inhibition of GNF-2. Results  103 
 
4.4.2  Targeting the oligomerization of BCR/ABL in combination with GNF-2 induces 
apoptosis in unmutated p185
BCR/ABL and p185
BCR/ABL harboring the T315I mutation 
To investigate whether the observed effects on proliferation were related to the induction of 
apoptosis, factor-independent p185
BCR/ABL-expressing Ba/F3 cells in the presence/absence of 
Helix-2 were exposed to 2 µM GNF-2 and stained with 7-AAD, which determines the 
apoptosis rate. As expected, GNF-2 increased the apoptosis rate as compared to the controls, 
whereas Helix-2 did not (Figure 33A). Interestingly, the combination of GNF-2 and Helix-2 
induced an apoptosis rate close to 100% (Figure 333A). 
Both GNF-2 and Helix-2 are known to have no effect on the induction of apoptosis in p185-
T315I expressing cells (Adrian et al., 2006; Beissert et al., 2008). To investigate whether the 
combination of these two approaches are able to induce apoptosis in p185-T315I, factor-
independent p185-T315I-expressing Ba/F3 cells in the presence/absence of Helix-2 were 
exposed to 2 µM GNF-2. The treated cells were stained with 7-AAD after 4 days. The known 
resistance of these cells against GNF-2 and Helix-2 alone was confirmed in the apoptosis 
assays (Figure 33B). Interestingly, in combination, the two compounds were able to induce 
more than 60% apoptosis and nearly abolish the capacity of the p185-T315I mutant to 
mediate factor-independent growth (Figure 33B). 
 
 
Figure 33 - Induction of apoptosis in Ba/F3 expressing pa185BCR/ABL and p185BCR/ABL-T315I by 
oligomerizatin inhibitor Helix-2 in combination with allosteric inhibitor GNF-2 (A)Apoptosis rate of Ba/F3 
cells expressing p185
BCR/ABL upon exposure to 2 µM GNF-2 in the absence/presence of Helix-2, as indicated. (B) 
Apoptosis rate of Ba/F3 cells expressing p185
BCR/AB-T315I upon exposure to 2 µM GNF-2 in the absence/presence 
of Helix-2, as indicated. The apoptosis rate was determined by staining with 7-AAD. The data represent the 
mean and SD of three independent experiments. 
  
Taken together, these results show that the GNF-2 induces apoptosis in p185-T315I 
expressing cells in combination with Helix-2 and increase sensitivity for Helix2 to overcome 
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4.4.3  Helix-2 in combination with GNF-2 reduce transformation 
potential of Fibroblast  
expressing unmutated p185
BCR/ABL and p185-T315I 
BCR/ABL-dependent signaling “substitutes” for IL-3 signaling in factor-dependent 
hematopoietic cell lines, such as Ba/F3. To further study the effects of GNF-2 in combination 
with the oligomerization inhibition, a soft agar assay was performed as a classic 
transformation assay in untransformed Rat-1 fibroblasts.  Sorted GFP or Helix-2 positive Rat-
1 cells were retrovirally transduced with p185
BCR/ABL  and  p185-T315I. The transduction 
efficiency was assessed by the detection of GFP and ∆LNGFR respectively. Empty-vector-
transduced Rat-1 cells (mock) were used as controls. For each construct triplicates of 5,000 
double infected Rat-1 cells were plated in soft agar and were then exposed to 2 µM of GNF-2. 
The colonies were counted after 15 days. GNF-2 alone was able to reduce the transformation 
potential of unmutated BCR/ABL to the same extent as Helix-2, but the combination of both 
nearly completely abolished the BCR/ABL-induced transformation (Figure 34A).  Alone 
Helix-2or GNF-2 were unable to change the transformation potential of fibroblast expressing 
p185-T315I but combining both the compounds significantly  reduced the transformation 
potential of fibroblast expressing p185-T315I did not change the transformation potential of 
fibroblast (Figure 34B). 
 
 
Figure 34 - Impairment of transformation potential of Fibroblast expressing unmutated p185BCR/ABL 
and p185BCR/ABL-T315I by GNF-2 in combination with Helix-2 (A) Transformation assay by colony for-
mation in soft aga for Rat-1 cells expressing p185
BCR/ABL. (B) Transformation assay for p185
BCR/ABL-T315I: Rat-1 
cells were retrovirally transduced with the indicated constructs, and seeded at 5x10
3 cells/well in soft-agar in 6-
well-plates. After 15 days, the colonies were counted, and the means +/- SD of triplicates obtained from two 
representative experiments are presented. 
 
In summary, these data  strongly suggest that the combination of the two molecular 
approaches completely abolish the leukemogenic potential of unmutated BCR/ABL and 
BCR/ABL horboringT315I mutation.  
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4.4.4  GNF-2 completely abolishes growth of p185
BCR/ABL and oligomerization-deficient  
p185-T315I 
To confirm the above data, we investigated the effects of GNF-2 on a BCR/ABL lacking the 
N-terminal coiled coil oligomerization (ΔCCp185 and ΔCCp185-T315I) interface in which 
the presence of T315I restores the transformation potential as well as the capacity to mediate 
factor-independent growth (Mian et al., 2009c). 
Therefore we retrovirally expressed the indicated constructs (Figure 35A) in Ba/F3 cells and 
controlled the transgene expression by Western blotting. The cells were grown without factor 
in the presence or absence of 2µM GNF-2. As reported in figure 35B, “unmutated” ΔCCp185 
and p185
BCR/ABL in the presence of GNF-2 did not grow upon factor withdrawal, in contrast to 
ΔCCp185 T315I, which exhibited growth curves identical to unmutated p185
BCR/ABL.  As 
expected, GNF-2 completely reverted the effect of T315I on this loss-of-function mutant 
(Figure 35B).   
Collectively, these data confirm the effect of oligomerization and the allosteric inhibition of 
GNF-2 in combination, which overcomes the resistance of BCR/ABL-T315I against the 
oligomerization inhibition of Helix-2 and the allosteric inhibition of GNF-2 alone.  
A            B 
 
 
 
Figure 35 - Role of oligomerization in the sensitivity of unmutated p185BCR/ABL and p185-T315I to-
wards allosteric inhibition by GNF-2. To determine the factor-independent growth, Ba/F3 cells were retrovi-
rally transduced with the indicated constructs and grown upon factor withdrawal with exposure to 2 µM GNF-2. 
For factor-independent growth, the number of viable cells was determined daily by Trypan blue dye exclusion. 
(A) Unmutated p185 
BCR/ABL.  (B) p185
BCR/ABL-T315I. Data represent the mean and SD of three independent experi-
ments. 
 
4.4.5  Effects of the combination of GNF-2 and Helix-2 on the autophosphorylation of 
BCR/ABL and its downstream signaling 
Our data suggest that only in  combination are GNF-2 and Helix-2 able to overcome the 
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combination on the autophosphorylation and downstream signaling of p185
BCR/ABL and p185-
T315I in Ba/F3 cells in comparison to the effects of the “single drug” approaches. We  
 
 
 
Figure 36 - The combination of Helix-2 and GNF-2 inhibits the autophosphorylation of p185-T315I and   
dependent signaling pathways. Western blot analysis of lysates of Ba/F3 cells expressing the indicated trans-
genes using antibodies directed against: (A) c-ABL, ABL Y245 (anti-phospho-ABL), BCR (anti-BCR, which 
did not detect BCR/ABL), BCR phosphorylated at Y177 (anti-phospho-BCR), STAT5,  (B)  phosphorylated 
STAT5 (anti-phospho-STAT5), (C) crkL and phosphorylated crkL. Molecular mass references (KDa) are pre-
sented, and c-ABL was used as a loading control. 
 
recently demonstrated that the capacity of T315I to restore leukemogenic potential to the loss-
of-function of BCR/ABL is closely related to its capacity to trans-phosphorylate endogenous 
BCR at position Y177 (Mian et al., 2009c). 
GNF-2 had a stronger effect on the autophosphorylation and substrate phosphorylation of 
unmutated p185
BCR/ABL than did Helix-2, and both interfered efficiently with the downstream 
signaling through, CrkL, STAT5 and inhibited the Y177 phosphorylation of endogenous BCR 
(Figure 37A-C). These effects were strongly increased by the combination of both, GNF-2 
and Helix-2. On p185-T315I, neither GNF-2 nor Helix-2 alone was able to inhibit 
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BCR. In contrast, the two agents in combination completely abolished the 
autophosphorylation, STAT5 activation, and BCR trans-phosphorylation, confirming the 
observations described above. The CrkL phosphorylation was slightly reduced (Figure 36A-
C). 
Taken together, these data show that GNF-2 in combination with Helix-2 was able to block 
the aberrant kinase activity of BCR/ABL harboring the T315I mutation, which is 
oligomerization-independent and is resistant to allosteric inhibition. 
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5  Discussion 
The tetramerization and the formation of HMW are crucial for the leukemogenic potential of 
BCR/ABL, and its inhibition increases the sensitivity for the kinase inhibitor Imatinib 
(Beissert et al., 2003; McWhirter et al., 1993; Zhang et al., 2001). The aim of the present 
study was to further develop the disruption of tetramerization as a therapeutic approach by 
reducing the size of the inhibiting peptide and exploring its effectiveness on p185
BCR/ABL 
mutants related to the resistance against kinase inhibitors such as Imatinib. 
Here, we show that the relevant interaction interface in the N-terminal BCR coiled coil region 
is the 39 a.a. sequence representing the Helix-2. Helix-2 binds to p185
BCR/ABL to the same 
extent as the entire CC-domain leading to the disruption of the HMW-complexes of 
p185
BCR/ABL. This allowed us to explore the effectiveness of the inhibition of the 
tetramerization using a small peptide which might be utilized in future for the treatment of 
Ph+ leukemia, or might represent a lead structure for the development of small molecules 
targeting the tetramerization of BCR/ABL. 
The therapeutic relevance of such an approach is given by the fact that the Helix-2 not only 
inhibited the function of p185
BCR/ABL in an artificial cell model such as the Ba/F3 and 32D 
cells retrovirally transduced and selected by IL-3 withdrawal, but also in the patient derived 
lymphatic Ph+ cell lines, SupB15 and BV173. Regarding the growth inhibition of Ba/F3 cells, 
the inhibitory effect of Helix-2 was similar to that of the CC-peptide, whereas in BV173 and 
SupB15 cells the inhibitory effect of Helix-2 was stronger than that of the CC-peptide. 
Regarding the decrease of p185
BCR/ABL  autophosphorylation, Helix-2 exhibited a similar 
inhibitory potential than the peptide representing the entire CC-domain.  
Current therapies often lack tissue specificity in the context of high variability in pharmaco 
kinetics. This deficit has led to multiple strategies for targeted therapy, including gene therapy 
(Ford  et al., 2000).  However; successful gene transduction has not always resulted in 
transcription to RNA or translation to functional protein. Regardless of the current progress in 
protein transduction technology, tools that will bypass conventional genetic routes for 
modulating the cells biological activity and will thus minimize the problems associated with 
genetic intervention, still need to be developed (Ford et al., 2000).The TAT-mediated protein 
delivery, a tool for the efficient and transient delivery of proteins, is one such example that 
has certain advantages over delivery of therapeutic genes. 
Here we show the evidence that membrane permeable Helix-2 (MPH-2) transduces several 
different cell types with high efficiency, and remains stable for several hours. Prior research 
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molecules to their desired sites of action, and was similarly effective as those introduced via 
ectopic over expression or microinjection. Overall, the transduction requires covalent 
attachment of cell permeable peptides (CPPs) to protein cargos; either through the generation 
of fusion protein product or chemical conjugation. Transduction aided by CPPs is often rapid, 
uniform, and synchronized. The level of cellular uptake can be controlled to a certain extent 
through adjusting the concentration of the fusion protein in the media (Schwarze and Dowdy, 
2000). 
The tetramerization and the formation of high molecular weight complexes are crucial for the 
leukemogenic potential of BCR/ABL, and inhibition of this process increases the sensitivity 
to the kinase inhibitor Imatinib (Beissert et al., 2003). Our aim was to develop a therapeutic 
approach, by creating membrane permeable inhibitory peptides and exploring their 
effectiveness in treating Ph+ leukemia. 
We previously showed that the 39 a.a. sequence of the N-terminal BCR coiled-coil region, 
representing the Helix-2, binds to BCR/ABL when expressed using a retroviral transduction 
system (Beissert et al., 2008).  Here, we show that MPH-2, representing the Helix-2, fused to 
a peptide transduction tag effectively binds to BCR/ABL, which inhibits the aberrant kinase 
activity of BCR/ABL, and suppresses the growth of BCR/ABL dependent leukemic cell lines. 
The therapeutic relevance of such an approach is given by the fact that the Helix-2 inhibited 
the function of BCR/ABL in the patient derived lymphatic Ph+ cell lines, SupB15 and BV173 
transduced with memebrane permeable peptides. Regarding the growth inhibition of 
lymphatic Ph+ cell lines, Tom-1 and BV173 and myeloid Ph+ cell line, K562, the inhibitory 
effect of MPH-2 in this study was similar or even stronger than that of retrovirally transduced 
Heix-2 as shown by (Beissert et al., 2008).  
We assumed that the inhibition of tetramerization by MPH-2 peptides should inhibit the 
kinase activity of BCR/ABL. Consistent with this hypothesis we found that MPH-2 reduces 
the autophosphorylation of Ph+ leukemic cells to extent as retrovirally transduced Helix2 
peptide.   
In this study, we found that the MPH-2 administrated by i.v. injection efficiently transduced 
the MNCs in the peripheral blood, bone marrow and spleen, and was stabile for about 6 hr, 
which correlated with its in vitro stability.  
The potential of the HIV-TAT  as a peptide transduction tag was previously extensively 
explored using the model of TAT fused to β-galactosidase. These studies showed that TAT 
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heart, muscle, lung, spleen, and brain of mice by i.p. injection, and it fully maintains its 
biological activity (Cai et al., 2006; Schwarze et al., 1999). 
A complex formed by TAT and technetium in 99 minutes after administering it by i.v. bolus 
in mice showed a rapid distribution throughout the body, with a gamma imaging pattern 
consistent with organ perfusion. The complex reached peak organ levels within 5 min after 
injection (liver > kidney > small intestine > lung > spleen > brain), and displayed modestly 
rapid blood clearance. Over the subsequent 2 hr, the complex was cleared by both renal and 
hepatobiliary excretion, with activity appearing in the urinary bladder and bowel (Polyakov et 
al., 2000). These findings along with our data strongly suggest that the TAT-delivered Helix-
2 peptide may provide the basis for a novel therapeutic approach to treat Ph+ leukemia. 
We assumed that the inhibition of tetramerization by Helix-2 peptides should inhibit the 
kinase activity and transforming capacity of BCR/ABL irrespective of the presence of point-
mutations in the tyrosine kinase domain that confer Imatinib-resistance. Consistent with this 
hypothesis we found that Helix-2 reduces the autophosphorylation of unmutated and mutant 
BCR/ABL to the same extend. Furthermore, Helix-2 inhibits the anchorage independent 
growth and restores the contact inhibition of Rat-1 fibroblasts transformed by unmutated 
BCR/ABL and partially restores the contact inhibition of mutant BCR/ABL. However, when 
we analyzed the inhibitory effects of Helix-2 on the factor independent proliferation of 
hematopoietic cells expressing p185
BCR/ABL harboring these mutations we revealed unexpected 
differences in the response of mutant BCR/ABL. Consistent with the inhibitory effects of 
Helix-2 on BCR/ABL-transformed fibroblasts we found that Helix-2 inhibits unmutated 
p185
BCR/ABL,  p185
BCR/ABL-E255K  and p185
BCR/ABL-Y253F  expressing Ba/F3 and 32D cells. In 
contrast, p185
BCR/ABL-T315I expressing hematopoietic cells did not respond to Helix-2. These 
data indicate that the point mutation T315I induces changes in the biological activity of 
BCR/ABL which alters the response towards Helix-2. This point mutation seemingly enables 
p185
BCR/ABL to mediate factor independence independently from its autophosphorylation. The 
observation that the unresponsiveness of T315I towards Helix-2 peptides manifest themselves 
in hematopoietic cells but not in fibroblasts is in accordance to our previously published data: 
several artificial ABL-chimeras between ABL and the isolated oligomerization domains 
derived from BCR, TEL, PLZF or PML lead to oligomerization of ABL and confer factor 
independence but are unable to satisfy classical criteria of oncogenic transformation (Beissert 
et al., 2003). The same results were observed for CC-deletion mutants of BCR/ABL (Beissert 
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Furthermore, these data are in accordance to a recently published study showing that 
p210
BCR/ABL  mutated at position T315I exhibits an increased transformation capacity of 
primary bone marrow cells despite a reduced kinase activity (Skaggs et al., 2006).  
Our HPLC studies revealed specific features of the T315I mutation which might explain the 
resistance towards Helix-2 peptides: p185
BCR/ABL-T315I exhibits a different HMW pattern as 
compared to unmutated p185
BCR/ABL and the other mutants. The HMW pattern of p185
BCR/ABL-
T315I was characterized by two different peaks: i) one of about 1070 kDa, less pronounced in 
unmutated p185
BCR/ABL and absent in the p-loop mutants, which did not respond to the Helix-
2; ii) and another peak at lower MW which is not present in unmutated p185
BCR/ABL, was 
shifted towards even lower MW in the presence of Helix-2 peptides. This p185
BCR/ABL-T315I 
specific HMW-complex pattern might be due to differences in the stability or the composition 
of the HMW-complexes. Although we observed HMW-complexes of 1070 kDa (fraction no. 
25) in unmutated p185
BCR/ABL, this fraction was not a peak fraction but the upper limit of the 
unmutated HMW-pattern. The predominat elution of the p185
BCR/ABL-T315I complexes at 1070 
kDa indicates that these complexes exhibit a higher stability as compared to those formed by 
unmutated p185
BCR/ABL, which are distributed over a wider MW-range. Furthermore, the 
p185
BCR/ABL-T315I complexes at 1070 kDa are not disrupted by Helix-2 which also indicates a 
higher stability. Another reason for the modified HMW-complex pattern of p185
BCR/ABL 
-T315I 
might also be an aberrant recruitment of unknown binding partners that do not interact with 
unmutated p185
BCR/ABL. In contrast the HMW-complexes of p185
 BCR/ABL-T315I of lower MW 
responded at least partially to Helix-2 peptides. This is in accordance to our co-
immunoprecipitation experiments which revealed that Helix-2 binds to p185
BCR/ABL-T315I. 
Therefore we can exclude a lack of interaction between Helix-2 and p185
BCR/ABL-T315I as a 
reason for resistance against the peptide. In summary our data indicate that p185
BCR/ABL-T315I 
forms a subset of complexes unresponsive towards Helix-2 that provides a sufficient survival 
signal.  
Regarding the response of mutated BCR/ABL towards Imatinib in presence of Helix-2 we 
found that Helix-2 expression overcomes the Imatinib-resistance of p185
BCR/ABL-Y253F  and 
p185
BCR/ABL-E255K, but not of p185
BCR/ABL-T315I). The fundamental difference between T315I and 
Y253F or E255K might be due to the gatekeeper function of T315.  It is widely accepted that 
Imatinib binds to the inactive ABL-kinase conformation (Schindler et al., 2000)  and thus one 
can hypothesize that the inhibition of the BCR/ABL TK-activity caused by the interaction 
with Helix-2 is related to conformational changes in the ABL-kinase domain that increase the Discussion  112 
 
affinity towards Imatinib of mutations that do not confer complete resistance such as the p-
loop mutations.  
Here we show for the first time that p185
BCR/ABL harboring mutations related to Imatinib-
resistance are responsive to the inhibition of the tetramerization by Helix-2 in classical 
transformation assays. This is of particular clinical significance, because it establishes the 
targeting of the tetramerization interface of BCR/ABL as a new therapeutic approach, which 
could contribute together with clinical relevant ABL-kinase inhibitors to an improved 
molecular targeting of BCR/ABL. 
T315I is the only mutation that confers resistance against virtually all ATP competitors and 
ologomerizaion inhibitors (Beissert et al., 2008; Druker, 2008). So we wanted to determine i.) 
Why p185
BCR/ABL can be inhibited by the exposure to competitive peptides in the presence of 
the Y253F or the E255K mutations but not in the presence of the T315I (Beissert et al., 2008) 
and ii.) whether the AKI-resistance mutations confer additional features to the biology of 
p185
BCR/ABL that modify its leukemogenic potential. 
Through our experiments on the oligomerization-deficient p185
BCR/ABL, we found that Y253F 
and E255K are not inert regarding the response to the inhibition of oligomerization. In 
contrast to T315I, which induces complete resistance, Y253F and E255K confer a partial 
resistance that is stronger in the case of Y253F as compared to E255K. This effect against 
oligomerization inhibition is hardly revealed in the available models of AKI-resistant 
BCR/ABL, and only by deleting the CC-domain were the effects of Y253F and E255K 
unmasked. The fact that these mutations were able to restore not only factor-independence but 
also full transformation potential indicates that they probably induce conformational changes 
within the molecule that allow the activation of BCR/ABL as a monomer. 
T315I requires the autophosphorylation at Y177 of BCR/ABL for the resistance against the 
inhibition of oligomerization. In fact, all mutants in which autophosphorylation at the Y177 
was present exhibited resistance against the competitive Helix-2 peptide. The phosphorylated 
Y177 represents the GRB-2 binding site, which is at the top of the RAS-signaling pathway 
initiated by BCR/ABL ((Faderl et al., 1999), suggesting an important role for RAS-signaling 
in the inhibition of the oligomerization. 
Interestingly the T315I was able to restore the activity of an oligomerization deficient 
BCR/ABL lacking also the Y177 phosphorylation site, the ΔCCp185-Y177F. Seemingly at 
odds with this finding is our observation that autophosphorylation at Y177 is a prerequisite 
for T315I mediated resistance against the treatment with Helix-2 suggesting that a mutant in 
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T315I in the presence of Helix-2. A possible explanation of this discrepancy is the ability of 
activated BCR to substitute the autophoshorylation of BCR/ABL. In addition the activation of 
BCR by the T315I does not appear to require the interaction between BCR/ABL and BCR, 
suggesting that in the case of the p185-Y177F-T315I there are two relevant targets of the 
Helix-2, being one the BCR/ABL mutants itself and the other endogenous BCR. Thus the 
Helix-2 might inhibit not only the oligomerization of BCR/ABL, but also that of BCR as well 
as the hetero-oligomerization between BCR/ABL and BCR.  
Until now, the grade of transformation activity of BCR/ABL was thought to be directly 
correlated to the degree of its kinase  activity  (Laurent  et al., 2001; Lugo  et al., 1990)  . 
Recently, the first evidence was raised that BCR/ABL harboring the “gatekeeper” mutation 
T315I mutation responsible for the resistance against kinase inhibitors such as Imatinib, 
Nilotinib, or Dasatinib exhibits ABL-kinase activity that may be higher or lower than that of 
unmutated BCR/ABL dependending on the model (Griswold et al., 2006). 
These findings suggested that the kinase activity might be not the decisive parameter causing 
T315I-positive cells to overgrow in the presence of cells whose unmutated BCR/ABL kinase 
activity is efficiently suppressed by inhibitors. Our findings on the different mutants clearly 
showed that the capacity of T315I to improve the functionality of the respective mutants is 
closely related to functional ABL-kinase activity. Thus, we can exclude the possibility that 
T315I confers activities that are independent of the ABL-kinase activity of BCR/ABL. In fact, 
in all cases, the presence of T315I led to an increase in or an activation of the kinase activity 
of the respective mutant. These data confirm recent findings showing that mutations of the 
highly conserved “gatekeeper” threonine, which lies within the hinge region of the enzymatic 
cleft of many kinases, represent a crucial structural feature. The mutation of threonine 
promotes kinase activation sufficient to confer the capacity to mediate factor-independent 
growth for several native non-receptor  and receptor tyrosine kinases, such as c-SRC, 
PDGFRA, and EGFR (Azam  et al., 2008). In the case of the isolated ABL-portion of 
BCR/ABL, either this activation was unable to reach levels high enough for biological 
activity or this activation, the intensity of which reached the level of other biologically active 
mutants, is not sufficient by itself to exert full biological activity. In fact, in cells expressing 
#ABL-T315I, endogenous BCR was not phosphorylated. Our results indicate a relationship 
between the phosphorylation of endogenous BCR and the biological activity of T315I. The 
BCR-phosphorylation is most likely the expression of an increased substrate phosphorylation 
activity of the ABL-kinase in the presence of the T315I an effect exerted by all mutants with 
biological activity. The phosphorylation seems to be independent of the overall kinase activity Discussion  114 
 
of the respective mutants, which was variable. One can speculate on the existence of a still 
unknown mechanism involved in the phosphorylation of BCR by the ABL-kinase, the 
inhibition of which is released in the case of the deletion of the SH3 domain of ABL. 
In summary, our data show that T315I not only interferes with the affinity of ATP-analogs for 
the ABL-kinase  but also increases the kinase activity of different ABL and BCR/ABL-
mutants, conferring strong biological activity that seems to be related to the phosphorylation 
of endogenous BCR. These findings introduce possible new approaches for the molecular 
therapy of patients harboring AKI-resistant BCR/ABL. 
Recently, much effort has been undertaken to solve the problem of Imartinib resistance in 
vitro, but not in patients, many point mutations are inhibited by increased doses of Imatinib, 
as the achievable serum levels of Imatinib are below the concentrations necessary to 
overcome resistance (O'Hare et al., 2005a; Weisberg et al., 2005). Therefore research focuses 
mainly on the development of second generation kinase inhibitors. Nilotinib (Novartis, 
Basle), like Imatinib, is a selective ABL-kinase inhibitor. Nilotinib inhibits many Imatinib-
resistant point mutants because of its 20-fold higher affinity for the ABL kinase domain and 
achievable plasma levels for Nilotinib are sufficient for inhibition (O'Hare et al., 2005b). The 
dual SRC-ABL kinase inhibitor Dasatinib (Bristol-Myer-Squibb, New York) takes advantage 
of a characteristic difference between SRC- and  ABL-kinase domain conformations to inhibit 
Imatinib-resistant mutations: the inactive conformations of SRC and ABL are different, while 
the active conformations are closely related (Schindler et al., 2000). Dasatinib has a 325-fold 
higher affinity towards ABL than Imatinib (O'Hare et al., 2005a). Imatinib and Nilotinib bind 
to the inactive ABL-kinase conformation which is the reason for their selectivity, while 
Dasatinib binds to active ABL and active  SRC. Therefore the binding of Dasatinib is 
dependent on another choice of aminoacid residues as Imatinib or Nilotinib (O'Hare et al., 
2005b; Schindler  et al., 2000).  Dasatinib inhibits most mutations identified in Imatinib 
resistant patients (O'Hare et al., 2005a). Unfortunately, the mutation T315I, which clinically 
accounts for about 20% of Imatinib-resistant  cases,  is neither inhibited by Nilotinib nor 
Dasatinib (O'Hare et al., 2005a; von Bubnoff et al., 2006).  
As outlined above, the possibilities to overcome resistance towards a particular kinase 
inhibitor by choosing a second or third inhibitor might finally fail. Therefore, a closer look to 
other critical functions of the BCR/ABL fusion protein itself or to the BCR/ABL activated 
signaling pathways is now undertaken. Strategies under investigation include: the 
tetramerization interface (Beissert et al., 2008; Beissert et al., 2003), targeting the substrate Discussion  115 
 
binding site, the allosteric site and downstream pathways (for review(Quintas-Cardama et al., 
2007). 
The major therapeutic challenge is to efficiently treat patients with BCR/ABL harboring the 
T315I mutation. Unfortunately, T315I not only confers resistance against AKI, but also 
against the inhibition of oligomerization by Helix-2 (Beissert et al., 2008) and the allosteric 
inhibition by GNF-2 (Adrian et al., 2006).  
The T315I mutation is the most recalcitrant to inhibition due to a combination of several 
factors, including steric hindrance of drug binding, loss of a key hydrogen-bonding interaction 
with the T315 side-chain hydroxyl group that is exploited by Imatinib, Nilotinib, and 
Dasatinib, and potentially through increasing aberrant intrinsic kinase activity accompanied 
by aberrant substrate phosphorylation (Azam et al., 2008; Mian et al., 2009b). 
Iacob et al. 2009 has detected conformational disturbances distant to the site of mutation in 
Abl(Myr)T315I. There was an unexpected alteration to deuterium exchange in the RT-loop of 
the SH3 domain in T315I whereas no changes were detected in any location in the other 2 
mutants. Activation by distant mutation may involve conformational changes that are 
communicated allosterically to the active sites like coiled coil (CC) doamin or Grb-2 binding 
site etc. We speculate that deleting of CC domain could assist inhibition of the T315I mutant 
when myristoylated (Iacob et al., 2009). 
Our data strongly suggest that both the sensitivity of unmutated p185
BCR/ABL and the resistance 
of p185-T315I toward the allosteric inhibition by GNF-2 are oligomerization-dependent. In 
fact, the inhibition of oligomerization by the competitive Helix-2 peptide not only increased 
the response of unmutated p185
BCR/ABL, but also restored the response of p185-T315I to the 
level of unmutated p185
BCR/ABL. This was also confirmed by the high sensitivity of the 
oligomerization-deficient p185-T315I mutant towards GNF-2. The relationship between the 
resistance against GNF-2 and oligomerization was already anticipated by the work of Adrian 
and co-workers, who showed that activation of the kinase activity of ABL by the 
oligomerization interfaces of NPM or of TEL was not reverted by GNF-2 (Adrian et al., 
2006). We previously showed that the helix-loop-helix (HLH) oligomerization interface of 
TEL directly fused to the ABL-portion of the fusion protein HLH/ABL showed enhanced 
ABL-kinase activity along with a decreased response to Imatinib, as compared to unmutated 
p185
BCR/ABL  or other ABL chimeras (Beissert  et al., 2003). Furthermore, the HLH/ABL 
chimera formed complexes of higher molecular weight than even the unmutated p185
BCR/ABL 
(Beissert  et al., 2003). This indicated that the level of resistance against GNF-2 might 
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proteins, which seems to parallel the sensitivity towards Imatinib, which also decreases with 
the oligomerization status of ABL fusion proteins (Beissert  et al., 2003). Thus, one can 
speculate that GNF-2 exhibits a reduced capacity to bind MBP when BCR/ABL is present as 
an oligomer as compared to a monomer. Given that the oligomerization of BCR/ABL is a 
dynamic process, equilibrium between monomers and oligomers must exist. It is possible to 
increase the sensitivity of unmutated p185
BCR/ABL, as well as that of p185-T315I, for allosteric 
inhibition through a switch of this balance in favor of monomers by competitive peptides such 
as Helix-2.  
Taken together, our results establish a new approach for the molecular targeting of unmutated 
BCR/ABL, as well as BCR/ABL harboring the multi-resistance mutation T315I, which is the 
combination of oligomerization inhibitors and allosteric inhibitors. 
To further develop competitive peptides as therapeutic approach the following aspects have to 
be addressed.i) Optimization of the peptides themselves. ii) peptides as lead structure for in 
silico drug designing. iii) Delivery of the peptides. 
The Helix-2 peptides will be further optimized by in Silico design for an improved affinity to 
the N-terminal oligomerization interface of BCR/ABL. Improving the current peptide design 
which included the entire CC-domain of BCR/ABL, will be performed by restricting the se-
quence optimization to the Helix-2 which represents most of the protein-protein interface po-
sitions, while the shorter Helix-1 only includes about 10% of the interface residues.  
Shortening that sequence to a single Helix-2 analog may increase flexibility thus requiring 
considering several structures. "Snapshots" from Molecular Dynamics (MD) of this peptide 
will be collected and the most diverse structures from MD will be used for the optimization of 
interface residues. Repeats of Polyethylene Glycol (PEG) will be covalently attached to the 
helical structure and their structural effect will be examined under similar MD conditions. The 
sequences of each of the unique structures will be optimized by applying our Iterative Sto-
chastic Elimination (ISE) procedure. ISE is interface optimization software give a binary pro-
tein-protein complex, in which we denote the proteins as A and B, we redesign B and create 
new proteins with stronger binding affinity to A than the binding affinity of B to A. We also 
demand that the self affinity of the designed protein (in a B-B complex) will be less than that 
of B to A. The computer designed peptides for improved affinity to the target will be vali-
dated in vitro by biochemical experiments like interaction with BCR/ABL and inhibition of 
BCR/ABL autophosphorylation/kinase activity. The improved BCR/ABL inhibition effect 
will be controlled by biological experiments like growth curves and proliferation competition 
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BCR/ABL, better growth inhibition and reduced self oligomerization. The peptides will be 
further optimized by reduction in size, reduction of self-oligomerization, increased affinity to 
the target and biological stability. 
The structures of biomolecular targets, proteins in most cases, must be presented as models 
from experiments or constructed by a reliable modeling method. Docking consists of ‘‘driv-
ing’’ a small molecule toward its target and finding the best possible positions for their mu-
tual interactions. Most current information on small molecule-target complexes is from X-ray 
crystallography (Berman et al., 2000) but nuclear magnetic resonance is becoming an addi-
tional major tool for probing biomolecular-ligand complexes(Meyer and Peters, 2003). A few 
recent studies suggest that a small molecule may be bound to its target in more than a single 
conformation (Cameron et al., 2005; Ekroos and Sjogren, 2006; Gales et al., 2005; Hamilton 
and Benson, 2001).  It has also been shown that conformations of bound ligands are structu-
rally different than their predominant solution conformations and are higher in energy (Perola 
and Charifson, 2004; Stockwell and Thornton, 2006). Many protein targets have flexible con-
formations, most frequently displaying variations of side chain positions in their active sites 
as well as in their backbone(Teague, 2003). ‘‘How to hit a moving target’’(Carlson, 2002) 
becomes a landmark title for the efforts to develop small molecules that bind efficiently to 
flexible proteins. 
Keeping in mind we have planned to shorten the Helix-2 peptide to 5-15 amino acids to serve 
as lead structure for computer-based design of small molecule.To exclude those peptides 
which will not have improved efficacy in comparison to the original Helix-2 peptide, the effi-
cacy of newly designed peptides will be investigated by expressing their cDNA by retroviral 
transduction into BCR/ABL transformed cells. The “read out” is represented by their effects 
on autophosphorylation and substrate phosphorylation of BCR/ABL and its Imatinib-resistant 
mutants by specific antibodies against ABL, Crkl, Stat5 and their phosphorylated forms in the 
Western blotting (Beissert et al., 2008; Beissert et al., 2003; Mian et al., 2009a) 
The most efficient peptides will be biochemically evaluated for i.) their capacity to disrupt the 
BCR/ABL oligomers in the cells by separating the cell lysates by  size exclusion 
chromatography (Beissert et al., 2008; Beissert et al., 2003) ; ii.) their binding affinity to the 
CC-domain of BCR/ABL using recombinant peptides produced in E.coli on a Biacore 
platform available in the “Biocenter” of the Goethe-University in Frankfurt on service for fee 
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At the final stage, the peptides will be biologically validated using different techniques like 
colony formation (Puccetti  et al., 2000), dye exclusion using Trypan-blue, Proliferation 
completion assay and apoptosis assay (Beissert et al., 2008; Mian et al., 2009b). 
One of the major problems hindering the use of peptides in therapy is their stability and their 
delivery to the target cells in vivo. There are several chemical methods to overcome this prob-
lem but none leads to the specific targeting of specific tumor cell subpopulations. Here we 
aim to combine efforts in order to develop suitable peptide delivery approach for the inhibi-
tion of oligomerization of BCRA/BL for the molecular therapy of Ph+ leukemia. 
A particular therapeutic challenge is represented by the Ph+ ALL whose prognosis notwith-
standing the recent advances of molecular therapy of Ph+ leukemia remains poor. This is 
mainly due to the fact that the actual therapy regimen are unable to eradicate a very small 
number of leukemic cells, which determine the long term growth of the leukemia - the so-
called “leukemia-stem cell” (LSC) - the source of the relapse, when not completely eradi-
cated. Very recent results indicate that the LSC of Ph+ ALL exhibit a CD34+, CD38+/- and 
CD19+ phenotype (Kong et al., 2008). These findings define CD19 as a valid therapeutic 
target for eradicating the Ph+ALL LSC as already shown for other disease entities such as the 
B-cell lymphomas. 
Liposomes are one of the best drug delivery systems for low molecular weight drugs, imaging 
agents, peptides, proteins, and nucleic acids (Barenholz et al., 1994, Gregoriadis, 2007, Lasic 
and Barenholz, 1996). Nanoliposomes (d. ≤120 nm), when administrated intravenously, may 
improve the therapeutic index of some drugs due to the enhancement of permeability and re-
tention effect (Barenholz, 2001; Barenholz, 2003; Voinea and Simionescu, 2002), while larg-
er liposomes (d.b2–6 µm) have a similar effect when administrated locally (Alam and 
Hartrick, 2005; Grant et al., 2004). Thus more than 11 liposome-based drugs are in clinical 
use. A major achievement in liposome medical application is the ability to load a sufficient 
amount of drug needed to achieve therapeutic efficacy. In most cases this requires a remote 
loading approach (Clerc and Barenholz, 1995; Clerc and Barenholz, 1998; Haran et al., 1993), 
where the drug is loaded into preformed liposomes.  
Liposomes and especially pegylated nano-liposomes (“sterically stabilized nano liposomes” = 
nSSL) are potent drug delivery systems protecting the drug from degradation and delivering a 
high drug payload to tumors. For an efficient attachment to the nSSL the effect of binding to 
several optional lengths of PEG will be examined by comparing the flexibility of the isolated 
Helix-2 with its N-terminus bound to PEGs. Discussion  119 
 
Together with other anti-leukemic drugs (Doxorubicin, Imatinib or GNF-2, respectively) 
these new peptides will be loaded on nano-liposomes for an improved drug delivery in vivo. 
Directing these nano-liposomes to the “right” cell in order to eradicate the leukemia will be 
obtained by loading them with specific scFv for the LSC-population. 
The vast majority of proteins do not enter the cytoplasm of living cells. An 11 a.a. peptide 
sequence derived from the human immunodeficiency virus protein TAT, the HIVTAT-
domain, leads to the transport of heterologous proteins or peptides into living cells when 
fused to them (Fawell et al., 1994). This phenomenon is called peptide transduction (PT). A 
number of other peptide transduction domains (PTD) have been identified or developed up to 
now. The common feature is that they are composed of basic a.a. sequence stretches of 
usually 9 – 11 a.a. which are rich in arginine residues (for review(Zhao and Weissleder, 
2004). 
In order to proceed with the development of Helix-2 peptides towards a therapeutic peptide, 
we have recently established the peptide transduction technology (Mian et al., 2009 
submitted).  
Multicellular spheroids are well defined three dimensional models that mimic the cellular 
environment in tissues in a much better way than monolayer cultures. These spheroids are 
aggregates of about 100000 cells and 250 µm in diametre that spontaneously form when 
stroma cell lines are plated in agarose coated microwell plates. The migration of 
hematopoietic cells into the stromal bone marrow microenvironment can be modeled using 
spheroids of stroma cell (Bug  et al., 2002). To this aim we co-cultivated spheroids with 
hematopoietic cells for 24 to 48 hours. After extensive washing in PBS and dissociation of the 
spheroids with trypsin the migrated cells were identified by FACS using surface markers 
specific for hematopietic cells (CD19, CD45). The ability of cells to migrate into spheroids is 
characteristic for different cell lines e.g. after 48h of migration spheroids contain 70% Nalm-6 
cells, 20% CD34+ cells and 10% K562 cells . Alternatively cryostat sections of paraffin 
embedded spheroids can be stained immune-histochemically to identify migrated cells (Bug 
et al., 2002). 
The efficient secretion of proteins requires an N-terminal signal peptide (SP) that targets the 
mRNA-ribosome complexes to the endoplasmatic reticulum (ER) (Walter et al., 1984). In 
addition to the SP the 3’ untranslated region (UTR) of the mRNA encoding the secretory 
protein plays an important role for the proper localization of the mRNA to the ER and 
subsequently for the efficiency of protein secretion: for the secretion of heterologous proteins 
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(Partridge  et al., 1999).  Furthermore the group of Beate Stern (University of Bergen & 
Unitargeting Research AS, Bergen, Norway) that cooperates with us for this proposal has 
shown that the level of synthesis and secretion is dependent on the choice of the SP. The SP 
of Gaussia princeps luciferase resulted in much more efficient secretion than Interleukin-2 or 
albumin SP (Knappskog et al., 2007). Mrs. Stern and Unitargeting, Research AS provided 
their optimized vector for the secretion of heterologous proteins which led to the efficient 
secretion of human endostatin under the control of the Gaussia princeps luciferase SP. This 
secretion system is destined for a commercial distribution by Unitargeting Research AS. 
This work is planned for the development of a cell based delivery system for biological active 
peptides  in vivo. The delivery will be accomplished by producer cells that secret cell 
permeable peptides in loco. In vitro the intercellular transfer of HIVTAT-tagged GFP has 
been demonstrated before(Barka et al., 2004). This paracrine peptide transduction system will 
avoid the systemic application of transducible peptides and reduce the risk of entrapment of 
the peptides in unspecific sinks in the organism. The sustained in loco secretion will result in 
a high local concentration in proximity of the target cells. Furthermore the repeated 
administration of the peptides to animals by injections or oral gavage which harbors  a 
manipulation related health risk will be omitted.  
Fibroblast cells secreting HIVTAT-tagged luciferase, GFP, Helix-2-GFP fusion proteins will 
be co- cultivated with hematopoietic cells. The transduction efficiencies and cell proliferation 
will be examined. We will study the inhibition BCR/ABL kinase activity and the inhibition of 
downstream pathways. 
To mimic the in vivo 3D organization of the bone marrow stromal microenvironment, we will 
use an in vitro 3D stroma cell spheroid model. Spheroids of peptide secreting stroma cells will 
be co-cultivated with hematopoietic cells which migrate into the spheroids. The paracrine 
delivery of the peptides will be measured. The inhibition of BCR/ABL kinase activity and 
downstream pathways will be assessed. 
Bone marrow hematopoietic cells and mesenchymal stem cells isolated from C57BL6/N 
donor mice will be used to secret peptides in loco. Upon transplantation in syngeneic hosts the 
serum level of the secreted peptides and the peptide delivery to host cells in hematopoietic 
organs will be examined. Human BCR/ABL negative cell lines and primary CDC34+ cells 
will serve as peptide secreting cells in a similar NOD/SCID mouse model. 
In order to examine the antileukemic potential of paracrine delivered peptides, the inhibition 
of leukemia induction will be studied by co-transplantation of BCR/ABL expressing cells 
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6  Summary 
In Philadelphia Chromosome (Ph) positive ALL and CML the fusion between BCR and ABL 
leads to the BCR/ABL fusion proteins, which induces the leukemic phenotype because of the 
constitutive activation of multiple signaling pathways down-stream to the aberrant BCR/ABL 
fusion tyrosine kinase. Targeted inhibition of BCR/ABL by ABL-kinase inhibitors induces 
apoptosis in BCR/ABL transformed cells and leads to complete remission in Ph
  positive 
leukemia patients. However, a large portion of patients with advanced Ph+ leukemia relapse 
and acquire resistance. Kinase domain (KD) mutations interfering with inhibitor binding 
represent the major mechanism of acquired resistance in patients with Ph+ leukemia.  
Tetramerization of BCR/ABL through the N-terminal coiled-coil region (CC) of BCR is 
essential for the ABL-kinase activation. Targeting the CC-domain forces BCR/ABL into a 
monomeric conformation, reduces its kinase activity and increases the sensitivity for Imatinib. 
Here we show that i.) targeting the tetramerization by a peptide representing the Helix-2 of 
the CC efficiently reduced the autophosphorylation of both WT BCR/ABL and its mutants; 
ii.) Helix-2 inhibited the transformation potential of BCR/ABL independently of the presence 
of mutations; iii.) Helix-2 efficiently cooperated with Imatinib as revealed by their effects on 
the transformation potential and the factor-independence related to BCR/ABL with the 
exception of mutant T315I. These findings suggest that BCR/ABL harboring the T315I 
mutation have a transformation potential which is at least partially independent from its 
kinase activity. 
Targeted inhibition of BCR/ABL by small molecule inhibitors reverses the transformation 
potential of BCR/ABL. We definitively proved that targeting the tetramerization of 
BCR/ABL mediated by the N-terminal coiled-coil domain (CC) using competitive peptides, 
representing the Helix-2 of the CC, represents a valid therapeutic approach for treating Ph+ 
leukemia. To further develop competitive peptides for targeting BCR/ABL, we created a 
membrane permeable Helix-2 peptide (MPH-2) by fusing the Helix-2 peptide with a peptide 
transduction tag. In this study, we report that the MPH-2: (i) interacted with BCR/ABL in 
vivo; (ii) efficiently inhibited the autophosphorylation of BCR/ABL; (iii) suppressed the 
growth and viability of Ph+ leukemic cells; and (iv) was efficiently transduced into 
mononuclear cells (MNC) in an in vivo mouse model. 
The T315I mutation confers resistance against all actually approved ABL-kinase inhibitors 
and competitive peptides. It seems not only to decrease affinity for kinase inhibitors but to 
confer additional features to the leukemogenic potential of BCR/ABL. To determine the role 
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of BCR/ABL, we investigated its influence on loss-of-function mutants with regard to the 
capacity to mediate factor-independence. Thus we studied the effects of T315I on BCR/ABL 
mutants lacking functional domains in the BCR portion indispensable for the oncogenic 
activity of BCR/ABL such as the N-terminal coiled coil (CC), the tyrosine phosphorylation 
site Y177 and the serine/threonine kinase domain (ST), as well as on the ABL portion of 
BCR/ABL (#ABL-T315I) with or without the inhibitory SH3 (ΔSH3-ABL) domain. Here we 
report that i.) T315I restored the capacity to mediate factor independence of 
oligomerization_deficient p185BCR/ABL; ii.) resistance of p185-T315I against inhibition of 
the oligomerization depends on the  phosphorylation at Y177; iii.) autophosphorylation at 
Y177 is not affected by the oligomerization inhibition, but phosphorylation at Y177 of 
endogenous BCR parallels the effects of T315I; iv.) the effects of T315I are associated with 
an intact ABL_kinase activity; v.) the presence of T315I is associated with an increased 
ABL_kinase activity also in mutants unable to induce Y177 phosphorylation of endogenous 
BCR; vi.) there is no direct relationship between the ABL-kinase activity and the capacity to 
mediate factor_independence induced by T315I as revealed by the #ABL-T315I mutant, 
which was unable to induce Y177 phosphorylation of BCR only in the presence of the SH3 
domain.  
In contrast to its physiological counterpart c-ABL, the BCR/ABL kinase is constitutively 
activated, inducing the leukemic phenotype. The N-terminus of c-ABL (Cap region) 
contributes to the regulation of its kinase function. It is myristoylated, and the myristate 
residue binds to a hydrophobic pocket in the kinase domain known as the myristoyl binding 
pocket in a process called “capping”, which results in an auto-inhibited conformation. 
Because the cap region is replaced by the N-terminus of BCR, BCR/ABL “escapes” this auto-
inhibition. Allosteric inhibition by myristate “mimics”, such as GNF-2, is able to inhibit 
unmutated BCR/ABL, but not the BCR/ABL that harbors the “gatekeeper” mutation T315I. 
Here we investigated the possibility of increasing the efficacy of allosteric inhibition by 
blocking BCR/ABL oligomerization. We demonstrate that inhibition of oligomerization was 
able not only to increase the efficacy of GNF-2 on unmutated BCR/ABL, but also to 
overcome the resistance of BCR/ABL-T315I to allosteric inhibition. These results strongly 
suggest that the response to allosteric inhibition by GNF-2 is inversely related to the degree of 
oligomerization of BCR/ABL. 
Taken together these data suggest that the inhibition of tetramerization inhibits BCR/ABL-
mediated transformation and can contribute to overcome Imatinib-resistance. The study pro-Summary  123 
 
vides the first evidence that an efficient peptide transduction system facilitates the employ-
ment of competitive peptides to target the oligomerization interface of BCR/ABL in vivo. 
Further the data show  that T315I confers additional leukemogenic activity to BCR/ABL, 
which might explain the clinical behavior of patients with BCR/ABL -T315I-positive blasts. 
In summary, our observations establish a new approach for the molecular targeting of 
BCR/ABL and its resistant mutants represented by the combination of oligomerization and 
allosteric inhibitors. 
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7  Zusammenfassung 
In der Philadelphia Chromosome (Ph) positiven ALL und CML hat die Fusion von BCR und 
ABL die Bildung eines BCR/ABL Fusionsprotein zur Folge. Dieses Fusionsprotein ist für den 
leukämischen Phänotypen aufgrund der konstitutiven Aktivierung vieler Signalwege 
unterhalb/Downstream  der veränderten BCR/ABL fusionierten Tyrosinkinase.Eine 
zielgerichtete Inhibierung von BCR/ABL mittels ABL-Kinase-Inhibitoren induziert Apoptose 
in BCR/ABL transformierten Zellen und hat eine komplette Remission in Ph
+  Leukämie 
Patienten zur Folge.  Eine große Anzahl an Patienten mit fortgeschrittener Ph
+  Leukämie 
erleiden einen Rückfall und entwickeln Resistenzen.  Die Mutation der Kinasedomäne 
verhindert die Bindung von Inhibitoren und stellt somit den häufigsten Mechanimus von 
erworbenen Resistenzen in Patienten mit Ph
+ Leukämie.  
Die Tetramerizierung von BCR/ABL mittels der N-Terminalen coiled-coil region (CC) von 
BCR ist notwendig für die Aktivierung der ABl-Kinase. Das Targeting der CC-Domäne 
zwingt BCR/ABL in eine monomere Konformation, was zu einer Reduzierung der 
Kinasaktivität und einer erhöhten Imatinib-Sensitivität führt. Wir können zeigen, daß i) das 
Angreifen der Tetramerisierung mittels einem Peptide, welches die Helix2 der CC-Domäne 
repräsentiert, reduziert die Autophosphorylierung sowohl von WT BCR/ABL, als auch seinen 
Mutanten. ii) Die Helix-2  inhibiert unabhängig von vorkommenden Mutationen das 
transformierende Potential von BCR/ABL. iii) Aufgrund der Effekte auf das transformierende 
Potential und dem Faktor unabhängigen Wachstum von BCR/ABL, mit Ausnahme der T315I-
Mutation, konnte eine effektive Kooperation zwischen Helix-2 und Imatinib gezeigt werden.  
Die gezielte Hemmung von BCR/ABL durch Inhibitoren in Form kleiner Moleküle macht das 
Potential zur Transformation von BCR/ABL rückgängig. Wir haben eindeutig bewiesen, dass 
das Zielen auf die, durch die N-terminale coiled-coil Domäne (CC) vermittelte, 
Tetramerisierung von BCR/ABL mithilfe kompetitiver Peptide, welche die Helix-2 von CC 
repräsentieren, ein wirkungsvoller therapeutischer Ansatz zur Behandlung der Ph+Leukämie 
ist. Um die kompetitiven Peptide zum Angriff auf BCR/ABL weiter zu entwickeln, erzeugten 
wir eine Membran permeables Helix-2 Peptid (MPH-2), indem wir die Helix-2 Peptide mit 
einem Peptid-Transduktions-Tag fusionierten. In dieser Studie berichten wir, dass MPH-2: (i) 
mit BCR/ABL in vivo interagierte; (ii) effizient die Autophosphorylierung von BCR/ABL 
hemmte; (iii) Wachstum und Viabilität von Ph+ leukämischen Zellen unterdrückte; und (iv) in 
einem in vivo Maus-Modell effizient in mononukleäre Zellen (MNC) transduziert wurde. 
Die T315I Mutation von BCR/ABL weist eine Resistenz gegen alle momentan sich in 
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Es scheint nicht nur die Bindungsaffinität der Kinase Inhibitoren zu vermindern sondern 
erzeugt zusätzliche Eigenschaften, die das leukämogene Potential von BCR/ABL verstärken.  
Um die Rolle der T315I Mutation auf dessen fehlender Inhibition der für das leukämogene 
Potential wichtigen Oligomerisierung von BCR/ABL näher zu bestimmen, untersuchten wir 
seinen Einfluß auf zusätzliche “loss-of-function” Mutanten von BCR/ABL in bezug auf deren 
Fähigkeit eine Faktor-Unabhängigkeit zu erzeugen. Entsprechend erzeugten wir BCR/ABL 
Mutanten, denen notwendige funktionale Domänen bezüglich des onkogenen Potenzials 
fehlen. Im BCR-Anteil deletierten wir die N-terminale coiled coil (CC) Domäne, die Tyrosine 
Phosphorylierungs Stelle Y177 und die Serine/Threonine Kinase Domäne (ST) sowie im 
ABL_Anteil die inhibitorische SH3 (ΔSH3-ABL) Domäne.  
Aus den vorliegenden Arbeiten ergaben sich folgende Ergebnisse i.) T315I stellt die fehlende 
Faktor Unabhängigkeit von hämatopoetischen Zellen mit Oligomerizations defizienten 
p185BCR/ABL Mutanten wieder her; ii.) Die Resistenz von p185-T315I gegen die Inhibition 
der Oligomerisation ist abhängig von der Phosphorylierung am Y177; iii.) Die 
Autophosphorylierung am Y177 wird durch die Inhibition der Oligomerisierung nicht 
beeinträchtigt, jedoch die Phosphorylierung am Y177 von endogenem BCR wird durch die 
T315I Mutation verstärkt; iv.) Die Effekte von T315I sind mit einer intakten ABL_Kinase 
Aktivität assoziiert; v.) Das Vorhandensein der T315I Mutation ist assoziiert mit einer 
verstärkten ABL_kinase Aktivität, welches sich auch in Mutanten zeigt, die die Y177 
Phosphorylierung von endogenem BCR nicht induzieren; vi.) Es gibt keinen direkten 
Zusammenhang zwischen der ABL-Kinase Aktivität und der durch T315I induzierten 
Faktorunabhängigkeit. Im Gegensatz zu der ABL-T315I Mutante, die nur in der Anwesenheit 
der SH3 Domäne nicht in der Lage war eine Phosphorylierung am Y177 von endogenem 
BCR zu induzieren. 
Im Gegensatz zu seinem physiologischen Pendant c-Abl, ist die BCR/ABL Kinase, die den 
leukämischen Phänotyp induziert, konstitutiv aktiviert. Der N-Terminus von c-ABL (Cap 
region) wirkt an der Regulation seiner Kinasefunktion mit. Er ist myristoyliert und in einem 
Prozess, genannt „capping“ bindet der Myristinsäurerest an eine hydrophobe Tasche in der 
Kinasedomäne, bekannt als Myristinsäurebindungstasche. Daraus resultiert eine 
autoinhibitorische Konformation. Da die Cap-region durch den N-terminus von BCR/ABL 
ersetzt wurde, entgeht BCR/ABL dieser Autoinhibition. Allosterische Inhibition durch 
Myristeinimitatoren, wie GNF-2, sind in der Lage nicht mutiertes BCR/ABL zu inhibieren, 
nicht jedoch BCR/ABL, das die „Gatekeeper“-Mutation T315I beherbergt.  Zusammenfassung  126 
 
Wir untersuchen hier die Möglichkeit die Effizienz der allosterischen Inhibtion durch 
Blockierung der BCR/ABL-Oligomerisierung zu erhöhen. Wir demonstrieren, dass die 
Inhibtion der Oligomerisierung nicht nur in der Lage war die Effizienz von GNF-2 auf das 
nicht mutierte BCR/ABL zu erhöhen, sondern auch die Resistenz von BCR/ABL-T315I zu 
überwinden hin zur allosterischen Hemmung. Diese Ergebnisse lassen stark annehmen, dass 
das Ansprechen der allosterischen Hemmung durch GNF-2 in umgekehrtem Verhältnis zum 
Grad der Oligomerisierung von BCR/ABL steht. 
Zusammengenommen deuten diese Daten auf eine Inhibierung der Tetramerizierung  hin, 
welsche die BCR/ABL vermittelte Transformation hemmt. Diese führt zu einer Überwindung 
der Imatinib Resistenz.  Diese  Studie bietet erste Evidenz, dass ein effizientes Peptid-
Transduktions-System die Anwendung von kompetitiven Peptiden, um auf die 
Oligomerisierungs-Schnittstelle von BCR/ABL zu zielen, in vivo  unterstützt.  Des weitern 
zeigen die Daten,  daß T315I zusätzliche leukämische Aktivität von BCR/ABL induziert, 
welches eine mögliche Erklärung für klinische Prognose von Patienten mit BCR/ABL-T315I 
positiven Blasten darstellt. Zusammenfassend lässt sich sagen, dass unsere Beobachtungen 
einen neuen Ansatz für molekulare Angriffspunkte für BCR/ABL und seine resistenten 
Mutanten etablieren, bestehend aus der Kombination von Oligomerisierungs-  und 
allosterischen Inhibitoren. 
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Abbreviations 
+        Positive 
-        Negetive 
%        Percent 
a.a        Amino acid 
7-AAD       7-Aminoactinomycin 
ABL         Abelson murine leukaemia virus homology gene 
ALL         Acute lymphatic leukemia 
AML        Acute myeloid leukemia 
AMP        Ampicillin 
Arg        Argenin 
ATP         Adenosin-5’-triphosphate 
attP site      Attachement site 
 
BCR        Breakpoint cluster region 
BCR/ABL      Breakpoint cluster region/ Abelson murine leukaemia virus 
BM        Bone marrow 
BrdU        5-bromo-2-deoxyuridine 
BSA         Bovine serum albumin 
 
°C        Celsius 
Ca
2+        Calcium 
CC        coiled-coil 
ΔCC        Deleted coiled-coil 
CD         Cluster of differentiation 
cDNA        Complementary DNA 
cm         Centimeter 
CSF         Colony stimulating factor 
CFU         Colony-forming unit 
CFU-GEMM      CFU-granulocyte erythroid megacaryocyte macrophage 
CFU-GM       Colony-forming unit granulocyte, macrophage 
CIP        Calf intestinal phosphatase       
CLL         Chronic lymphatic leukaemia 
CLP        Common lymphoid progenitors Abbreviations  138 
 
CML         Chronic myeloid leukaemia 
CMP         Common myeloid progenitors  
CMV        Cytomegalovirus 
CR        Complete remission 
CTP        Cytoplasmic transduction peptide 
dATP        desoxy Adenintriphosphat 
dCTP        desoxy Cytosintriphosphat 
ddH2O       Double distilled water  
DEPC        Diethylpyrocarbonate 
dGTP        desoxy Guanosintriphosphat 
DMEM       Dulbecco’s Modified Eagle Medium 
DMSO       Dimethyl sulfoxide 
DSMZ       German Collection of Microorganisms and Cell Cultures 
DNA         Desoxyribonucleic acid 
DNTPs      deoxyribonucleotide triphosphate 
DTT         Dithiothreitol (Threo-1,4-Dimercapto-2,3-Butandiol) 
dTTP        desoxy Thymintriphosphat 
 
E. coli        Escherichia coli 
EBV         Epstein Barr virus 
ECL         Enhanced chemiluminescence 
EDTA         Ethylenediaminetetraacetate 
EGFR       epidermal growth factor receptor 
eGFP        Enhanced green fluorescent protein 
ERK        extracellular signal regulated kinase 
 
FAB classifikation     French American British classification 
FACS        Fluorescence activated cell sorting 
Fak         Focal adhesion kinase 
FCS         Fetal calf serum 
FITC         Fluorescein Isothiocyanate 
 
g        Gram 
Gal         Galactose Abbreviations  139 
 
GFP         Green fluorescent protein 
Grb-2        Growth factor receptor-bound protein 2 
GST        Glutathione S-transferase  
GTP         Guanosintriphosphate 
Gy         Gray 
 
HEPES       4-2-hydroxyethyl-1-piperazineethanesulfonic acid 
HIV        Human immunodeficiency virus 
HMW       High molecular weight 
HPLC       High performance liquid chromatography 
HRP        Horse radish peroxidase 
HSCs        Hematopoietic stem cells  
 
IFN-α        Interferon alpha 
IgG         Immunglobulin G 
IMDM       Iscove’s Modified Dulbecco’s Medium 
IL-3         Interleukin 3 
IPTG         Isopropyl-1-thio-Beta-D-galactopyranoside 
ISE        Iterative Stochastic Elimination 
i.v        Intravenous  
 
Jak-Stat       Janus kinase-signal transducers and activators of transcription 
JNK        c-Jun-N-terminal kinase 
 
Kb        Kilo base pairs 
kDa         Kilodalton(s) 
 
LB-Medium       Luria-Bertani-Medium 
ΔLNGFR      Low affinity nerve growth factor receptor 
LSC        Leukemic-stem cell 
LT-HSC       Long-term hematopoietic stem cells 
M         Molar 
MACS       Magnetic activated cell sorting 
MAPK       Mitogen activated protein kinase Abbreviations  140 
 
M-BCR       Major Breakpoint cluster region 
m-BCR      Minor Breakpoint cluster region 
μ-BCR       Third Breakpoint in the BCR gene, downstream of the M-BCR 
MBP        Myristoyl binding pocket 
mg        Milligram 
Min        Minutes 
ml         Milliliter 
 
µg         Microgram 
ml        Milli Liter 
μl         Microliter 
μM         Micro molar 
mM        Milli Molar 
MNCs         Mononuclear 
MPD        Myeloproliferative diseases 
MPH-2      Membrane permeable helix-2 
MPP        Multipotent progenitor cells 
mSCF       Murine stem cell factor 
 
N        Amino 
Ng        nano gram 
NK         Natural killer 
NLSs        Nuclear localization signal sequences 
 
nSSL        Sterically stabilized nano liposomes 
OD         Optical density 
ORF         Open reading frame 
 
p185
BCR-ABL      185 kDa fusion protein of t(9;22) 
p210
BCR-ABL      210 kDa fusion protein of t(9;22) 
PAGE        Polyacrylamide gel electrophoresis 
PBS         Phosphate-buffered saline 
PCR         Polymerase chain reaction 
PE        Phycoerythrin Abbreviations  141 
 
pH  Reverse logarithmic representation of hydrogen ion 
concentration  
Ph+         Philadelphia chromosom positive 
Ph−         Philadelphia chromosom negativ 
PI         Propidium iodide 
PI3K        Phosphatidylinositol-3-kinase 
PLZF        Promyelocytic leukemia zinc finger 
PML        Promyelocytic leukemia protein 
Pmol        Pico Molar 
PT        Peptide transduction 
PTD        Peptide transduction domains  
 
RAR        retinoic acid receptor 
RNA        Ribonucleic acid 
rmIL-3       Recombinant murine interleukin-3 
rmIL-6       Recombinant murine interleukin-3  
RNA        Ribonucleic acid 
Rnase        Ribonuclease 
rpm         Revolution per minute 
RPMI-Medium     Roswell Park Memorial Institute-Medium 
RT         Reverse Transcriptase 
 
Sca-1        Stem cell antigene 1 
SCF         Stem cell factor 
SDS         sodium dodecyl sulfate 
SDS-PAGE       SDS-Polyacrylamide gel electrophoresis 
Ser        Serin 
S/T         Serine/threonine 
 
STAT       Signal transducers and activators of transcription 
ST-HSC      Short-term hematopoietic stem cells  
STI        Signaltransductions inhibitor 
SOS         son of sevenless 
 
T        Translocation Abbreviations  142 
 
t(9;22)       Translocation of Chromosom 9 and 22 
TAE        Tris-acetate-EDTA 
TAT        Trans-Activator of Transcription 
TBS         Tris-buffered saline 
TBST        Tris-buffered saline plus Tween 20 
TE        Tris-EDTA 
TEMED        Tetramethylethylenediamine 
Thr        Threonin 
TK        Tyrosine kinase 
Tris         Tris(hydroxymethyl)aminomethane 
TSA        Trichostatin A 
Tyr        Tyrosin 
 
U         Enzyme unit 
UTR        Untranslated region 
UV         Ultraviolet 
 
V         Volt 
v/v         volume per volume 
 
w/v         weight per volume 
WBC        White blood cell count 
WT         Wildtype 
XTT        Tetrazolium salt 
Y177        Tyrosine at a.a. position 177 
Y177F       Tyrosine mutated to phenylalanine at a.a. position 177 Ehrenwörtliche Erklärung  143 
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